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Lay Summary 
Antibiotic resistance is a rapidly spreading global phenomenon causing common infectious 
diseases to become untreatable. It is paramount that new antibiotics are brought to the clinic 
to combat this problem, as without new discoveries all bacterial infections will become 
resistant. Many of the antibiotics currently in use, like penicillin, were isolated from bacteria, 
as they produce defensive molecules to gain a competitive advantage in their ecosystem. 
Therefore, a better understanding of the different molecules that bacteria produce and how 
they produce them is crucial for the discovery and development of new antibiotics as well as 
other medicines. 
This thesis investigates tambjamine YP1, a molecule produced by a marine microorganism 
called Pseudoalteromonas tunicata. This molecule has both antibacterial and anticancer 
activity and could be developed for use in the clinic. Learning how this antibiotic is produced 
in the bacterium will allow us to harness this process and make new and improved 
tambjamines that have better and more specific activity. Therefore, this work explores the 
many different protein molecular machines (enzymes) that work together to make 
tambjamine YP1.  
Tambjamine YP1 consists of two fragments that are joined together to form the final product. 
This thesis has elucidated the method of creating each one of these fragments and has 
explored the incorporation of new building blocks into the fragments to make novel 
molecules. Eventually, this research could be taken forward to produce new tambjamines to 
treat resistant bacterial infections.   
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Abstract 
Natural products are secondary metabolites produced by many different organisms such as 
bacteria, fungi and plants. These biologically active molecules have been widely exploited for 
medicinal purposes generating a large proportion of the drugs in clinical use today. 
Tambjamine YP1 is an antimicrobial, antimalarial and cytotoxic bipyrrole natural product 
produced by the anti-biofouling marine microorganism Pseudoalteromonas tunicata. Its 
biosynthetic pathway is encoded in an operon (the tam cluster) consisting of 19 genes, 10 of 
which have proposed biosynthetic functions involved in bipyrrole formation and attachment 
of a fatty amine tail. However, details of the biosynthesis of these moieties have not been 
elucidated. This thesis presents studies on the characterization of four of the recombinant 
enzymes isolated from Escherichia coli (TamA, TamD, TamF and TamH) and identifies their 
roles in the biosynthetic pathway of tambjamine YP1. 
Biosynthesis of the bipyrrole backbone is proposed to begin with the formation of the first 
pyrrole ring from L-proline, a common route to pyrrole biosynthesis in natural products. In 
contrast, the second pyrrole ring is assembled in an unusual linear manner by two didomain 
enzymes, TamF and TamD. Sequence analysis of TamF suggests it is a didomain fusion 
composed of a chain length factor (CLF) and a ketosynthase (KS). Similarly, TamD is also an 
unusual didomain fusion of an acyl carrier protein (ACP) and an α-oxoamine synthase (AOS). 
Together TamF and TamD produce the first bipyrrole intermediate in the tambjamine YP1 
biosynthetic pathway, 4-hydroxy-2,2’-bipyrrole 5-methanol (HBM). Mass spectrometry (MS) 
analysis shows that TamF can be loaded with a cysteine-bound, β-ketopyrrole thioester and 
the TamD ACP domain can be converted to the malonyl-ACP form. TamF then catalyzes the 
Claisen-like condensation between the malonyl-TamD ACP and its β-ketopyrrole substrate to 
elongate the chain by two carbons. The resulting TamD ACP-bound diketopyrrole product is 
a substrate for the TamD AOS domain that catalyzes a second Claisen-like condensation with 
L-serine to release the product, HBM. This work defines a role for TamF and TamD in HBM 
biosynthesis and presents the first in vitro production and detection of this key bipyrrole 
intermediate by high performance liquid chromatography (HPLC) and MS analysis.  
Attached to the tambjamine YP1 bipyrrole backbone is a fatty amine tail predicted to be 
derived from a C12 fatty acid. Previously, this moiety was proposed to be activated as a CoA 
thioester by a fatty acid CoA ligase (FACL) from outside the tam cluster. However, sequence 
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analysis of TamA, an enzyme in the tam cluster with no previously assigned function, 
suggested that it is an unusual didomain fusion of a fatty acid AMP ligase (FAAL) with a C-
terminal ACP domain that could carry out this function. Surprisingly, MS analysis of 
recombinant TamA revealed the presence of bound C11 and C12 fatty acid adenylates, which 
can be transferred to the ACP domain upon attachment of a 4’-phosphopantetheine (4’-PP) 
to a conserved serine residue. An in trans acyl-transfer assay was developed using the 
recombinant TamA ACP domain and was used to screen fatty acid substrates with variable 
chain lengths (C2-C16). It was found that TamA can efficiently transfer several fatty acids (C6-
C13) with the best substrate being the C12 acid. Contrary to the previous hypothesis, MS 
analysis showed that the C12 acylated TamA ACP domain acts as a substrate for TamH, a 
downstream enzyme in the pathway. This interesting didomain fusion contains thioester 
reductase (TR) and transaminase (TA) domains which work sequentially to produce the C12 
amine from the TamA ACP-bound fatty acid thioester. This amine product can subsequently 
combine with an HBM-derived aldehyde to generate the mature tambjamine YP1 natural 
product. Furthermore, preliminary data on the use of TamA for the production of the recently 
discovered class of N-acyl histidine amides from Legionella pneumophila is presented.  
In summary, key enzymes from the tambjamine YP1 pathway have been functionally 
characterized. As well as defining their roles in the pathway, this work also has potential 
impact on understanding the biosynthesis of other pyrroles (e.g. prodiginines) and 
polyketides. This work lays the foundations for engineering of the Tam proteins to produce 
novel tambjamine derivatives for biological testing. 
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1 Introduction 
1.1 Natural Products  
Nature has produced a breadth of molecules that have had a significant impact on human 
history. Many plants, bacteria and fungi, as well as other organisms, produce small molecule 
secondary metabolites with potent biological activity. These molecules have been exploited 
for use in many industries but have most notably impacted on medicine.  In the period 
between 1981 and 2014, 60% of newly approved small molecule drugs (n = 1211) were 
natural products, derivatives or mimics.1 These figures are even higher for antibacterial and 
anticancer medications which rely heavily on natural product discovery. Traditional 
pharmaceutical drug discovery, utilizing high throughput screening of large libraries of 
synthetically accessible molecules, has a worryingly low hit rate of less than 0.001%. 
Comparing this figure to one example class of secondary metabolites, the polyketides (PKs), 
illustrates the utility of focusing on natural products; of the 7000 known structures of 
polyketides, more than 20 are used clinically, a hit rate of 0.3%.2 However, though natural 
products lay the groundwork for potent biologically active compounds, many of these will 
require derivatization to improve activity, stability or uptake. Indeed, natural products have 
inspired many synthetic chemists to produce novel scaffolds or develop new chemistry to 
make these complex structures.3,4 Therefore, there is an evident need for identification and 
understanding of new natural products for use as drugs or for inspiring new synthetic 
derivatives and mimics for the clinic.  
Unfortunately, the rate of discovery of natural products has been decreasing over the past 
three decades with a concomitant decrease in drug approvals.5 This reduction stems from 
the difficulty of identifying new biologically active molecules.6 Conventional discovery relies 
on screening of extracts for killing activity against bacteria or fungi. However, as many species 
produce the same antimicrobial products, the risk of rediscovery and therefore duplication 
of effort is high. Supply of natural products for screening can also be a barrier, as the 
biological source of the molecule is required. Many of these sources are difficult to culture 
in the laboratory and may require sampling from their native environment. However, 
environmental or seasonal changes can significantly affect the production of these 
metabolites in the source organism.6  
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Novel approaches in the field are seeking to tackle the slowing rate of natural product 
discovery. Soil bacteria have traditionally been a fruitful source of biologically active 
molecules,7 however only around 1% of these can be cultured in the laboratory. The advent 
of iCHIP,8 a method of culturing bacteria using a diffusion chamber has radically improved 
this figure to 50%. Less well characterized environments like marine ecosystems are now 
being probed and exploited for novel chemistry.9 Expanded access to genetic information 
with the improvement in speed and cost of sequencing technology has been a significant 
development for the field.10,11 We now have a much greater understanding of the enzymes 
involved in natural product biosynthesis and we can use this knowledge to probe genomes 
for the production of unique secondary metabolites. Expanding our understanding of natural 
product biosynthetic genes and enzymes is of utmost importance to facilitate their discovery. 
 
1.2 Pyrrole Natural Products 
Nitrogen heterocycles are the building blocks of nature, appearing in many vital molecules 
including deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins.12 Pyrrole 
moieties are particularly ubiquitous and constitute part of many interesting natural products. 
The versatile pyrrole motif is planar and electron rich, resulting in its ability to form hydrogen 
bonds, chelate metal ions and participate in π-stacking interactions.13 One of the most 
notable pyrrole containing compounds is heme, the tetrapyrrole porphyrin cofactor (Figure 
1.1). This structure consists of four pyrrole rings attached in a larger, planar system. The ring 
system is able to chelate iron to carry out various activities including electron shuttling in 
cellular respiration, oxygen binding and oxygenation.14 Pyrrole is also a key component in the 
indole structure of tryptophan, where it forms an integral part of the majority of proteins.  
Pyrrole natural products constitute a large number of biologically active molecules that have 
potential for use as drugs (Figure 1.1). Clorobiocin is a bacterial DNA gyrase inhibitor effective 
against Escherichia coli whose pyrrole ring is essential for activity;15 pyoluteorin induces 
Mcl-1 degradation and apoptosis in cancer cells;16 prodigiosin is both an antibacterial and 
anticancer agent able to intercalate and cleave DNA;17 the makaluvamines are DNA 
topoisomerase II inhibitors with anticancer activity18 and the newly isolated heronapyrroles 
have strong Gram-positive antibacterial activity.19 Though these natural products have yet to 
make it to the clinic they have inspired several novel derivatives with enhanced activity.16,20,21 
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Figure 1.1: Molecules with biological activity containing pyrrole groups (purple). Heme b and L-
tryptophan form essential components of hemoglobin and proteins. Clorobiocin, pyoluteorin, 
prodigiosin, makaluvamine A and heronapyrrole C are all pyrrole containing natural products with 
potential for use as drugs. Atorvastatin, tolmetin, sunitinib and pyrvinium are FDA or EU approved 
drugs containing pyrrole moieties. 
The potential of pyrrole containing molecules is exemplified by the incorporation of pyrrole 
into several approved drugs with a wide variety of indications, including atorvastatin, 
tolmetin, sunitinib and pyrvinium (Figure 1.1). Atorvastatin is an inhibitor of the enzyme 
3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase which catalyzes the rate-
limiting step of cholesterol biosynthesis in the liver. This causes the liver to uptake 
cholesterol from the blood, lowering its concentration and decreasing the patient’s risk of 
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cardiovascular disease.22 Though tolmetin’s mode of action is unknown, it is a non-steroidal 
anti-inflammatory drug (NSAID) that has been successfully used for the treatment of pain 
and inflammation in arthritis and other diseases.23 Sunitinib is another enzyme inhibitor 
which binds to receptor tyrosine kinases involved in tumor cell angiogenesis and 
proliferation. It has been approved for use in renal cell carcinoma and gastrointestinal 
stromal tumour.24 The final pyrrole-containing drug is pyrvinium, which is used as an 
antihelminthic25 and has also been employed to treat infection of the parasite 
Cryptosporidium.26 These molecules illustrate that pyrrole rings are distinctly important 
elements in biologically active molecules and natural products. Identification of new pyrrole 
containing natural products and elucidation of their biosynthesis will be an important step in 
developing new medications. 
 
1.3 Tambjamines  
1.3.1 Structure and Activity 
One interesting family of pyrrole natural products containing two rings in a core 
2,2’-bipyrrole structure are the tambjamines, a family of yellow pigments (Figure 1.2). Their 
bipyrrole core is similar to that of a well characterized natural product family – the red-
coloured prodiginines,27 which share the 4-methoxy-2,2’-bipyrrole carbaldehyde (MBC, 
Figure 1.2) backbone. Tambjamines consist of the MBC aldehyde (sometimes containing 
bromine substituents) attached to a fatty amine tail via an enamine linkage.  
 
Figure 1.2: General structures of the tambjamines (R = hydrocarbons between C2 and C12), the 
prodiginines (R = various hydrocarbons and cyclisations) and 4-methoxy-2,2’-bipyrrole carbaldehyde 
(MBC), the bipyrrole core of these molecules. 
In contrast, the prodiginines consist of a third pyrrole ring attached to the bipyrrole backbone 
via a methylene bridge, resulting in a conjugated tripyrrole system. The third ring in the 
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prodiginines is generally substituted with hydrocarbon chains that can also be cyclized, as in 
the case of streptorubin B.27 
The first tambjamine molecules were isolated in 1982 by Carté and Faulkner who elucidated 
the structures of tambjamines A-D28 (Figure 1.3). These molecules originated from the 
marine environment in the Tambja genus of nudibranchs and their bryozoan prey 
Sessibugula translucens. The tambjamines appeared to be utilized as defensive chemicals to 
ward off predators like the carnivorous nudibranch Roboastra tigris.29 A few years later, 
tambjamines E and F were identified in another marine feeding association between 
Nembrotha nudibranchs and the Atapozoa ascidians.30 These molecules play the same 
defensive role in these food chains, also deterring predatory fish.31 Four other tambjamines 
(G-J) were subsequently extracted from a different bryozoan, Bugula dentata.32 These new 
molecules showed strong biological activity in a killing assay of brine shrimps, suggesting the 
same defensive function.  
 
Figure 1.3: Structures of the naturally occurring tambjamines A-K, YP1 and BE-18591 isolated from 
nudibranchs, bryozoans, ascidians and bacteria. 
Only one tambjamine, named BE-18591, has thus far been identified outside the marine 
environment, isolated from a Japanese plant dwelling Streptomyces sp.33,34 BE-18591 has a 
much longer fatty acid chain than the tambjamines previously characterized, consisting of 12 
carbons (Figure 1.3). The most recent naturally occurring tambjamine identified is 
tambjamine YP1 which was isolated from the marine bacterium Pseudoalteromonas 
tunicata.35 This molecule has a very similar structure to BE-18591 but contains a double bond 
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at position 3 of the hydrocarbon tail. YP1 also has deterrent properties as it is responsible for 
preventing the biofouling of its host organism, the common alga Ulva australis. 
Since the tambjamines are thought to be involved in chemical defense and also show killing 
activity, these molecules have been explored for their potential therapeutic value. They 
display potent antimicrobial activity against the pathogens Candida albicans, E. coli, Vibrio 
anguillarum and Malassezia furfur28,36 as well as cytotoxic activity against mammalian cancer 
cells.36–41 This activity arises from two mechanisms of action. The tambjamines bind DNA in 
the minor groove and are able to intercalate between adenine-thymine base pairs (bp).36–38 
They subsequently catalyze copper dependent oxidative cleavage of the DNA leading to DNA 
fragmentation and apoptosis. Though the naturally occurring tambjamines have not shown 
particular selectivity for cancer cells, they have inspired new tambjamine analogues with 
improved activity and selectivity.40 The second mechanism of action of the tambjamines is 
transmembrane anion exchange.42 These molecules can transport bicarbonate and chloride 
ions across cell membranes which is likely to play a role in their antimicrobial and cytotoxic 
activity. However, this activity could also be tuned for therapeutic use in the treatment of 
channelopathies. The Quesada group has shown that increasing lipophilicity of the 
tambjamine hydrocarbon tail improves anion transport up to a chain length of 9-carbons.43 
Unnatural analogues have also been designed with different aromatic substituents that have 
even greater anion transport activity.42,44 Finally, novel tambjamines have also been created 
with excellent activity against malaria.45 The best performing molecule, KAR425, a 
tambjamine with a saturated 7-membered ring in place of its hydrophobic tail, showed 
greater efficacy than any other tambjamine or prodiginine analogue and was curative in mice 
at 80 mg/kg in a single dose. Taken together, these results suggest that tambjamine 
molecules have very promising potential as medicinal candidates. 
 
1.3.2 Tambjamine YP1  
Tambjamine YP1 is the most recently isolated natural tambjamine, extracted from the marine 
bacterium P. tunicata by the Kjelleberg group.46 P. tunicata was discovered both on the 
surface of tunicates and alga where it competed against other biofouling organisms for space 
and nutrients.47,48 Its success in these environments relies on the production of a number of 
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secondary metabolites with inhibitory activity, including the well-known antibiotic 
violacein,49 along with tambjamine YP1.   
In order to better understand tambjamine YP1 biosynthesis, the Kjelleberg group identified 
and cloned the gene cluster responsible for its production in P. tunicata.50 To date, this is the 
only known tambjamine producing gene cluster. The group generated a P. tunicata genomic 
library of ~35 kb fragments expressed in E. coli and determined which clones produced 
tambjamine by fungal growth inhibition assay. Three clones were able to biosynthesize the 
yellow pigment and inhibit fungal growth. Analysis of these clones revealed an overlapping 
region of 21 open reading frames (ORFs), 19 of these forming a 26 kb unidirectional cluster 
(Figure 1.4). Mutants of the genes in the cluster resulted in abolition of pigment production 
and fungal growth inhibition. Therefore, this cluster was designated as the tam cluster. 
 
Figure 1.4: The tam gene cluster responsible for the biosynthesis of Tambjamine YP1 containing 19 
open reading frames (ORFs), annotation according to Burke et al.50 
Each of the 19 ORFs from the cluster were subjected to Basic Local Alignment Search Tool 
(BLAST)51 analysis to identify the conserved protein domains. The genes were also compared 
to the red and pig clusters of Serratia marcescens and Streptomyces coelicolor.27,52 These 
clusters produce the tripyrrolic prodiginines with the same core bipyrrole structure. Table 
1.1 shows the predicted functions of the proteins as well as their size, GenBank access codes 
and their homologues from the prodiginine biosynthetic gene clusters.  
The conserved domain analysis is immediately interesting as 4 of the 19 ORFs in the cluster 
encode fused didomain enzymes that have multiple functions (TamA, TamD, TamF and 
TamH). Utilizing the predicted domains of each protein, as well as their homology to the 
closely related clusters, Burke et al.50 postulated the biosynthesis of tambjamine YP1. This 
biosynthetic pathway is presented in Figure 1.5 with some updates, including the correction 













Page | 8  
 






BLAST Conserved Domains 
tamA EAR29369 - 75 Fatty acid AMP-ligase/ACP 
tamB EAR29368 pigG/redO 10 PCP 
tamC EAR29367 redG 43 Rieske oxidase 
tamD EAR29366 pigH/redN 58 8-Amino-7-oxononanoate synthase 
tamE EAR29365 pigI/redM 56 Amino acid adenylating enzyme 
tamF EAR29364 pigJ/redX 81 β-ketoacyl synthases (2 domains) 
tamG EAR29363 pigA/redW 43 Acyl CoA dehydrogenase 
tamH EAR29362 pigE 104 TA/Acyl-ACP reductase 
tamI EAR29359 - 50 ABC transporter permease 
tamJ EAR29361 pigM/redV 40 FMN nitroreductase 
tamK EAR29360 - 29 Periplasmic sorting protein 
tamM EAR29358 - 45 ABC transporter permease 
tamN EAR29357 - 26 ABC transporter ATPase 
tamO EAR29356 - 45 Unknown 
tamP EAR29355 pigF/redI 37 SAM-dependent methyltransferase 
tamQ EAR29354 pigC/redH 100 Phosphoenolpyruvate synthase 
tamR EAR29353 pigK/redY 12 Unknown 
tamS EAR29352 pigL/redU 25 PPTase 
tamT EAR29351 - 62 Acyl-CoA dehydrogenase 
Table 1.1: The tam cluster genes with their GenBank codes, homologues from the pig and red clusters, 
predicted protein size and conserved domains; updated from Burke et al.50 
MBC is a common intermediate of the prodiginine and tambjamine natural products and the 
biosynthesis of this molecule has been explored and reviewed.27,52 Therefore, the predicted 
pathway to MBC production in P. tunicata is largely based on the information obtained from 
the pig and red clusters. Generation of the bipyrrole fragment is predicted to begin with 
TamE, a putative adenylation enzyme (ANL) which is specific for L-proline. This enzyme 
activates L-proline using adenosine triphosphate (ATP) to form a proline adenylate 
intermediate which can then be transferred onto TamB, a peptidyl carrier protein (PCP). PCPs 
and acyl carrier proteins (ACPs) are non-catalytic and serve to anchor natural product 
intermediates while they are being extended or modified.53 The substrates are bound to their 
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4’-phosphopantetheine (4’-PP) post-translational modification as thioester intermediates. 
Once the proline residue is bound, the PCP conveys it to the active site of TamG, a putative 
flavin adenine dinucleotide (FAD)-dependent dehydrogenase. TamG is likely to carry out a 
two-step oxidation of the proline heterocycle to the aromatic pyrrole. The β-ketopyrrole is 
subsequently handed off to TamF, a ketosynthase (KS) / chain length factor (CLF) didomain 
protein. TamD, another interesting didomain enzyme works with TamF to effect chain 
extension. TamD contains an ACP which becomes loaded with a malonyl group by an as yet 
unknown mechanism and an α-oxoamine synthase (AOS) domain. TamF performs a Claisen-
like condensation of the malonyl-TamD ACP with its β-ketopyrrole intermediate. This extends 
the chain by two carbons and the TamD ACP thioester can now act as a substrate for the 
TamD AOS domain. This domain is expected to bind L-serine and carry out a pyridoxal 5’-
phosphate (PLP)-dependent decarboxylative condensation to release an α-oxoamine. This 
linear molecule can spontaneously cyclise to produce 4-hydroxy-2,2’-bipyrrole-5-methanol 
(HBM), the first bipyrrole intermediate in the pathway. Two additional tailoring reactions are 
required to reach the final bipyrrole fragment: oxidation of the alcohol group originating 
from the serine side chain by TamJ and methylation of the 4-hydroxy group by TamP, an S-
adenosyl methionine (SAM)-dependent methyltransferase.  
The evidence for this predicted MBC pathway is based on knockout experiments in the red 
cluster of S. coelicolor and in vitro studies of the Pig enzymes from S. marcescens. Knockouts 
of the red genes showed that RedM, W, X and N (homologues of TamE, G, F and D, the 
adenylation enzyme, FAD dehydrogenase, KS and AOS respectively) are necessary for the 
formation of the prodiginines produced by S. coelicolor.54 However, feeding of these mutants 
with synthetic MBC restored production of the natural products, showing that these enzymes 
are responsible for biosynthesizing this fragment. The Challis group also demonstrated that 
feeding of a small molecule pyrrole-PCP mimic to RedM and RedW mutants (the adenylation 
and FAD dehydrogenase domains respectively) restored natural product production.54 
However, pyrrole carboxylic acid (an oxidized proline molecule) was unable to restore 
production, illustrating that this intermediate is never released. This strongly suggests that 
the pyrrole ring is transferred directly from the PCP to the KS. In the same year, the Walsh 
group expressed and characterized the proteins involved in HBM biosynthesis in the pig 
cluster.55 They were able to detect all enzyme bound intermediates from L-proline to the 
diketopyrrrole-ACP. However, they were unable to identify the final HBM product, thus, it 
has never been confirmed as the first bipyrrole intermediate in the pathway.  




Figure 1.5: Predicted biosynthetic pathway to tambjamine YP1 from L-proline, malonyl-CoA, L-serine 
and lauric acid in P. tunicata, adapted and corrected from Burke et al.50 
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Burke et al.50 postulated that the tambjamine YP1 amine tail originates from lauric acid, C12 
carboxylic acid. This pathway would be initiated by AfaA, an enzyme from outside the tam 
cluster that has homology to fatty acid coenzyme A ligases (FACLs). When this gene is 
knocked out in P. tunicata, yellow pigment formation is abrogated, so it was predicted that 
AfaA produces a coenzyme A (CoA) bound lauric acid via an adenylate intermediate. The CoA 
derivative can then be dehydrogenated by the FAD-dependent dehydrogenase TamT, to 
introduce the 3,4 double bond. Finally, the bifunctional TamH can produce the amine by 
reductive amination. This unusual enzyme consists of an N-terminal transaminase (TA) and a 
C-terminal thioester reductase (TR). The reductase domain should reduce the CoA thioester 
to produce free CoA and C12 aldehyde using nicotinamide adenine dinucleotide (or 
phosphate, NAD(P)H). This aldehyde can subsequently be transaminated by the TamH 
N-terminal domain to produce the final amine fragment. However, none of these 
biosynthetic transformations have been probed as this pathway is not shared with 
prodiginine biosynthesis.  
After completion of the building blocks, the final step is condensation of the two fragments 
by TamQ to form tambjamine YP1. The condensation enzymes of the prodigiosin pathways 
have been well studied and have been exploited for the formation of novel natural products 
as they accept a variety of substrates.21,56,57 As TamQ is similar to these enzymes, it is possible 
that it will also accept a range of building blocks to produce new and improved tambjamines. 
 
1.4 Non-Ribosomal Peptide (NRP) and Polyketide (PK) Biosynthesis 
1.4.1 Biosynthetic Pathway 
Many of the predicted genes in the tambjamine YP1 pathway share similarity to genes 
involved in the biosynthesis of two groups of natural products, the PKs and the non-
ribosomal peptides (NRPs). A marked increase in the understanding of the genomics of these 
natural products arrived with the cloning of 6-deoxyerythronolide B synthase (DEBS), an 
enzyme involved in erythromycin biosynthesis by both Leadlay58 and Katz59 in the early 
1990s. This introduced us to the ‘assembly line’ biosynthesis of PKs by PK synthases (PKSs) 
and shortly after a similar arrangement was described for NRP synthases (NRPSs).60 In these 
examples, large polypeptides containing several functional domains grouped into modules 
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act as a conveyor belt for their natural products.61,62 A collinearity was found between the 
number of modules and their specific domains and the number of building blocks 
incorporated and how they are modified.10 
Both systems have a very similar assembly line which is analogous to the biogenesis of fatty 
acids in primary metabolism by the fatty acid synthase (FAS).63,64 They begin with activation 
of a substrate and transfer to a carrier protein (CP). Elongation occurs by activation of a 
second substrate and Claisen-like condensation between the second and the first. This cycle 
can be repeated several times before chain termination, releasing the product (Figure 1.6).  
 
Figure 1.6: General biosynthetic route of (a) polyketide (PK) and (b) non-ribosomal peptide (NRP) 
natural products adapted from Weissman.61 
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The PKS carries out highly similar reactions to the FAS utilizing the same set of starter and 
elongation units, usually acetyl-CoA and malonyl-CoA respectively. The PKS begins with an 
initiation module containing an acyltransferase (AT) domain and an ACP which load up the 
starter unit for the elongation module. The initiation domain AT transfers the starter unit 
from an activated CoA substrate onto its conserved serine residue before delivering it to the 
4’-PP modified ACP. Transthioesterification can now occur from the ACP to the cysteine 
residue of the elongation module KS. This module also contains an AT domain that loads the 
second building block, containing a free carboxylic acid, onto the second ACP. Claisen-like 
condensation is catalyzed by the KS which decarboxylates the second building block to form 
a carbanion to attack the KS bound starter unit, increasing the chain length by two carbons. 
The first ketone can now be modified, if required, by reduction to an alcohol by a 
ketoreductase, dehydration to a double bond by a dehydratase and further reduction to the 
single bond by an enoyl reductase. Any or all of these modifications can be performed, 
increasing the variability of PKS products. This is in contrast to fatty acid biosynthesis where 
all of these steps would be performed at every stage to yield a saturated hydrocarbon. The 
variability of PKs can also be increased with the incorporation of alternative starter or 
extender units such as propionyl-CoA or methylmalonyl-CoA. After extension by a defined 
number of building blocks, the chain is terminated and released, most commonly by a 
thioesterase (TE). This enzyme attacks the ACP thioester forming an ester on its conserved 
serine residue. This ester is subsequently hydrolyzed to release the polyketide chain with a 
terminal carboxylic acid.  
Rounds of extension are carried out in a similar way in the NRPS, where an amino acid is 
activated by an ANL domain using ATP to produce an amino acid adenylate. This adenylate 
can be attacked by the thiol of the PCP to form the activated thioester in the initiation 
module. A second ANL domain activates a second amino acid in the elongation module and 
the condensation (C) domain catalyzes the Claisen-like condensation between the two. 
Though condensation domains carry out a reaction analogous to the KS, they do this in a 
slightly different manner. The starter unit is not transferred to the condensation domain, 
instead, this enzyme catalyzes the extension between the two amino acids bound to each 
PCP. Similarly, this can occur several times before chain termination by a TE to release the 
peptide.  
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These two modular constructs utilize very similar methodology, including CPs and 
condensation reactions. For this reason they can also form hybrid synthases allowing both 
PKS and NRPS modules to work together to create natural products containing elements of 
each type.65 Further research into the area has also identified synthases with only one 
module that incorporate more than one building block, known as iterative synthases.66 Type 
II PKSs have also been described, which consist of discrete enzymes containing only one 
catalytic domain per polypeptide, similar to the type II FASs of bacteria.67 These proteins are 
usually also iterative, with the ACP moving between its catalytic partners several times. The 
predicted tambjamine YP1 pathway is comprised of elements from both PKS and NRPS 
biosynthesis as it incorporates proline and malonyl units in a type II style system with only 
one or two functional domains per polypeptide.  
 
1.4.2 Carrier Proteins (CPs)  
The overview of FAS, PKS and NRPS biosynthesis, as well as the predicted pathway to the 
biosynthesis of tambjamine YP1 has shown that CPs are the backbone of natural product 
pathways, shuttling the growing chain between the many different catalytic partners they 
encounter.68 These systems have similar domain organization, but FAS and PKS are 
evolutionarily distinct from NRPS suggesting that CPs are employed in many different 
carboxylate-utilizing reactions.69 These proteins are small, at less than 100 amino acids, they 
have a molecular weight between 8 and 10 kDa.53  
CPs must be post-translationally modified with a 4’-PP arm derived from CoA to convert them 
from apo- to holo-form. This modification is necessary for CPs to attach their substrates as 
activated thioesters and is carried out by the phosphopantetheinyltransferases (PPTases, 
Figure 1.7).69 The 20 Å length of the 4’-PP arm also allows it to stretch directly into the active 
sites of partner enzymes.70 




Figure 1.7: Activation of carrier proteins (CPs) by transfer of 4’-phosphopantetheine (4’-PP) from 
coenzyme A (CoA) onto a conserved serine residue by a phosphopantetheinyltransferase (PPTase).71 
The ACP was first identified in the bacterial type II FAS where it transports developing fatty 
acids between each discrete catalytic enzyme. The first defined structure of an ACP was the 
solution NMR structure of the E. coli FAS ACP72 which has since been crystallized in various 
forms.73,74 The E. coli ACP structure illustrates the now canonical ACP fold (Figure 1.8a) 
consisting of three parallel α-helices (helices I, II and III) with a fourth shorter anti-parallel 
helix (helix IV) running across these. The three parallel helices contain mainly hydrophilic 
residues on the solvent exposed surface and hydrophobic residues facing inwards, forming a 
hydrophobic cleft in the center of the protein. The helices are connected by flexible loop 
regions with loop I and helix II showing the highest flexibility.75 The dynamic structure of 
these proteins has resulted in the difficulty of obtaining crystal structures of ACPs, so NMR 
has often been used in its place.76  
The 4’-PP modification of CPs takes place at the top of Helix II, on a serine residue in the 
conserved DSX motif where X is usually leucine or another small hydrophobic amino acid.77 
This modification confers greater stability to the ACP structure77,78 causing it to contract 
slightly.79 The holo-forms of ACPs are mainly stabilized by hydrophobic interactions of the 
4’-PP arm with the protein structure53 including the X amino acid from the DSX motif.79 




Figure 1.8: Crystal structures of E. coli acyl carrier protein (ACP) showing the conserved four-helix 
structure (a) in its apo-form, protein data bank (PDB) code: 1T8K73 and (b) in its 4’-
phosphopantetheine (4’-PP) modified holo-form with an attached hexanoyl substrate (grey), PBD 
code: 2FAC.74 The conserved serine residue (Ser36) that becomes post-translationally modified is also 
shown as sticks in each structure. 
ACPs are additionally stabilized by acylation during biosynthesis when the hydrophobic cleft 
contracts even further.80 Type II ACPs have been shown to sequester their 4’-PP arms 
containing acyl substrates to protect the thioester from hydrolysis (Figure 1.8b).81,82 The 
chains are bound in the central hydrophobic cavity of the protein formed predominantly by 
Helices II and IV53 and can expand to accommodate longer chains.74 When the ACP is required 
to deliver its substrate to a catalytic partner the 4’-PP arm ‘flips out’ of the hydrophobic cavity 
into the active site of the partner enzyme.70,83 This ACP-partner interaction is very specific, 
exchanging ACPs between catalytic systems rarely results in full activity and often shows no 
activity at all. Helix II, containing the 4’-PP modification, is mainly responsible for mediating 
this interaction and thus is termed the ‘recognition helix’.84 This part of the protein contains 
conserved acidic residues which form specific contacts with the partner enzymes.85 Although 
specific, these interactions are also transient as the ACP must be able to move on and off its 
respective partner enzymes with ease.84 
The majority of ACP structural data has been derived from type II systems. However, more 
recently structures of type I ACPs that form part of megasynthases have also been 
determined. These proteins are very similar in structure but there are some differences 
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between the two, as protein-protein interactions are less important for the type I ACPs 
whose partners are generally fused.69 This results in the type I proteins being less acidic than 
their type II counterparts.86 Additionally, type I ACPs do not sequester their substrates in 
hydrophobic pockets as they are less likely to suffer from hydrolysis.87 
 
1.4.3 Phosphopantetheinyltransferases (PPTases) 
CPs require post-translational modification with a 4’-PP arm in order to transport 
biosynthetic intermediates. The enzymes responsible for this modification are the PPTases 
which transfer 4’-PP from CoA onto the conserved serine residue of a CP (Figure 1.7). These 
proteins fit into three families:88 the AcpS family, the Sfp family and the megasynthase family. 
The AcpS and Sfp families have been most widely researched and are much more common 
than PPTases as part of megasynthases.89 As it is a stand-alone protein, the predicted PPTase 
in the tambjamine YP1 pathway must be similar to AcpS or Sfp. Though it is currently unclear 
which family this protein belongs to, it is likely to be an Sfp type protein as these are more 
commonly found in secondary metabolite biosynthesis.71 
AcpS is the holo-ACP synthase for the type II FAS ACP from E. coli and other bacteria. The first 
purification of E. coli AcpS showed that its activity relies upon divalent metal ions, either Mg2+ 
or Mn2+.90 It has some substrate promiscuity for other similar type II ACPs but is not able to 
modify any type I ACPs including E. coli EntF from the enterobactin synthase.91 The first 
structure of the B. subtilis enzyme indicated that it is a homotrimer with three active sites at 
each interface between the monomers (Figure 1.9a).85 The Mg2+ ion is responsible for 
coordinating the diphosphate of CoA in the active site and stabilizing the anion during attack 
of the ACP serine. 
In contrast, Sfp is a PPTase from secondary metabolism responsible for loading the surfactin 
synthase PCP in B. subtilis. Its discovery led to the realization that different biosynthetic 
pathways require different PPTases.71 This enzyme was also crystalized, revealing an 
alternative structure to the AcpS family (Figure 1.9b).92   




Figure 1.9: Crystal structures of B. subtilis (a) AcpS, showing the homotrimeric structure with three 
CoA molecules (yellow sticks) bound at the interfaces between the monomers, PDB code: 1F7L85 and 
(b) Sfp, showing the pseudodimeric structure resembling two AcpS monomers with a single catalytic 
site containing CoA (yellow sticks) coordinated by an Mg2+ ion (grey sphere), PDB code: 1QR0.92  
Sfp is a pseudo-homodimer, resembling two monomers of AcpS. However, it only has one 
active site at the interface of the pseudodimer which is similar to the AcpS active site and 
also contains a divalent cation. Sfp is much more promiscuous than AcpS and is now used as 
a tool enzyme for the loading of many different ACPs, both with CoA and other analogues 
and derivatives as the terminal portion of the CoA molecule is not recognized by this 
enzyme.79,83,93–95 For this reason, PPTases in general and especially Sfp are invaluable tools 
for the study of biosynthetic pathways. 
 
1.4.4 Ketosynthases (KSs) 
Ketosynthases are essential components of FAS and PKS biosynthesis which catalyze the 
formation of new carbon-carbon bonds between two acyl chains. This is a three step reaction 
beginning with (1) transfer of an acyl chain from an ACP to a conserved cysteine residue in 
the KS active site, (2) decarboxylation of an ACP bound malonyl group to generate a 
carbanion and (3) attack of the carbanion on the KS thioester to form a new carbon-carbon 
bond between the two chains (Figure 1.10).96 Three conserved active site residues are 
involved in catalysis: the active site cysteine that retains the acyl chain and two histidine 
residues that are required for efficient chain translocation and malonyl decarboxylation.97 




Figure 1.10: The ketosynthase (KS)-catalyzed decarboxylative, carbon-carbon bond forming 
condensation involving three conserved residues (Cys, His, His) in the KS active site, adapted from 
Robbins et al.97 
The predicted KS in the tambjamine YP1 pathway is similar to KSs belonging to type II PKS 
systems. These assemblies contain discrete enzymes with single functions that usually 
produce aromatic PKs.98 Type II PKSs also commonly have two different KS domains which 
have been termed KSα and KSβ or KS and CLF. The CLF looks very similar to a KS domain but 
is missing the conserved active site residues required for catalysis. These two domains 
generally form heterodimers,99 in contrast to the homodimer KSs of the type II FAS.63 
The function of the CLF domain is unclear and has been the subject of intensive research. It 
was designated as a CLF after research into the actinorhodin, granaticin and tetracenomycin 
KS genes showed that exchange of the CLF from different PKSs resulted in products of altered 
chain length.100 However, later research suggested that this wasn’t exclusively a function of 
the CLF but of the whole PKS system.101 This became clearer with the first and only crystal 
structure of a KS-CLF heterodimer from actinorhodin biosynthesis (Figure 1.11a).102 The 
overall structure of the heterodimer is similar to the FabF dimer of the E. coli FAS but is more 
tightly bound as the two subunits have evolved complimentary contacts. There is only one 
active site that lies at the dimer interface which creates a tunnel that the growing PK chain 
extends into (Figure 1.11b). The KS catalytic residues lie at the entrance to the tunnel with 
the end bound mainly by residues from the CLF. These bulky CLF residues can be mutated to 
extend the length of the pocket.103 This results in biosynthesis of longer PKs suggesting that 
the CLF plays an important role in the control of chain length, utilizing a molecular ruler 
mechanism.  




Figure 1.11: Crystal structure of the ketosynthase – chain length factor (KS-CLF) heterodimer from the 
actinorhodin synthase, PDB code: 1TQY102 (a) overview of the heterodimer with the KS (blue) and the 
CLF (green) and (b) surface representation of the PK binding pocket with the catalytic resides (Cys, His, 
His) from the KS at the top of the pocket and the bottom bound by residues from the CLF. 
Other biochemical assays have proposed that the CLF is also responsible for decarboxylation 
of malonyl to generate the starter acetyl group for the PKS. As type II PKSs do not have an 
initiation module, the starter acetyl group needs to be generated from an extender malonyl. 
In the CLF, the absent KS active site cysteine is often replaced by a glutamine residue which 
has been shown to promote malonyl decarboxylation.101 KS proteins have been converted to 
malonyl-CoA decarboxylases by mutating the active site cysteine to a glutamine or by 
acetylating the cysteine residue with iodoacetamide.104,105 This domain has also been 
hypothesized to have AT activity as it contains the GHS AT motif and type II PKSs usually lack 
encoded ATs.106 However, this hypothesis has not yet been explored and many type II PKSs 
have been shown to rely upon malonyl-CoA:ACP transacylases (MATs) from the native FAS 
for ACP loading.107 
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1.4.5 Adenylating Enzymes (ANLs) 
The first ANL enzyme was identified during exploration of acetate activation in yeast.108 Berg 
showed that production of acetyl-CoA proceeded through an adenylate intermediate, as the 
purified enzyme required acetate for exchange of ATP and pyrophosphate (PPi) and could 
turn over synthetic acetyl-adenylate to produce acetyl-CoA. This observation led to the 
proposal of the now established mechanism of ANL enzymes used to activate carboxylic acids 
for nucleophilic attack (Figure 1.12).109  
 
Figure 1.12: Adenylation enzyme (ANL) reaction scheme beginning with attack of the carboxylic acid 
on the α-phosphate of ATP to form an adenylate intermediate with loss of pyrophosphate (PPi), then 
attack of a nucleophile (usually an amine, alcohol or thiol) on the adenylate to form the product amide, 
ester or thioester with release of AMP. 
These enzymes use ATP as the activating agent in two independent half reactions. The first 
half reaction is attack of the deprotonated carboxylic acid on the α-phosphate of ATP creating 
an adenylate intermediate; driven by liberation of the PPi side product. The nucleophile can 
subsequently attack the adenylate intermediate, releasing adenosine monophosphate 
(AMP), which is the driving force for the second half reaction. This approach is often used by 
nature to react weakly nucleophilic carboxylic acids to produce esters, amides, and 
thioesters. It is commonly used to create ACP and CoA thioesters, which is the predicted 
method of lauric acid activation in tambjamine YP1 biosynthesis. 
There are four identified structural classes of adenylating enzyme. Class I is the largest and 
best characterized of these families and comprises NRPS adenylation domains, acyl- and aryl-
CoA synthetases and luciferases.109,110 Class II and III are defined by the aminoacyl-tRNA 
synthetases and adenylation enzymes involved in NRPS-independent siderophore (NIS) 
synthesis. The newly proposed class IV group of ANLs are the pimeloyl-CoA synthetases 
(BioWs) involved in the biosynthesis of biotin in certain bacteria.111,112 
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Class I ANLs are those most commonly found in secondary metabolite biosynthesis and 
several structures in this class have been elucidated. The first structure to be solved was that 
of firefly luciferase113 which revealed that ANLs contain two domains, a large N-terminal 
domain connected to a smaller C-terminal domain via a disordered loop. The authors 
suggested that this protein would have to undergo conformational change to bind the 
substrate as no binding sites could be observed. These enzymes were also known to undergo 
drastic conformational changes during catalysis as detected by tritium exchange.114 The 
second structure from this class confirmed this hypothesis when an adenylation domain from 
the gramicidin synthase NRPS was crystallized with a phenylalanine adenylate intermediate 
bound. A 90° rotation of the two domains with respect to one another was observed, as 
compared to the luciferase structure.115 A crystal structure of bacterial acyl-CoA synthetase 
with a non-hydrolysable adenylate mimic (adenosine-5’-propylphosphate) and CoA showed 
that the N- and C-terminal domains are rotated ~180° between the adenylation 
conformation in gramicidin synthase and the observed thiolation conformation. As a result 
of this data, it was also suggested that the luciferase structure was not functionally relevant 
and that the adenylation and thiolation conformations are the two catalytic forms. 
These two binding modes were further explored when two enzymes, the human medium-
chain acyl-CoA synthetase (ACSM2A) and 4-chlorobenzoate CoA ligase were crystallized in 
both conformations.116,117 Figure 1.13 shows the structures of ACSM2A first bound to ATP 
then bound to butyryl-CoA and AMP. The ATP bound structure shows the adenylation 
conformation with the active site at the interface between the two dimers. The β and γ 
phosphates are coordinated by an essential Mg2+ ion and the yellow P-loop. This loop is 
conserved in all ATP binding proteins and is responsible for orienting the β and γ phosphates 
in the active site (conserved motif A3 in NRPS62 Z2X(S/T)(S/T/G)G(S/T)TGXPK, where Z is a 
medium hydrophobic amino acid). In ACSM2A, some of these residues can be seen forming 
hydrogen bonds to the γ phosphate, including the side chains of Thr221, Ser225 and Lys229 
and the backbone nitrogen atoms of Gly223 and Ser225 (Figure 1.13b).  




Figure 1.13: Crystal structures of ACSM2A showing the N-terminal domain (blue), the C-terminal 
domain (purple), the P-loop (yellow) and the hinge region (pink), PDB codes: 3C5E and 3EQ6.116 (a) Full 
structure with bound ATP (grey sticks) and Mg2+ (grey sphere) and (b) close up of the active site, (c) 
full structure with AMP and butyryl-CoA (grey sticks) and (d) close up of the active site.  
Another conserved motif (Motif A8, RX(D/K)X6G) makes up the hinge region between the two 
protein domains (shown in pink). This region is flexible and disordered to allow rotation of 
the domains but contains a conserved arginine residue (Arg461) which interacts with the 
ribose hydroxyls of ATP. The aspartic acid or lysine residue in this motif is the hinge residue 
and is essential for conformational change. 
The second ACSM2A structure displays the thiolation conformation bound to the reaction 
products, AMP and butyryl-CoA. Here, the C-terminal domain is rotated 135° with respect to 
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the N-terminal domain. This results in contraction of the nucleoside binding pocket so that 
ATP can no longer be accommodated and the P-loop has moved away from the active site. A 
CoA binding pocket has been created that runs along the interface of the two domains. The 
conserved glycine residue (Gly470) and other backbone amides of the hinge region hydrogen 
bond to the amide nitrogen of the 4’-PP. Similar observations, including a 140° rotation of 
the C-terminal domain were observed for 4-chlorobenzoate-CoA ligase.117 Mutants of 4-
chlorobenzoate-CoA ligase also revealed that areas important for adenylation and thiolation 
reactions are separate and these residues correlate well with the structural data.118 
 
1.4.6 Thioester reductases (TRs) 
The end of every natural product assembly line requires a chain release mechanism to 
liberate the covalently bound product from its attached ACP. The most commonly observed 
release mechanism for PKS and NRPS natural products is by TE, producing a natural product 
with a terminal carboxylic acid. However, several other release mechanisms have been 
identified.119 One of these is by TR, an enzyme that reduces the ACP-product thioester bond 
to discharge the extended product as an aldehyde (2e- reduction) or an alcohol (4e- 
reduction).120 TRs can be NADH121 or NADPH122 dependent, using the ‘hydride’ from this 
molecule to reduce the thioester. This is the mechanism by which the tambjamine YP1 
hydrocarbon tail is proposed to be separated from CoA, producing a fatty aldehyde. This 
aldehyde is ready for transamination by the downstream TA which is commonly found with 
TR domains in order to produce amine functional groups.121 
The first TR domain was discovered by Walsh and coworkers in Saccharomyces cerevisiae and 
is involved in the biosynthesis of lysine.123 This enzyme releases α-aminoadipate 
semialdehyde which can subsequently be transaminated to produce lysine in an analogous 
pathway to tambjamine YP1. Since its discovery several other natural product pathways 
containing TR domains have been identified producing a wide range of natural products such 
as the ones identified in Figure 1.14. 




Figure 1.14: Structures of natural products containing functional groups produced by a thioester 
reductase (TR) or a TR in combination with a transaminase (TA). These functional groups are indicated 
in purple. 
Four structures of TR domains have been solved, one from the Mycobacterium tuberculosis 
NRPS (producing glycopeptolipids),122 the myxalamid NRPS124 and two from carboxylic acid 
reductases (CARs).125 Each of these structures show the overall fold of the enzyme to be 
similar to the short chain dehydrogenases (SDRs). The N-terminal NAD(P)H binding region is 
a Rossman fold containing the GXXGXXG nucleotide binding motif, as can be seen for the M. 
tuberculosis NRPS TR (Figure 1.15a). The small C-terminal region is larger than those of the 
SDRs and this domain is more variable as it is responsible for binding the CP or CoA substrate. 
These enzymes also possess the SDR catalytic triad of threonine, lysine and tyrosine (Thr193, 
Lys232 and Tyr228 in the M. tuberculosis NRPS) which have been proposed to directly reduce 
the CP or CoA bound thioester (Figure 1.15b).122 Though some have been crystallized as 
dimers these proteins appear to be monomers in solution, consistent with the SDR 
structures. All TR structures display a helix-turn-helix (HTH) motif in the C-terminal substrate 
binding domain which is not present in SDRs. Molecular dynamics of the M. tuberculosis TR 
and its cognate PCP showed that the HTH motif is very dynamic and frequently associates 
with Helix II (the ‘recognition’ helix) of the PCP.124 PCP binding also stabilized the HTH motif 
and the C-terminal portion of the reductase in general. The 4’-PP arm of the PCP regularly 
connected with the catalytic triad, lending credence to this binding mode. 




Figure 1.15: (a) Crystal structure of a TR domain from Mycobacterium tuberculosis NRPS showing the 
catalytic triad (Thr, Tyr, Lys) in yellow and the helix-turn-helix (HTH) motif in orange, PDB code: 
4DQV122 and (b) the proposed mechanism of ACP or CoA thioester reduction adapted from Chhabra 
et al.122 
Though the TR crystal structures have implied a direct reduction of the thioester bond, 
biochemical assays with ACP reductases employed in the production of hydrocarbons, have 
suggested that the acyl chain is initially transferred onto a conserved cysteine residue prior 
to reduction. This mechanism was proposed by Lin et al. who observed a mass increase in 
Synechococcus elongatus ACP reductase after incubation with its cognate acyl-ACP.126 This 
hypothesis was supported by the observation that modification with iodoacetamide 
rendered the enzyme inactive. A similar study was also carried out with the acyl-ACP 
reductase from Nostoc punctiforme which showed the same mass increase.127 This study also 
identified the cysteine residue which accepts the acyl chain (Cys294) whose mutagenesis 
resulted in abolition of enzyme activity. Further research will have to be carried out to 
establish the exact mechanism of this class of enzyme. 
The TR domain from myxochelin (Figure 1.14) biosynthesis has also been extensively studied. 
Initial assays illustrated that this enzyme could produce not only the aldehyde but also the 
alcohol form of the product.128 This demonstrates that the TR can perform a two-step, 4e- 
reduction from thioester to alcohol which has also been observed in lyngbyatoxin 
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biosynthesis.129 This process was later determined to be a non-processive mechanism122 
according to both the enzyme kinetics and crystal structure that indicates the cofactor sits 
beneath the substrate in the active site. Therefore, the substrate must exit the active site 
before the cofactor can be recycled. This mechanism is consistent with the observation that 
several reductases can produce the alcohol product (as in the case of myxalamid128 and 
coelimycin121) but the aldehyde is the desired product as it is the substrate of a downstream 
TA. Therefore, the reductase and the TA are in competition for the aldehyde to produce 
either the alcohol or the amine. This can result in a mixture of these two products, as in the 
case of myxochelin A and B.130 
However, biochemical assays of Mycobacterium marinum CAR (mmCAR) show that some TRs 
only produce the aldehyde in a 2e- reduction and are not able to carry out the second step. 
The Leys group observed a structural reason for this phenomenon as the enzyme was 
crystallized in two different conformations. In the active conformation, an aspartic acid 
residue (Asp984) pointed out of the active site, forming contacts with buried residues and 
positioning NADH next to the Thr and Tyr residues of the catalytic triad. However, this residue 
can change conformation to point into the NADPH pocket causing surrounding residues to 
be disordered and the NADPH molecule to move away from the active site. This 
conformational change is linked to 4’-PP binding and the position of the small C-terminal 
domain, which is necessary to access the active conformation. This precludes the aldehyde 
from being turned over as it is no longer associated with the 4’-PP arm. The tambjamine YP1 
biosynthetic pathway may use either competition of the transaminase with the TR or indeed 
this conformational change mechanism to ensure that the desired amine product is produced 
rather than the alcohol product of the 4e- reduction. 
 
1.5 Pyridoxal 5’-Phosphate (PLP)-Dependent Enzymes 
1.5.1 PLP-Dependent Reactions 
PLP131 is a cofactor commonly employed by many different enzymes for the production of 
both primary and secondary metabolites. PLP exists as a free aldehyde in solution, but binds 
to enzymes via a Schiff base/imine with a conserved lysine residue.132 This covalent 
interaction, known as the internal aldimine, anchors the cofactor in the active site in its 
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resting state (Figure 1.16). It can exist in two tautomeric forms, the enolimine form when the 
alcohol oxygen is protonated and the ketoenamine form when the imine nitrogen is 
protonated (Figure 1.16).133  
 
Figure 1.16: The pyridoxal 5’- phosphate (PLP) cofactor and its protein bound, internal aldimine and 
amino acid bound, external aldimine forms. 
PLP dependent enzymes most often use amino acids as substrates and almost all function by 
a similar mechanism (excluding the PLP-dependent phosphorylases). The amino acid 
substrate enters the enzyme active site and undergoes transaldimination from the enzyme 
bound internal aldimine to form a non-covalently bound external aldimine (Figure 1.16). As 
PLP is a conjugated, positively charged system it has electron sink properties and can easily 
stabilize a negative charge on the amino acid substrate by forming a quinonoid intermediate. 
Therefore, this amino acid can undergo many different reactions such as: racemization, α, β 
or γ elimination or replacement, decarboxylation, aldol cleavage, cyclisation or 
transamination.134,135 Dunathan proposed that the reaction specificity depends on the 
orientation of the substrate, as the bond to be broken must lie perpendicular to the plane of 
the PLP ring.136 This conformation results in overlap of the PLP π-orbital with the σ-bonding 
orbital, allowing the PLP to act as the electron sink when the bond is broken.  
Though an abundance of PLP dependent enzymes have been identified and many of their 
crystal structures solved, they all fit into seven fold types.132 The vast majority of these are 
homodimers with some other higher order structures observed. The PLP active site sits at 
the dimer interface where the cofactor is held in place by a number of hydrogen bonding and 
electrostatic interactions from both monomers. Most PLP enzymes belong to the fold type I 
aspartate amino transferase (AAT)137 family, and these have many different functionalities. 
Fold types II, III and IV (the tryptophan synthase,138 D-amino acid aminotransferase139 and 
alanine racemase140 families respectively) also contain several different catalysts, though 
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these families are much smaller. Finally, fold types V, VI and VIII contain single functionalities 
including the afore-mentioned PLP-dependent phosphorylases which catalyze reactions 
through the PLP phosphate group. 
AAT was the first enzyme in the fold type I family to have its structure solved.137 The protein 
comprises of two domains with the large central domain accommodating a seven stranded 
β-sheet where catalysis occurs, common to all fold type I enzymes.132 The type I structures 
also have a second small domain usually comprising of the C-terminal and sometimes the N-
terminal region.  However, there is much less homology between the members in the N-
terminal section which has led to subgroups being defined within this fold. 
 
1.5.2 α-Oxoamine Synthases (AOSs)  
The AOS enzymes catalyze the PLP-dependent reaction between an amino acid and acyl-CoA 
or ACP (Figure 1.17). This creates a new carbon-carbon bond between the α-carbon of the 
decarboxylated amino acid and the acyl group, resulting in an α-oxoamine.  
 
Figure 1.17: General reaction scheme for the α-oxoamine synthases (AOSs) which produce α-
oxoamines from amino acids and acyl-CoAs or ACPs. 
AOSs are widely found in primary metabolism, contributing to the biosynthesis of heme, 
biotin (vitamin H) and the membrane components, sphingolipids.141–144 However, they have 
also been found in the biosynthetic pathways of secondary metabolites, including the 
prodiginines, saxitoxin (paralytic shellfish toxin) and fumonisin.27,145,146 In these pathways the 
enzymes act as an alternative chain release mechanism to the TEs and TRs, which is the 
function this enzyme is also expected to play in the tambjamine YP1 pathway. 
Biochemical analysis of this family of enzymes has shown a common mechanism for all but 
one of those studied (Figure 1.18). This is a six step mechanism beginning with (1) 
transaldimination of the internal aldimine to the external aldimine, (2) abstraction of the 
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amino acid α-carbon to form a substrate quinonoid, (3) attack of the carbanion on acyl-CoA 
or ACP, (4) decarboxylation of the amino acid to form the product quinonoid, (5) 
reprotonation of the product and (6) transaldimination back to the internal aldimine with 
release of the product.  
 
Figure 1.18: Mechanism of α-oxoamine synthase (AOS) reaction beginning with transaldimination, 
deprotonation of the amino acid, attack on acyl-CoA/ACP, reprotonation of the product and further 
transaldimination coupled to product release. 
This mechanism was elucidated for serine palmitoyl transferase (SPT), the first enzyme in 
sphingolipid biosynthesis, 5-aminolevulinate synthase (ALAS)147 involved in heme 
biosynthesis and 8-amino-7-oxononanoate synthase (AONS),142,148,149 a biotin biosynthetic 
enzyme. This reaction is irreversible due to the release of the carbon dioxide molecule. There 
is only one known exception to this mechanism, which is the reaction catalyzed by 
ketobutyrate ligase (KBL), a threonine metabolic enzyme.150 In this pathway, the 
decarboxylation step is not carried out, instead glycine is condensed with acetyl-CoA to 
produce a product containing the carboxyl group. Therefore, this is the only enzyme that 
catalyzes a reversible reaction. 
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The crystal structures of five of the enzymes from the AOS family have been determined, 
originating from various organisms (SPT,93,151,152 ALAS,153 AONS,142 KBL154,155 and CqsA,156 a 
biosynthetic enzyme producing a quorum sensing molecule). The crystal structure of S. 
paucimobilis SPT shown in Figure 1.19 illustrates the characteristic, homodimeric type I fold 
of PLP enzymes. The PLP binding sites located at the interface of the dimer contain several 
conserved residues that are involved in stabilization of the PLP cofactor.  
 
Figure 1.19: Crystal structure of S. paucimobilis SPT, PDB code: 2JG2151 (a) overall structure with 
monomers shown in dark and light blue and (b) active site with PLP (yellow sticks) internal aldimine 
and conserved residues responsible for orienting the cofactor. 
The SPT active site shows the universally conserved lysine residue (Lys265) which binds 
covalently to the PLP cofactor forming the internal aldimine. Asp231 is also conserved across 
all fold type I enzymes and hydrogen bonds to the pyridine nitrogen. Two histidine residues 
conserved only in the AOS family are His159 that engages in π-stacking with the PLP ring and 
His234 that forms a hydrogen bonding interaction with the PLP hydroxyl. Additionally, 
Thr262 forms a stabilizing hydrogen bond with the PLP phosphate group. Finally, the active 
site also contains Arg390 which does not appear to form a bond to the PLP while in its resting 
state but is universally conserved in AOSs. This residue hydrogen bonds to the amino acid 
substrate carboxylate, orienting the substrate in the active site with the Cα-H bond 
perpendicular to the PLP plane and is therefore essential for formation of the quinonoid 
intermediate.157 
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1.5.3 Transaminases (TAs) 
TAs employ PLP in a different reaction to catalyze the exchange of an amine group from one 
molecule to another (Figure 1.20).133,158 The amine donor is usually an amino acid such as L-
glutamic acid or L-alanine that is transformed to α-ketoglutarate or pyruvate, forming 
pyridoxamine 5’-phosphate (PMP) in the process. The amino acceptor must be a ketone or 
aldehyde to accept the amino group from PMP, introducing a new stereocenter to the 
molecule and recycling the cofactor. The transaminases have been exploited for biocatalytic 
use in several applications as they have excellent enantioselectivity and do not require 
expensive cofactors.159 
 
Figure 1.20: Transaminase (TA) reaction scheme beginning with removal of an amine group from the 
amine donor to produce PMP, then recycling of the cofactor back to PLP by transfer of the amine onto 
the amino acceptor.  
The ping-pong reaction mechanism of transaminases has been well established160–162 and is 
shown in Figure 1.21. As with other PLP enzymes, the first step of the mechanism is (1) 
transaldimination of the lysine-bound internal aldimine to the amino donor-bound external 
aldimine; (2) abstraction of the α-proton from the amino donor by the displaced lysine 
residue, forming the substrate quinonoid; (3) transfer of the proton to the PLP carbon to 
generate a PMP imine and (4) hydrolysis of the imine to yield PMP and the keto coproduct, 
finishing the first half reaction. The second half reaction begins with (5) condensation of the 
amino donor with PMP to form an imine; (6) generation of a product quinonoid by the 
deprotonation of the PMP; (7) protonation of the α-carbon to produce the product aldimine 
(this occurs stereospecifically on the re or si face of the PLP163) and finally (8) displacement 
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of the product from the active site by transaldimination with the conserved lysine residue. 
Each of the steps in this reaction are reversible resulting in an equilibrium between the 
products and reactants. 
 
Figure 1.21: Reaction mechanism for transamination by a PLP-dependent transaminase (TA). Steps 
include, transaldimination, deprotonation of the substrate, protonation of PLP, hydrolysis of the 
amino donor to yield PMP, condensation of the amino acceptor, deprotonation of PLP, protonation of 
the product and transaldimination to release the product. 
The TAs fall into two of the seven fold types identified for PLP enzymes. These are the fold 
type I and fold type IV structures. In fold type I, the TAs are grouped into four different 
subclasses based mainly on their differing N-terminal regions.158 TamH from the tambjamine 
YP1 cluster is predicted to be a class III TA. The class III TAs tend to utilize glutamic acid, 
alanine or more rarely other amino acids as the amine donor.133 They have dual substrate 
recognition with amine donors either utilizing different binding pockets or alternative protein 
conformations to the amino acceptors. This is due to the often large difference in structure 
between the donor and acceptor substrates. 
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Ornithine aminotransferase (OAT) was one of the first class III enzymes to be crystallized.164 
Its overall structure is very similar to all fold type I enzymes as it is a homodimer with a large 
central PLP binding region (Figure 1.22). The active site contains the PLP molecule bound to 
the conserved lysine residue (Lys292) observed in all PLP-dependent enzymes. It also shows 
many of the other conserved residues responsible for coordinating PLP in the active site in 
class III TAs.165–167  
 
Figure 1.22: Crystal structure of the H. sapiens OAT, PDB code: 1OAT164 (a) overall structure with 
monomers shown in pink and orange and (b) active site with PLP (grey sticks) internal aldimine and 
conserved residues responsible for orienting the cofactor. 
The class III TAs also contain the conserved aspartic acid residue (Asp263) that hydrogen 
bonds to the pyridine nitrogen, as in the AOS SPT structure. The OAT active site includes two 
amino acids that are conserved among class III TAs that interact with and stabilize the PLP 
phosphate group. The hydrogen bonds are formed between the phosphate oxygen atoms 
and the backbone nitrogen of Gly142 and the side chain of Thr322 (deriving from the 
opposite monomer). In this class, the PLP ring does not form a π-stacking interaction but 
instead appears to engage in a C-H-π interaction with the usually conserved Phe177 (or other 
aromatic amino acid) residue. Class III TAs also contain a conserved residue that binds to the 
PLP hydroxyl group, however, unlike the AOSs this residue is a glutamine (Gln266). Other 
active site amino acids are responsible for binding and orientating substrates, however, these 
are highly variable reflecting the wide substrate variability in this class. 
 
Page | 35 
 
 
1.6 Tambjamine YP1 Summary 
The tambjamine YP1 biosynthetic pathway contains at least 11 biosynthetic proteins with 
various catalytic roles (Figure 1.5). Many of these proteins belong to the previously discussed 
NRPS and PKS superfamily. However, this pathway also contains alternative chain release 
and tailoring enzymes such as the AOS TamD and the bispecific TR/TA TamH which are less 
commonly found in secondary metabolite biosynthesis. None of these enzymes have ever 
been characterised in vitro and many of the transformations postulated in the published 
biosynthetic pathway have not been observed for tambjamine YP1 biosynthesis or even 
other similar natural products such as the prodiginines. 
Further research into the mechanisms of the enzymes involved in tambjamine YP1 
biosynthesis is necessary to fill in the gaps in our knowledge of this biosynthetic pathway. It 
will also help to gain a better understanding of hybrid biosynthetic systems containing 
proteins from many and varied families. More in-depth knowledge of the specific enzymes 
and the substrates that they utilize will also be important in the generation of new 
biologically active molecules and potentially in the biocatalytic synthesis of many important 
organic molecules.  
  




The main aim of this work is to characterize the enzymes involved in the biosynthesis of 
tambjamine YP1 in vitro. The biosynthesis of the first bipyrrole intermediate, 4-hydroxy-2,2’-
bipyrrole-5-methanol (HBM), has had limited characterization and this intermediate has 
never been identified. Therefore the first part of this thesis aims to: 
• Clone, express and purify the TamD and TamF enzymes involved in the biosynthesis 
of the second pyrrole ring of HBM 
• Characterize these enzymes using mass spectrometry and identify each of the 
intermediates in the reaction 
• Identify the HBM product and monitor its formation 
• Probe the substrate specificity of the system for producing alternate bipyrroles and 
tambjamines 
The second part of this work aims to investigate the roles of TamA and TamH in the 
production of the tambjamine YP1 amine tail by: 
• Cloning, expressing and purifying the TamA and TamH enzymes 
• Characterizing these enzymes and their products by mass spectrometry 
• Confirming the role of the enzymes in the pathway 
• Exploring the substrate scope of each of these transformations 
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3 Biosynthesis of a Bipyrrole 
3.1 Introduction 
The biosynthesis of 4-hydroxy-2,2-bipyrrole-5-methanol (HBM) in Pseudoalteromonas 
tunicata from its basic building blocks is predicted to require five proteins encoded in the 
tam operon: TamE, TamB, TamG, TamF and TamD.50 These enzymes utilize L-proline, 
malonyl-CoA and L-serine to form the first bipyrrole intermediate in the tambjamine YP1 
pathway (Figure 3.1). 
 
Figure 3.1: Predicted pathway for the biosynthesis of HBM in P. tunicata from L-proline, malonyl-CoA 
and L-serine building blocks by TamE, TamB, TamG, TamF and TamD from the tam operon, adapted 
from Burke et al.50 
In the initial steps, L-proline is activated, then anchored onto the peptidyl carrier protein 
(PCP, TamB) by an adenylation enzyme (ANL, TamE). It is subsequently oxidized to the pyrrole 
form by the flavin adenine dinucleotide (FAD)-dependent dehydrogenase TamG, before 
being passed to TamF, a ketosynthase (KS) – chain length factor (CLF) didomain. Once the 
pyrrole is bound to the KS active site cysteine, TamF can catalyze the Claisen-like 
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condensation of malonyl-TamD ACP with the pyrrole. Finally, the TamD α-oxoamine synthase 
(AOS) uses L-serine and its ACP-bound thioester to catalyze a second Claisen-like 
condensation and release the extended chain. The terminal amine of this chain can attack 
the first ketone to cyclise and form HBM in a spontaneous reaction.  
Oxidation of a proline ring is a common biosynthetic route to pyrrole in the production of 
secondary metabolites, so these enzymes have been well characterized in other natural 
product pathways.13,55,168 However, the biosynthesis of the second pyrrole ring is an 
interesting and unique method of creating this moiety. Therefore, the aim of this study was 
to reconstitute the biosynthesis of the second pyrrole and show that HBM is the first 
bipyrrole intermediate formed in the tambjamine YP1 and thus also in other 4-methoxy-2,2’-
bipyrrole natural product pathways.  
To bypass the initial steps of activation and oxidation of proline and focus on the less well 
characterized transformations carried out by the interesting TamF and TamD didomain 
proteins, the pyrrole could be fed as a substrate mimic directly to TamF. Many KS enzymes 
accept N-acetylcysteamine (SNAC) thioesters attached to an acyl or peptide chain, a mimic 
of the terminal portion of 4’-phosphopantetheine (4’-PP).54,169,170 Utilizing the SNAC substrate 
mimic, the TamD and TamF reactions could be more easily probed and the biosynthetic 
pathway to HBM could be reconstituted in vitro.  
 
3.2 TamF Protein 
3.2.1 Bioinformatic Analysis 
Burke et al. suggested that the tamF gene encodes a KS enzyme that is likely to deliver the 
first pyrrole ring to malonyl-TamD via a Claisen-like condensation, elongating the chain by a 
two carbon unit.50 To investigate this hypothesis, the gene sequence was accessed from NCBI 
(2.3 kb, Appendix 1) and the corresponding protein sequence (Figure 3.2) showed that this 
gene encodes an 82 kDa protein. The protein sequence was analyzed using the Basic Local 
Alignment Search Tool (BLAST),51 which proposed that TamF contains not one but two KS 
domains, shown on the amino acid sequence in green (residues 1-398) and blue (residues 
411-759) respectively. The TamF sequence was also aligned with other enzymes carrying out 
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the same function in homologous natural product pathways for the biosynthesis of the 
prodiginines54,55 (RedX and PigJ, Appendix 2, carried out in ESPript171). These sequences show 
highest similarity in the C-terminal domain where by alignment with other similar known KSs 
(Mycobacterium smegmatis mycocerosic acid synthase (MAS), 5BP1;172 Moorea producens 
CurL, 4MZ0173 and Bacillus subtilis BacS, 5ENY174 in Appendix 3) the three conserved residues 
required for catalysis (Cys507, His637 and His675 in TamF, described in Section 1.4.4) were 
identified.  
 MSKQKYVISL LDAAIQRGDA ETGMLAVLTD LKQYAKYGIP PIYRNAINRM QLPLLELASE 60 
 LVTRNKEQLT GRTDVILCAH PGTEQQLQNH YRVTTNAMIR EIMAVTSPST QAQLAAFLPA 120 
 HSGSSHDKVG EMATTMATRI AQSCQLQGRA FAINSGDNSF AQAISIANDG LKSGKSDAVL 180 
 VLIANEVLTV SKDTPLAVGA VLLQRSDENH HQDKKAYLHA TQTVSQQGWP ASVDLAAQWY 240 
 MTSPVNTSQC EPIASSGLIA QPVAEDEQVL GCVAPLAVLL KWLDSDLSSP TMVLSPGQPN 300 
 EADIALVFGR EPLVFSQAVA PKVVINAQQV WFAGCQGVEA YWQGLNDDQG GMVNIVHEAL 360 
 ASSQVHVAQG ATFDSYYSNK AALLQPASRD KMGHVAVASV MQTVLESFPT VVLPTNAKGM 420 
 VITAGNLAPY AQRRVALLPM FTTLTLQIEE VLQANQEVSA QQLLQQWLQQ FAGDAHTKEQ 480 
 PTWMLSKQIA NFFSKPDWQQ LALEAACAGS IAAIDCAVNA ITSGRVDFAF VAAAEMPVNL 540 
 HDLCLCSSQQ MLSHSVIATF TEQADGFTPG EGCALILLSR VDATVHLPKL AVIEAIGSST 600 
 YSKSMIAPNS DGQVNAMRHA FTQTSLLPSD IEFVETHGTG TPIGDLVETQ ALSTVYQASN 660 
 ERPLNLGALK TQFGHTFAAA GLASVCKVAL CFEHQWQPHN LIRGVLRDQL QLPELNFNPL 720 
 CQGKPFLSPR GQRHAAVNGF GTGGVNYHLI ISDYCGSQV        759 
Figure 3.2: The TamF amino acid sequence (UniProtKB: A4C5W0) encoding a 82 kDa protein with the 
predicted chain length factor (CLF, green, 43 kDa) and the predicted ketosynthase (KS, blue, 38 kDa) 
with catalytic residues (Cys507, His637 and His675) in bold. 
In contrast, in the N-terminal domains the sequence similarity is low and these sequences 
also lack the KS catalytic residues, suggesting an alternate role for this domain. Inactive KS 
domains associated with an active KS often act as CLFs (Section 1.4.4) in type II PKSs that 
regulate the length of a growing natural product.103 These domains may also have other roles 
including malonyl decarboxylation and acyl transfer.104,106 Therefore, the N-terminal domain 
of TamF could be a CLF that ensures the extension reaction only occurs once before the 
product is released by the AOS domain.  
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3.2.2 Cloning, Purification and Characterization  
The tamF gene was cloned from P. tunicata D2 genomic DNA into a pET22b vector to express 
the protein with a C-terminal hexahistidine (6xHis) tag (83kDa, recombinant sequence in 
Appendix 4). Test expression was carried out in BL21 (DE3) E. coli cells at 30 °C and 16 °C for 
3 h, 5 h and ~18 h at 0.1, 0.5 and 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) 
concentrations to identify conditions producing the most soluble protein. No soluble protein 
was observed at 30 °C at any time points, however at 16 °C the soluble protein bands 
increased in size over the observed time period. This trend may be due to the increased 
stability of the enzyme at the lower temperatures at which P. tunicata grows.46 Figure 3.3 
shows the insoluble and soluble fractions for the 18 h expressions at the various tested 
temperatures and IPTG concentrations. The IPTG concentration did not appear to affect the 
amount of soluble protein produced, so gene expression was carried out with 0.1 mM IPTG 
at 16 °C for ~18 h in 2 L of BL21 (DE3) cells.  
 
Figure 3.3: SDS-PAGE analysis of the tamF pET22b construct ~18 h test expression in BL21 (DE3): (M) 
Marker (1) insoluble and (2) soluble fractions of expression at 30 °C with 0.1 mM IPTG, (3) insoluble 
and (4) soluble fractions of expression at 30 °C with 0.5 mM IPTG, (5) insoluble and (6) soluble fractions 
of expression at 30 °C with 1 mM IPTG, (7) insoluble and (8) soluble fractions of expression at 16 °C 
with 0.1 mM IPTG, (9) insoluble and (10) soluble fractions of expression at 16 °C with 0.5 mM IPTG and 
(11) insoluble and (12) soluble fractions of expression at 16 °C with 1 mM IPTG.  
The protein was subsequently purified from the cell lysate using nickel immobilized metal 
affinity chromatography (IMAC) which left the protein ~95% pure but with a small 
contaminating band (Figure 3.4, lanes 3-8). Therefore, TamF was further purified by gel 
filtration chromatography (GFC) on a HiLoad 16/60 Superdex S200 column to yield a 
symmetrical peak at an elution volume of 60.7 mL (Figure 3.4b). Comparison of this elution 
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volume to a calibration curve of the gel filtration column (Appendix 5) suggests the protein 
is in a dimeric form. Typical protein yields were 7 mg/L culture after the two purification 
steps.  
 
Figure 3.4: TamF purification (a) SDS-PAGE analysis: (M) marker, (1) insoluble and (2) soluble fractions 
of the cell pellet, (3-8) fractions from the nickel IMAC chromatography and (9-13) fractions from the 
Superdex S200 GFC and (b) chromatogram of Superdex S200 GFC showing peak elution at 60.7 mL, 
indicating that the protein is in dimeric form. 
Though FAS KS enzymes are usually homodimers,175–177 when a KS is associated with a CLF 
domain as in type II PKSs, the two domains form a heterodimer.102 In this configuration, 
catalysis occurs at the dimer interface, allowing the CLF to control the chain length. However, 
if the protein is already expressed as a fused heterodimer (as with TamF) this would suggest 
an α2β2 tetramer topology in the globular protein, which is an interesting and unexplored 
architecture. 
The mass of pure TamF was obtained using denaturing liquid chromatography electrospray 
ionization – mass spectrometry (LC ESI-MS). The resulting spectrum (Figure 3.5) shows 
several peaks, representing the many charge states of the protein. The molecular mass was 
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deconvoluted from this spectrum using the maximum entropy (MaxEnt) algorithm from 
smoothed and centroided data. The observed mass for TamF is 82555.2 Da ±1.6 Da which is 
consistent with the expected mass of 82554.3 Da calculated from the recombinant protein 
sequence (benchling.com).  
 
Figure 3.5: Denaturing LC ESI-MS spectrum of recombinant TamF with a deconvoluted mass of 82555.2 
Da ± 1.6 Da. 
 
3.2.3 SNAC Substrate Loading  
With pure protein in hand, the pyrrole moiety could be loaded onto TamF using a SNAC 
substrate analogue. This compound was produced by coupling reaction between N-
acetylcysteamine and pyrrole-2-carboxylic acid using 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) and 4-dimethylaminopyridine (DMAP, Figure 3.6). The pyrrole SNAC was 
obtained in 75% yield after purification by flash column chromatography and spectroscopic 
analysis was consistent with previously reported data.178  
 
Figure 3.6: Synthesis of pyrrole SNAC by coupling pyrrole-2-carboxylic acid and N-acetylcysteamine 
with EDC, DMAP and triethylamine at room temperature for 16 h. 
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The resulting pyrrole SNAC thioester (1 mM) was added to TamF (10 µM) before subjecting 
the protein to LC ESI-MS (Figure 3.7) to determine whether KS loading had occurred. 
 
Figure 3.7: Denaturing LC ESI-MS spectrum of recombinant TamF showing the 67 - 65+ charge states 
(a) as purified and (b) with 1mM pyrrole SNAC, the mass change is presented as a deconvoluted mass. 
After addition of pyrrole SNAC, the TamF peaks are shifted and have a new deconvoluted 
mass of 82648.7 Da ±1.2 Da. This value is 93.5 Da larger than the unmodified protein, 
consistent with the predicted mass (93.1 Da) of the addition of a pyrrole group. This data 
demonstrates that TamF can be easily fully modified with a SNAC thioester 4’-PP mimic in 
place of the PCP-bound substrate. Using SNAC substrate mimics elegantly avoids the 
expression and purification of three additional biosynthetic enzymes (TamE, TamB and 
TamG). 
 
3.3 TamD Protein 
3.3.1 Bioinformatic Analysis 
Following TamF modification, the KS requires malonyl-TamD to perform chain extension. 
Bioinformatic analysis of the TamD sequence (1.6 kb gene sequence in Appendix 6, protein 
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sequence in Figure 3.8) using BLAST indicates that the 58 kDa protein is comprised of two 
domains: an N-terminal ACP domain and a C-terminal AOS domain, which are shown on the 
amino acid sequence in purple (residues 1-97) and blue (residues 131-536) respectively. This 
is unusual within the AOS family as these enzymes tend to have discrete ACP partners or 
instead utilize CoA substrates.93,141,179 Between the two functional domains, there is also a 
linker region whose purpose is unknown and shows no similarity to other protein sequences. 
Regional order neural network (RONN) analysis (Figure 3.9) predicts a large disordered region 
of the protein spanning residues 93-129 (highlighted in blue on the TamD sequence). This 
sequence overlaps with the putative linker region between the two domains. As ACP domains 
are highly dynamic, this disordered linker could confer the necessary flexibility for the protein 
to move between the active sites of the upstream TamF enzyme and the TamD AOS domain.  
 MTDNKNTAIE QIHALVIDVV TEQTCYAESD LILDAPMEEG LGIDSIILAS IVSEIQKLFM 60 
 FETRLNTGSF NTIQALLDIC HNAMLSDAGV QKLAQLGLAA APQAVCVSSQ PEPEQRSTQA 120 
 QTMRDFVADG SPDLFSKVRK FDQFYKNQAE QGNFWYGMPL SSRCENRATI YDGYQKKERE 180 
 FLMFASNNYL GLANDPRVIK AICDATQKYG ATNTGCRLIG GTNHLHLELE ARLAAFKGRE 240 
 ACIVFPSGYS ANLGTISALT GPKDTVISDV YNHMSIQDGC KLSGAKRRIY KHNDMDSLEE 300 
 VLKGCSESEG GKLIVADGVF SMHGNIVKLP EMVRLARKYQ ARILIDDAHS TGVLGAMGSG 360 
 TAEHFNLKHE VDLELGTMSK TLAGMGGFVC GDKEVIEYLR FYANSYVFAA TIPANIAAGL 420 
 IQCIDIIEKE PERISRLRQN ADYLRSALQE CGFNTGDSES AVIPVVIGDE AVAMAMGHQV 480 
 RQQGMFCQTV VFPGVAVGDA RLRISVLAQH TKEDLDSAIE ILVNSAKTVK LPGFVA     536 
Figure 3.8: The TamD amino acid sequence (UniProtKB: A4C5W0) encoding a 58 kDa protein with 
predicted acyl carrier protein (ACP, purple) with its conserved DSX motif (bold) that becomes 4’-PP 
modified and predicted α-oxoamine synthase (AOS, blue) with conserved lysine residue (bold) that 
binds PLP. Highlighted in light blue is the regional order neural network (RONN) predicted disordered 
region. 
As with TamF, TamD has homology with enzymes from the analogous natural product 
pathways of the prodiginines (RedN and PigH, alignment in Appendix 7). However, these 
enzymes have two ACP domains at their N-termini as opposed to one, both of which can act 
as carriers for their respective AOS domains.55 The sequence alignment shows that the AOS 
domains of these enzymes are very similar, with large areas of identity and similarity. Though 
the ACP domains have less identity, the TamD ACP is most similar to the second ACP in the 
RedN and PigH enzymes. The alignment highlights the conserved DSI/V motif (bold, Figure 
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3.8) which should contain the conserved serine residue that becomes post-translationally 
modified with 4’-PP.  
 
Figure 3.9: Regional order neural network (RONN) analysis of the TamD sequence predicting a 
disordered region (residues 93-129) overlapping with the predicted linker between the two domains. 
Another alignment of TamD with RedN, PigH, Sphingomonas paucimobilis SPT, 2JG2,151 and 
E. coli AONS, 1DJE,180 (Appendix 8) highlights the many residues conserved within the AOS 
family (as identified in Section 1.5.2). These include the conserved lysine residue that binds 
PLP (Lys380, bold in Figure 3.8), several other residues involved in hydrogen bonding to the 
PLP ring and Arg503 which is essential for catalysis and formation of the quinonoid 
intermediate. 
 
3.3.2 Cloning, Purification and Characterization 
A tamD construct in pEHISTEV,181 previously prepared by Daynea Wallock-Richards was used 
to produce recombinant TamD with a Tobacco Etch Virus (TEV)-cleavable 6xHis tag (Appendix 
9). The gene was expressed with 0.1 mM IPTG at 20 °C for 4 h in 2 L of BL21 (DE3) cells. The 
protein was purified from the cell lysate (Figure 3.10) using nickel IMAC before subjecting it 
to cleavage by TEV protease. The TEV protease cleavage removed the 6xHis tag and a second 
nickel IMAC purification allowed cleaved TamD to be collected in the flow-through separated 
from the 6xHis tag, uncleaved TamD and TEV protease bound to the column. Finally, GFC 
purification provided a symmetrical peak at 64.0 mL with an excellent yield of 22 mg/L 
culture. The elution volume is that expected of the protein dimer, consistent with AOS and 
other PLP-enzymes which are almost all dimers.135  




Figure 3.10: TamD purification (a) SDS-PAGE analysis: (M) marker, (1) insoluble and (2) soluble 
fractions of the cell pellet, (3-6) fractions from the nickel IMAC chromatography, (7) wash of TEV-
cleaved TamD, (8) elution of uncleaved TamD and TEV protease (9-14) fractions from the Superdex 
S200 GFC, (b) chromatogram of Superdex S200 GFC showing peak elution at 64.0 mL, elution volume 
of a protein dimer. 
 
Figure 3.11: Denaturing ESI-MS spectrum of recombinant TamD with a deconvoluted mass of 58550.4 
Da ± 0.4 Da. 
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LC ESI-MS analysis of TamD showed the deconvoluted mass expected of the apo-protein at 
58550.4 Da ± 0.4 Da consistent with the calculated mass of 58550.3 Da (sequence in 
Appendix 9). This confirmed that the endogenous E. coli phosphopantetheinyltransferase 
(PPTase) is unable to modify TamD with 4’-PP during expression since this would have added 
a mass of 340 Da. 
  
3.3.3 Post Translational Modification 
As the protein was expressed in its unmodified form, the ACP domain requires post-
translational modification (PTM) with 4’-PP from CoA. In P. tunicata this PTM is likely to be 
carried out by a PPTase encoded in the tam operon (TamS). This enzyme was cloned in four 
different constructs with N- and C-terminal 6xHis tags, with no tag and as a maltose binding 
protein (MBP) fusion. Only the MBP fusion produced soluble protein, however, when the 
protein was purified it began to rapidly degrade and was unable to modify TamD.  
Instead, the well-known promiscuous PPTase Sfp from B. subtilis was employed (Section 
1.4.3).182 The Sfp reaction was carried out with CoA and Mg2+ at 4 °C for ~18 h which resulted 
in a TamD deconvoluted mass shift from 58550.4 Da ± 0.4 Da to 58890.9 ± 1.1 Da (Figure 
3.12a,b). This is an increase of 340.5 Da, consistent with the mass of 4’-PP (340.1 Da), 
indicating complete modification of TamD from its apo- to its holo-form.  
The TamD ACP also requires a malonyl unit bound to the 4’-PP before reaction with TamF. It 
is unclear where the malonyl group originates from in the native organism and how it is 
transferred onto the ACP. As some ACPs are able to self-acylate from a CoA derivative,183 
holo-TamD was incubated for ~18 h at 4 °C with 500 µM malonyl-CoA to determine if this 
ACP is able to self-acylate. There was a change observed in the spectrum (Figure 3.12c) as a 
peak appeared to the right of holo-TamD with a deconvoluted mass increase of ~87 Da. This 
is possibly malonyl-TamD (predicted mass Δ86 Da) but since the mass difference is small and 
the protein is large and highly charged, the changes are difficult to confirm with absolute 
accuracy.  




Figure 3.12: Denaturing ESI-MS spectrum of recombinant TamD showing the 56 - 54+ charge states (a) 
as purified, (b) after incubation with Sfp, CoA and Mg2+ at 4 °C for ~18 h and (c) after further incubation 
with malonyl-CoA at 4 °C for ~18 h. 
 
3.3.4 ACP Cloning, Purification and Characterization 
As ACP domains are small at around 10 kDa, it is much easier to track covalently bound 
modifications in these proteins as they have fewer charge states by ESI. A clone provided by 
Daynea-Wallock Richards of the TamD ACP domain included TamD residues 1-95 without an 
affinity tag. However, this domain was difficult to purify and lacked stability, as it would begin 
to precipitate after purification. Without a 3D structure of TamD, it is unclear where the 
domain boundaries lie, however, BLAST analysis suggested the ACP domain spans residues 
1-97 so extra residues may be necessary for protein stability. 
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Therefore, new TamD ACP clones of different lengths (with 3, 6 and 9 amino acid extensions, 
sequences in Appendix 10) were produced with TEV cleavable 6xHis tags: ACP95, ACP98, ACP101 
and ACP104 to determine if increasing chain length improved stability. Test expression of the 
new constructs (Figure 3.13) showed clearly that the ACP domain requires more than 95 
residues to produce a stable protein. No soluble protein can be observed for ACP95 whereas 
the majority is soluble for ACP98 and above. There was no significant difference in solubility 
after increasing the ACP length beyond 98 residues, suggesting the domain boundary is 
consistent with the BLAST prediction. 
 
Figure 3.13: SDS-PAGE analysis of test expression of TamD ACP constructs in BL21 (DE3): (M) Marker 
(1) insoluble and (2) soluble fractions of expression of TamD ACP95, (3) insoluble and (4) soluble 
fractions of expression of TamD ACP98, (5) insoluble and (6) soluble fractions of expression of TamD 
ACP101, (7) insoluble and (8) soluble fractions of expression of TamD ACP104. 
Therefore, the TamD ACP98 construct was used for further experiments and was expressed 
with 0.1 mM IPTG at 16 °C for ~18 h in 2 L of BL21 (DE3) cells. The ACP98 protein was purified 
by the same method as TamD: using nickel IMAC, TEV cleavage, a second nickel IMAC and 
finally GFC (Figure 3.14). GFC for this protein was carried out on a HiLoad 16/60 Superdex 
S75 column for low molecular weight proteins. TamD ACP98 GFC produced a peak at 72.7 mL, 
an elution volume expected of the protein monomer (calibration curve in Appendix 11). A 
monomeric protein is to be expected for a stand-alone ACP as the TamD protein is likely to 
dimerise via the AOS domain.135 The purification yielded only 2 mg/L culture of the TamD 
ACP however, this was sufficient for further analyses due to its small molecular mass 
(11 kDa). 




Figure 3.14: TamD ACP98 purification (a) SDS-PAGE  analysis: (M) marker, (1) protein after nickel IMAC 
purification, (2) after TEV protease cleavage, (3) wash of TEV protease cleaved TamD ACP98, (4-9) 3 mL 
fractions from the Superdex S75 GFC, (b) chromatogram of Superdex S75 GFC showing peak elution at 
72.7 mL, indicative of a protein monomer. 
 
Figure 3.15: Denaturing ESI-MS spectrum of recombinant apo-TamD ACP98 domain with a 
deconvoluted mass of 10997.0 Da ± 0.1 Da. 
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TamD ACP98 was also subjected to LC ESI-MS analysis and produced a spectrum (Figure 3.15) 
with a deconvoluted mass of 10997.0 Da ± 0.1 Da, which is consistent with the predicted 
apo-protein mass of 10997.5 Da. The protein mass spectrum now shows far fewer charge 
states which are better separated compared to the full-length TamD (Figure 3.11). 
 
3.3.5 ACP98 Post Translational Modification 
The TamD ACP98 could now be post-translationally modified with B. subtilis Sfp. The ACP 
domain was subjected to the same reaction containing Sfp, CoA and Mg2+ as the full-length 
enzyme with the equivalent result of complete modification to the holo-form. To speed up 
the modification process and to avoid having to express and purify another protein, TamD 
ACP98 was subsequently coexpressed with untagged Sfp protein. Coexpression resulted in an 
increase of the deconvoluted mass of TamD ACP98 to 11336.6 Da ± 0.4 Da (Δ 339.6 Da) 
consistent with the 340.5 Da increase expected of 4’-PP modification and apo-ACP98 is no 
longer observed (Figure 3.16).  
 
Figure 3.16: Denaturing ESI-MS spectrum of the recombinant TamD ACP98 domain showing the 7+ 
charge states (a) as purified and (b) after coexpression with Sfp, the mass change presented is a 
deconvoluted mass. 
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3.4 TamF and TamD ACP98 Claisen-like Condensation 
Previously, loading of TamF with its pyrrole substrate was achieved with pyrrole SNAC 
(reaction A) and holo-TamD ACP98 was produced in vivo.  However, TamD ACP98 also needs 
to be loaded with a malonyl group (reaction B) before Claisen-like condensation can occur 
between these two enzymes (reaction C, Figure 3.17). The malonyl loading reaction was 
previously attempted with full-length TamD by self-acylation (Figure 3.12). The reaction 
appeared to be very slow, as TamD was allowed to self-acylate for ~18 h and reached less 
than 50% conversion. However, many studies of type II PKSs have shown that they are reliant 
on malonyl-CoA:ACP transacylases (MATs) from their endogenous fatty acid synthase 
(FAS).99,102,184 These enzymes transfer the malonyl group from malonyl-CoA to ACPs, usually 
for fatty acid chain extension, but can also be employed in the type II PKS. Though P. tunicata 
is likely to have its own MAT enzyme, FabD, the E. coli MAT was available in the laboratory 
(provided by Alex Ekström). Therefore, this enzyme was employed to attempt catalysis of 
acyl transfer from malonyl-CoA to TamD ACP98 (reaction B, Figure 3.17).  
 
Figure 3.17: Reaction scheme for the loading of TamF with pyrrole SNAC (A), TamD ACP98 with malonyl-
CoA catalyzed by E. coli FabD (B) and the Claisen-like condensation between these Tam proteins to 
extend the chain (C).  
When holo-TamD ACP98 is incubated with only malonyl-CoA for 15 min, a very small malonyl 
peak appears at 11423.6 ± 0.1 Da (pink, Figure 3.18b) as compared to the control (Figure 
3.18a). Excitingly, with addition of E. coli FabD, around 50% of the ACP is converted to the 
malonyl form after the same period of time (Figure 3.18c). This demonstrates that the TamD 
ACP98 domain is a substrate for FabD and can be used to speed up the acylation reaction.  




Figure 3.18: Denaturing ESI-MS spectrum showing the 7+ charge state of (a) holo-TamD ACP98, (b) 
holo-TamD ACP98 after 15 min incubation with malonyl-CoA, (c) holo-TamD ACP98 after 15 min 
incubation with malonyl-CoA and E. coli FabD and (d) holo-TamD ACP98 after 15 min incubation with 
malonyl-CoA, E. coli FabD, TamF and pyrrole SNAC. 
Page | 54 
 
 
Once TamD ACP98 malonation was achieved, TamF and the ACP could be coupled in the fully 
reconstituted chain extension reaction. Addition of TamF and pyrrole SNAC to the reaction 
along with malonyl-CoA and E. coli FabD resulted in the appearance of a new peak (green, 
Figure 3.18d), with a deconvoluted mass 49 Da larger than the malonyl peak. This mass is 
consistent with malonyl decarboxylation and addition of the pyrrole ring from TamF, 
demonstrating that the system is functional and the first Claisen-like condensation between 
Tam enzymes has been achieved. Additionally, a second peak also appears (purple) which is 
smaller in mass than the malonyl peak. This deconvoluted mass is 43 Da larger than 
holo-ACP98 corresponding to acetyl-ACP (predicted mass: Δ 42 Da) which would be produced 
if TamF catalyzed an unproductive decarboxylation. The appearance of acetyl-ACP was 
unexpected because it suggests the reaction is not particularly efficient, with acetyl-ACP 
accounting for nearly 50% of the product. The acetyl-ACP product is not observed when the 
TamF reaction is carried out in the absence of pyrrole SNAC, illustrating that the KS must be 
acylated before it catalyzes decarboxylation.105 However, since the product was observed, 
the Claisen-like condensation was successful on the stand-alone ACP domain. Though this 
could not be monitored on full-length TamD, the assumption was made that this would also 
occur on the didomain protein. 
 
3.5 TamD Amino Acid Binding 
Once the TamD ACP is primed with the correct substrate, the AOS domain must bind L-serine 
before carrying out a Claisen-like condensation between the amino acid and the ACP-bound 
thioester (Figure 3.1). Binding of amino acid substrates to pyridoxal 5’-phosphate (PLP)-
dependent enzymes can be monitored through the ultraviolet (UV)/visible absorption profile 
of the PLP cofactor. PLP exists in two isoforms when bound as a Schiff base: the enolimine 
and ketoenamine forms (Figure 3.19).93  
 
Figure 3.19: Enolimine and ketoenamine forms of enzyme-pyridoxal 5’-phosphate (PLP) Schiff bases. 
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The enolimine form absorbs at approximately 350 nm and the ketoenamine form at 420 nm. 
After buffer exchange of the enzyme to remove any free PLP, the TamD PLP absorption peaks 
can be seen at 341 and 428 nm (Figure 3.20a). In its resting state, the TamD PLP equilibrium 
lies towards the ketoenamine form though a peak can still be observed for the enolimine 
isoform. Varied concentrations of L-serine (0-80 mM) were subsequently added to the 
enzyme and the change in the UV/Visible spectrum monitored.  
 
Figure 3.20: (a) UV/visible spectrum of TamD with varying concentrations of L-serine (0-80 mM) 
showing an increase and shift in the 428 nm peak to 426 nm and a decrease in the 341 nm peak with 
increasing concentrations of L-serine and (b) plot of the change in absorbance at 426 nm to calculate 
the dissociation constant (Kd) for L-serine (4.88 mM ± 0.35) with error bars indicating standard 
deviation of three repeats. 
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When L-serine is added to TamD, its PLP absorption spectrum shifts further towards the 
ketoenamine and away from the enolimine, so a concurrent decrease in the 341 nm peak 
and an increase and slight shift in the 428 nm peak to 426 nm is observed. The change in the 
UV/visible spectrum at different L-serine concentrations can then be used to calculate the 
dissociation constant (Kd) of TamD for L-serine (Figure 3.20b). This is calculated by plotting 
the change in the absorbance at 426 nm for each L-serine concentration. The points are fitted 
with a hyperbolic saturation curve and the asymptote of this curve is ΔAmax. The Kd is 
calculated as the concentration at ½ ΔAmax according to the equation in Section 6.8.1.  The Kd 
for L-serine was determined as 4.88 mM ± 0.35, which is in a similar range to the other AOS 
enzyme which utilizes L-serine, SPT, whose homologues typically have a Kd of approximately 
1 mM.93 Binding of other amino acids to TamD was also tested, starting with the substrate 
enantiomer, D-serine.   
Interestingly, D-serine has a slightly lower calculated dissociation constant than L-serine for 
TamD at just 3.97 mM ± 0.30. Though this is unexpected for an AOS to bind the D-enantiomer 
with similar affinity to the L-enantiomer, some AOSs, like the M. tuberculosis AONS can bind 
and turn over both L- and D-alanine.185  Therefore, it is possible that TamD can use both 
enantiomers to produce HBM.  
In addition to D-serine, five other amino acids were combined with TamD to determine their 
dissociation constants (L-alanine, glycine, L-threonine, L-aspartic acid and L-asparagine). If 
TamD is promiscuous and able to bind a variety of substrates, other unnatural amino acids 
may also be accepted in the reaction. This would result in the formation of novel bipyrroles 
which could be interesting building blocks for useful organic molecules. The tested amino 
acids produced no significant changes in the PLP spectra suggesting poor binding, so much 
so that the dissociation constants could not be calculated. For L-asparagine, the higher 
concentrations of the amino acid caused the protein to precipitate, resulting in the changes 
observed across the spectrum. The amino acid binding reactions indicate that TamD may 
have a narrow substrate specificity. This could be necessary in the cellular environment to 
ensure that only HBM is produced, as opposed to other bipyrroles which cannot be further 
modified by downstream Tam enzymes. 
 




Figure 3.21: UV/visible spectra of TamD with varying concentrations of (a) D-serine, (b) L-alanine, (c) 
glycine, (d) L-threonine, (e) L-aspartic acid and (f) L-asparagine. 
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3.6 In vitro HBM Biosynthesis 
MS analysis of each of the proteins and covalently bound intermediates involved in HBM 
biosynthesis has shown that the combination of TamF, pyrrole SNAC, TamD ACP, E. coli FabD 
and malonyl-CoA produce diketopyrrole-TamD ACP as in Figure 3.22. UV/visible analysis of 
the TamD protein in combination with its predicted amino acid substrate L-serine, indicated 
that this amino acid binds with the expected affinity to the AOS PLP domain. Therefore, the 
final step in the biosynthesis of HBM can be carried out, which is the second Claisen-like 
condensation of L-serine with the ACP-bound diketopyrrole thioester (Figure 3.22). This 
should release a linear product which subsequently cyclizes to yield HBM. 
 
Figure 3.22: In vitro biosynthesis of HBM using TamF, TamD, E. coli FabD, pyrrole SNAC, malonyl-CoA 
and L-serine.  
In the analogous Pig system from Serratia marcescens, Garneau-Tsodikova et al. were also 
able to follow the initial intermediates of these reactions via mass spectrometry or high 
performance liquid chromatography (HPLC) techniques, but they were unable to detect the 
final product, HBM.55 As such, HBM has never previously been detected in an in vitro 
reaction. One drawback to the reaction method used by Garneau-Tsodikova et al., was that 
malonyl groups were installed directly onto the ACP with Sfp, so the enzymes could only 
undergo one turnover, limiting the HBM concentration. Thus a different approach was 
developed overcoming this limitation with the use of the E. coli MAT FabD. 
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Another potential limitation is that HBM is a bipyrrole and is likely to have a higher 
absorbance than those typically used for HPLC. To pre-empt this problem, the reaction was 
initially monitored by scanning the UV/visible spectrum from 320 nm to 480 nm every 30 sec 
(Figure 3.23a). The scans showed a peak clearly increasing over time with a λmax of 
approximately 345 nm. The exact λmax is not clear as other components of the reaction begin 
to interfere in the spectrum below this wavelength.  
 
Figure 3.23: (a) UV/visible spectra of the HBM producing reaction containing TamF, TamD, E. coli FabD, 
pyrrole SNAC, malonyl-CoA and L-serine, at 30 sec intervals showing an increase in a peak at 345 nm, 
(b) HPLC traces at 345 nm showing the HBM peak increasing over time and (c) area under curve (AUC) 
of the HBM peak versus time for the control (without L-serine) and full reaction showing that the 
reaction has almost reached a plateau at 60 min. The error bars indicate the standard deviation of 
three repeats. 
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As a result of the UV/visible spectrum of the reaction, HPLC of the quenched reaction mixture 
was carried out using a reverse phase C18 column monitoring the eluent at a wavelength of 
345 nm at different time points (0-5 h). Over this period, a new peak was observed at 17.4 
min which appeared to correspond to the HBM product (Figure 3.23b). The reactions were 
repeated in triplicate and the area under the curve (AUC) calculated for each time point 
(Figure 3.23c) which produced a clear hyperbolic curve that reached a plateau around 60 
min.  
Since an analytical standard was not available for the HBM molecule, the HPLC peak believed 
to correspond to HBM, was analyzed by LC ESI-MS using a MicroTOF MS (Figure 3.24). An m/z 
of 179.0794 was detected, which is consistent with the predicted m/z of 179.0821 for 
C9H11N2O2 (error 15 ppm). This provides very strong evidence that the peak eluting at 
17.4 min with an absorbance maximum of 345 nm is indeed HBM. 
 
Figure 3.24: ESI-MS spectrum of the peak produced in the HBM biosynthetic reaction absorbing at 345 
nm containing the exact m/z of HBM (179.0794) which is consistent with the predicted m/z of 
179.0821 for C9H11N2O2 (error 15 ppm). 
 
3.7 Amino Acid Specificity of HBM Biosynthesis 
Once HBM production could be routinely monitored by HPLC, the amino acid specificity of 
TamD was probed to see if it matched that of the binding assays or whether it has wider 
substrate promiscuity. Reactions were set up in the same way as previously, substituting 
L-serine with other amino acids at the same concentration. If successful, these reactions 
would produce the alternative bipyrrole products displayed in Figure 3.25. L- and D-serine 
would both produce HBM as the stereochemistry at the α-carbon is lost when the linear 
product is deprotonated upon cyclisation.   




Figure 3.25: The bipyrrole HBM analogues that would be produced with alternative amino acid 
substrates in the bipyrrole producing reaction (Figure 3.22). Amino acid incorporation into the product 
is indicated in purple. 
A peak was observed at the same retention time for the natural substrate (L-serine) when 
using D-serine (Figure 3.26a) though the new peak had a smaller area than the results from 
reaction with L-serine after 5 h reaction time (Figure 3.26b). The MS spectra also show that 
a product with the same mass is produced for both L- and D-serine (Figure 3.27a,b). 
 
Figure 3.26: (a) HPLC traces at 345 nm of the reactions between TamF, TamD, E. coli FabD, pyrrole 
SNAC, malonyl-CoA and alternative amino acid substrates after 5 h incubation and (b) relative 
percentages of the area under the curve (AUC) compared to the native substrate (L-serine) and a 
control without amino acid. Error bars indicate standard deviation of three repeats. 
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However, the ability of this enzyme to accept both enantiomers is unusual with regards to its 
mechanism. All AOS enzymes studied thus far, first deprotonate the amino acid substrate at 
the α-carbon before catalyzing attack of the thioester (Section 1.5.2).142,157,186 This 
deprotonation only occurs when the proton on the α-carbon is perpendicular to the plane of 
the PLP-ring forming a Dunathan intermediate.136 Therefore the D-enantiomer often acts as 
an inhibitor for the enzyme as it cannot bind in the required orientation. However, M. 
tuberculosis AONS is also able to turn over L- and D-alanine so some AOS enzymes accept 
both enantiomers.185 A structure of TamD would be helpful to rationalize this observation as 
it would indicate how these enantiomers bind and are deprotonated in the active site. 
 
Figure 3.27: ESI-MS spectra of HBM analogues produced with (a) L-serine (b) D-serine and (c) L-alanine. 
Despite being unable to calculate a Kd for L-alanine in the binding assays, this amino acid 
appears to be utilized by TamD. A new peak is observed in the HPLC trace at 17.2 min (Figure 
3.26a), eluting just ahead of HBM. The average relative peak area is ~30% of the L-serine 
peak which suggests that L-alanine is reasonably well accepted in this reaction. MS analysis 
of the peak does not show the HBM m/z but instead the predicted m/z for the bipyrrole 
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without the hydroxyl group is detected (predicted mass for C9H11N2O: 163.0871 Da, 
observed: 163.0869 Da, Figure 3.27c). Glycine, L-threonine, L-aspartic acid and L-asparagine 
are not substrates for TamD as no other peaks were found in the HPLC traces. This agrees 
with the observations in the binding assays, suggesting that TamD does have a very narrow 
substrate specificity, probably in order to biosynthesize tambjamine YP1 with high fidelity. 
 
3.8 Pyrrole Specificity of HBM Biosynthesis 
In order to produce tambjamine analogues which may have improved or more specific 
biological activity, the TamF/TamD reaction system will need to accept different heterocyclic 
substrates. To probe the specificity of the TamF and TamD enzymes for the first heterocycle, 
synthesis of alternative SNAC molecules was undertaken. Several alterations to the 
heterocycle moiety of the SNACs were made: substitution of the pyrrole ring to a furan, 
expanding the ring size by one carbon to a pyridine, adding a halogen substituent to the 
pyrrole and finally substituting the pyrrole for an expanded indole ring system (Figure 3.28). 
The indole analogue was chosen because obatoclax, an indole derivative of this molecule is 
an important anti-cancer drug.187 
 
Figure 3.28: Synthesis of alternate SNAC molecules from carboxylic acids and N-acetylcysteamine to 
test the specificity of the TamF/TamD reaction system. 
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Three of the carboxylic acid substrates for the coupling reaction were commercially available, 
only the 4-bromopyrrole derivative was only available as an ethyl ester. The ester was 
hydrolyzed using potassium hydroxide in methanol and recovered in 94% yield. Coupling of 
the SNACs was performed using the same method as previously described for pyrrole-SNAC 
(NMR and MS data can be found in Appendix 12-15). Despite the 4-bromopyrrole and indole 
SNACs containing small impurities, the desired molecules were synthesized and it was 
assumed that these impurities would not affect the enzymatic reaction. 
The four new SNACs were tested for binding to TamF by LC ESI-MS. When the natural pyrrole 
SNAC is combined with TamF, a shift from one single peak to another occurs as the pyrrole is 
loaded onto the active site cysteine (Figure 3.29a,b and deconvoluted masses in Table 3.1).  
 
Figure 3.29: Denaturing LC ESI-MS spectrum of recombinant TamF showing the 66+ charge state (a) 
as purified, (b) with 1 mM pyrrole SNAC, (c) with 1 mM furan SNAC, (d) with 1 mM pyridine SNAC, (e) 
with 1 mM 4-bromopyrrole SNAC and (f) with 1 mM indole SNAC. 
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Protein Predicted mass Observed mass Δ Predicted Δ Observed 
TamF 82554.3 82555.2+/-1.6   
TamF + pyrrole 82647.3 82648.7+/-1.2 93.1 93.5 






















TamF + 4-bromopyrrole 82726.3 82728.0+/-1.5 172.0 172.8 
TamF + indole 82697.4 82693.9+/-1.9 143.1 138.7 
Table 3.1: Predicted and deconvoluted observed masses and mass differences (Da) for modifications 
of TamF. 
In contrast, when furan SNAC is employed as the substrate, two new peaks appear in the 
TamF spectrum (Figure 3.29c) corresponding to the addition of one and two furan moieties 
to the protein. This suggests that furan SNAC is reactive enough to modify other cysteine or 
lysine residues on the protein surface. Without further analysis of the protein, the positions 
of these moieties are unclear and may not include the active site cysteine. The same pattern 
is also observed for pyridine SNAC (Figure 3.29d). This substrate is even more reactive as 
higher intensity is observed for the twice modified protein than that of the once modified. 
The 4-bromopyrrole substrate modifies TamF only once, with a very small peak which may 
be a twice modified protein (Figure 3.29e). For the indole substrate, two peaks are detected, 
the first is the unmodified protein which is higher in intensity than the modified protein peak 
(Figure 3.29f).  
The ability of the alternate SNACs to modify the TamF protein follows the order of increasing 
reactivity: indole < pyrrole < 4-bromopyrrole < furan < pyridine. This trend is aligned with the 
chemical reactivity of these molecules and may not be dependendent on the enzymatic 
activity. As these molecules have aromatic rings conjugated to the thioester carbonyl, their 
reactivity increases with decreasing resonance stability. This is likely to be the reason why 
the furan and pyridine SNACs are able to modify the protein multiple times. 
In order to test whether the new heterocycles are binding at the TamF active site and can 
subsequently be turned over in a Claisen-like condensation, they were also incubated with 
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TamD ACP98, malonyl-CoA and E. coli FabD and subjected to LC ESI-MS (Figure 3.30). The 
deconvoluted masses of each of the TamD ACP modifications can be found in Table 3.2. 
 
Figure 3.30: Denaturing LC ESI-MS spectrum of recombinant holo-TamD ACP98 showing the 7+ charge 
state after 15 min incubation with malonyl-CoA, E. coli FabD and TamF (a) only, (b) with pyrrole SNAC, 
(c) with furan SNAC, (d) with pyridine SNAC, (e) with 4-bromopyrrole SNAC and (f) with indole SNAC. 
In the control reaction (Figure 3.30a), holo-TamD ACP is incubated with malonyl-CoA, FabD 
and TamF to show that without binding of a SNAC substrate to the TamF active site cysteine, 
decarboxylation does not occur, as no acetyl-ACP is observed. Though the furan and pyridine 
based substrates are able to react with malonyl-TamD ACP98 in the Claisen-like condensation 
(product peaks in green Figure 3.30c,d), it appears that these SNACs are so reactive that other 
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new peaks corresponding to addition of extra heterocycles to the TamD ACP also appear 
(particularly for the pyridine based substrate). 
Protein Predicted mass Observed mass Δ Predicted Δ Observed 
holo-TamD ACP 11337.6 11336.6 ± 0.4   
holo-TamD ACP + 
malonyl 
11423.6 11423.6 ± 0.1  86.0 87.0 
holo-TamD ACP + 
acetyl 
11379.6 11379.5 ± 0.1  42.0 42.9 
holo-TamD ACP + 
pyrrole product 
11472.7 11472.7 ± 0.1 135.1 136.1 
holo-TamD ACP + 
furan product 
11473.6 11473.5 ± 0.1 136.0 136.9 
holo-TamD ACP + 
pyridine product 
11484.7 11483.7 ± 0.5 147.1 147.1 
holo-TamD ACP + 4-
bromopyrrole product 
11551.6 Not observed 214.0 NA 
holo-TamD ACP + 
indole product 
11522.7 Not observed 185.1 NA 
Table 3.2: Predicted and deconvoluted observed masses and mass differences (Da) for modifications 
of TamD ACP98. 
In contrast, the 4-bromo and indole substrates are not transferred to the ACP by the Claisen-
like condensation. However, they do induce decarboxylation of malonyl-TamD ACP 
illustrated by the disappearance of the malonyl peak (pink) and appearance of the acetyl 
peak (purple). For the bromo-substituted pyrrole, the decarboxylation is complete and no 
more malonyl-ACP can be observed, whereas, the indole substrate only induces partial 
decarboxylation consistent with fully and partially modified TamF respectively. These data 
illustrate that both the bromo and indole substrates are bound in the active site of TamF (as 
they are able to induce decarboxylation105) but are not captured by the TamD ACP98 
carbanion after decarboxylation. The lack of 4-bromopyrrole condensation product is not in 
line with the reactivity of this thioester which should be slightly more reactive than the 
pyrrole thioester. Therefore, the absence of product may be due to the steric hindrance of 
the bromine substituent which inhibits the attack of the TamD ACP carbanion. Indeed, 
though some bromine substituted tambjamines have been identified, none of these contain 
the bromine in the 4-position. For the indole substrate, along with its inherent stability, steric 
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hindrance is likely to be a contributing factor for its low reactivity. This may prevent it from 
entering the TamF active site as well as inhibit attack of the TamD ACP carbanion. The 
TamF/TamD system would have to be engineered to accept bulkier substrates like the 4-
bromopyrrole and indole derivatives. 
The furan and pyridine SNAC substrates were also combined in reactions with the other 
components required for HBM production (TamF, TamD, E. coli FabD, malonyl-CoA and L-
serine). The reactions were monitored both by UV/visible spectroscopy and HPLC, however, 
neither of these produced the expected novel bicyclic systems. It is surprising that these 
substrates were not turned over by TamD, as the first Claisen-like condensation product 
could be observed. Since these molecules are so reactive and are able to modify the proteins 
unspecifically, it may be that the surface modifications inactivate TamD and thus no product 
can be formed. In this case, utilizing the preceding enzymes in the pathway and feeding the 
carboxylic acid substrates may be necessary to observe product formation. 
 
3.9 HBM Biosynthesis with Unfused TamD Domains 
As the TamD ACP domain was successfully truncated from the AOS domain, the AOS was also 
truncated from the ACP to reconstitute the activity of the two unfused domains. Fusion of an 
ACP and an AOS is unusual so this may be necessary due to the low binding affinity of the 
two domains for one another. A construct produced by Daynea Wallock-Richards without the 
first 95 residues of TamD (the ACP domain) left the linker region and AOS domain in pET22b 
with a C-terminal 6xHis tag (TamD AOSΔ95, sequence in Appendix 16). This protein was 
expressed in the same way as TamD in 2 L of E. coli BL21 (DE3) cells with 0.1 mM IPTG at 20 
°C for 4 h. The protein was purified by nickel IMAC and GFC (Figure 3.31), resulting in a broad 
peak eluting at 63.9 mL consistent with the expected protein dimer (calibration curve in 
Appendix 5). The final yield of this protein was excellent at 27 mg/L culture. 
LC ESI-MS showed TamD AOSΔ95 to have a deconvoluted mass of 49278.7 Da ±1.3 Da (Figure 
3.32) consistent with the calculated mass of 49268.7 Da. A smaller secondary peak can also 
be seen at each of the charge states with a mass increase of 230.3 Da, the calculated mass of 
PLP, which is still attached to some of the denatured protein. 




Figure 3.31: TamD AOSΔ95 purification (a) SDS-PAGE analysis: (M) marker, (1) insoluble and (2-3) 
soluble fractions of cell pellet, (4-11) 3 mL fractions from the Superdex S200 GFC, (b) chromatogram 
of Superdex S200 GFC showing peak elution at 63.9 mL, indicative of a protein dimer. 
 
Figure 3.32: Denaturing ESI-MS spectrum of recombinant TamD AOSΔ95 with a deconvoluted mass of 
49278.7 Da ± 1.3 Da. 
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The Kd of the TamD AOSΔ95 for L-serine was measured to ensure it had similar properties to 
the full-length enzyme. The Kd value for the AOS domain was the same order of magnitude 
as the full-length protein at 3.1 mM ± 0.1 (Figure 3.33).  
 
Figure 3.33: UV/visible spectrum of TamD AOSΔ95 with varying concentrations of L-serine (0-60 mM) 
showing an increase in the 426 nm peak and a decrease in the 347 nm peak with increasing 
concentrations of L-serine.  
The TamD AOSΔ95 subunit was subsequently used in the HBM assay with TamD ACP98 to 
determine whether the separated subunits are able to work together to produce HBM. The 
reaction was also monitored by HPLC (Figure 3.34a) showing that it does produce a peak at 
the same retention time (17.4 min) as the reaction with the full-length protein. However, 
analysis of the AUC (Figure 3.34b) shows that much less HBM is produced over the 5 h time 
period when using the two independent domains. Fusion of the domains clearly increases 
the rate of reaction as it holds the two domains in place and reduces the freedom of 
movement. Gene fusion is not only used by nature to improve product formation but has 
also been used biocatalytically to improve turn over and rates of reaction.188 
 




Figure 3.34: Reactions for producing HBM with TamD ACP98 and TamD AOSΔ95 in place of full-length 
TamD containing TamF, E. coli FabD, pyrrole SNAC, malonyl-CoA and L-serine (a) HPLC traces at 345nm 
showing the HBM peak increasing over time and (b) area under curve (AUC) for the HBM peak versus 
time for the reaction with the full-length protein as well as the separated subunits and the control 
without L-serine. The error bars indicate standard deviation of three repeats. 
 
3.10 HBM Protein Structural Studies 
3.10.1 TamF X-ray Crystallography 
TamF is one of only a few characterized KS-CLF dimers and is particularly interesting as it is a 
fusion protein which may form an α2β2 tetramer. Therefore, it would be very interesting to 
obtain a crystal structure of this enzyme to shed light on the CLF mechanism of action. TamF 
was prepared for crystal trials by purification as previously reported, followed by 
concentration of the protein to 12 mg/mL by Vivaspin membrane. Crystallization of this 
protein mixture was subsequently attempted in five 96-well plate sitting drop screens 
prepared using a Gryphon robot (in collaboration with Dr. Stephen McMahon and Prof. Jim 
Naismith, University of St. Andrews). Two of the screens were the commercially available 
WIZARD and JCSG+, along with three bespoke University of St. Andrews polyethylene glycol 
(PEG) based screens PEGS1-3. From the five screens, two hits were identified for TamF 
crystals: PEGS1 A9 - 51.12% PEG400, 100 mM HEPES pH 7.5, 40 mM magnesium formate and 
PEGS2 H9 - 34% PEG400, 100 mM MOPS pH 6.5, 120 mM calcium acetate, 0.02% BOG. 
Though these crystals were small and amorphous, optimization plates were nonetheless 
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created from these conditions, varying the pH and concentration of each of the additives. 
However, all the crystals produced were of a similar shape and size and the best diffracting 
crystal was only able to diffract to 20 Å.  
The crystals from PEGS1 H9 were subsequently used as seed for four new screens (PEGS1-3 
and JCSG+). These screens produced more hits with larger and more defined crystals; the 
best conditions identified are summarized in Table 3.3. Five crystals from each of these wells 
were shot on the St. Andrews X-ray source however, the best diffracting crystal diffracted to 
only 7.5 Å. As this is not enough to characterize the structure of a protein, no further 
crystallography was attempted for TamF. 
Screen Well Conditions 
JCSG+ A12 20% (w/v) PEG3350, 200 mM KNO3 
PEGS1 B12 34% (w/v) PEG3350, 100 mM bicine pH 9.5, 30 mM ammonium tartrate 
PEGS3 C2 24% (w/v) PEG4000, 100 mM CHES pH 9.0, 300 mM LiCl 
Table 3.3: Conditions of TamF crystals that were shot on the University of St. Andrews X-ray source. 
 
3.10.2 Full-length TamD X-ray Crystallography 
TamD is also an interesting target for crystallography as it is an unusual ACP-AOS didomain 
and it is one of only a few AOS domains that accept aromatic substrates. A structure of this 
enzyme would not only give an insight into the interaction between an ACP and an AOS 
domain but it may also shed light on the specificity of AOS enzymes in general. Therefore, 
TamD crystal trials were carried out by the same method as TamF. The protein was 
concentrated to 10 mg/mL and sitting drop crystal trials were set up using a Gryphon robot. 
Eight different screens were utilized: WIZARD, JCSG+, PEGS1-4 and two other bespoke 
University of St. Andrew’s screens, SA19 and SA20. For TamD there were several conditions 
which produced crystals however, these were all thin needle-like crystals which are difficult 
to mount for crystallography. The best conditions for the TamD crystals are outlined in Table 
3.4. Despite optimizing around all of these conditions and using these crystals for seeding in 
new screens, no improved crystals were obtained.  
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Screen Well Conditions 
WIZARD F6 20% (w/v) PEG3000, 100 mM Tris/HCl pH 7.0, 200 mM calcium acetate 
JCSG+ A5 20% (w/v) PEG3350, 200 mM magnesium formate 
PEGS1 A6 
20.29% (w/v) PEG4000, 100 mM MOPS pH 7.0, 110 mM magnesium 
formate 
PEGS1 A8 12.6% (w/v) PEG8000, 100 mM HEPES pH 8.0, 190 mM KCl 
PEGS3 G6 33.19% (w/v) PEG3350, 100 mM MOPS pH 7.0, 120 mM CaCl2 
Table 3.4: Conditions of the best TamD crystals that were used to further optimize the crystallization 
conditions. 
 
3.10.3 TamD AOS X-ray Crystallography 
The presence of a flexible linker region between the two TamD domains could explain the 
difficulty observed in obtaining TamD crystals. Since the two domains are dynamic with 
respect to one another, this could make uniform crystal packing less accessible. Therefore, 
TamD AOSΔ95 crystal trials were also carried out without its ACP partner. 
As before, eight screens were set up: WIZARD, JCSG+, PEGS1-4 and SA19-20. Though more 
conditions were identified containing AOSΔ95 crystals than for the full-length protein, these 
were still needles. However, some needles were longer and thicker so the best conditions 
(Table 3.5) were shot on the St. Andrews X-ray source.  
Screen Well Conditions 
WIZARD F6 20% (w/v) PEG3000, 100 mM Tris HCl pH 7.0, 200 mM calcium acetate 
PEGS1 A8 12.6% (w/v) PEG8000, 100 mM HEPES pH 8.0, 190 mM KCl 
PEGS3 G6 33.19% (w/v) PEG3350, 100 mM MOPS pH 7.0, 120 mM CaCl2 
PEGS3 H5 18.29% (w/v) PEG3350, 100 mM MOPS pH 6.5, 220 mM Li2SO4 
SA20 A5 22.78% (w/v) PEGMME2k, 100 mM MES pH 6.0, 130 mM Li2SO4 
SA20 G2 
14.69% (w/v) PEGMME5k, 100 mM sodium cacodylate pH 7.0, 70 mM 
calcium acetate 
Table 3.5: Conditions of TamD AOSΔ95 crystals produced in Tris buffer that were shot on the University 
of St. Andrews X-ray source. 
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However, unfortunately, again none of these crystals produced any diffraction. The crystals 
were also colourless, suggesting a lack of PLP which results in bright yellow protein. TamD 
and its subunits were purified in Tris buffer, an amine that binds to PLP and can remove the 
cofactor from proteins that do not bind it tightly. Therefore, the buffer was swapped from 
Tris to 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) to combat this potential 
problem and determine if it has an effect on crystal formation.  
Six crystal trials were set up with the protein in HEPES buffer: WIZARD, JCSG+, PEGS1-4. 
Despite changing the buffer, the crystals appeared very similar in the new screens. 
Nonetheless, crystals from the conditions in Table 3.6 were also shot on the X-ray source but 
none of these diffracted either. 
Screen Well Conditions 
WIZARD F6 20% (w/v) PEG3000, 100 mM Tris/HCl pH 7.0, 200 mM calcium acetate 
JCSG+ D6 20% PEG8K, 50 mM Tris pH 8.5, 200 mM MgCl2 
PEGS1 D11 16% PEG3350, 100 mM MOPS pH 7.0 
PEGS2 C10 
28% PEG3350, 100 mM CHES pH 9.0, 180 mM potassium thiocyanate, 
3% methanol 
PEGS3 F11 27% PEG6K, 150 mM magnesium formate 
Table 3.6: Conditions of TamD AOSΔ95 crystals produced in HEPES buffer that were shot on the 
University of St. Andrews X-ray source.  
Though the TamD AOSΔ95 construct does not include the ACP domain which is flexible with 
respect to the AOS domain, it still contains the flexible and disordered linker region. The 
presence of the disordered region on its own may still affect the ability of the protein to 
crystallize. Therefore, new AOS constructs were created, attempting to cut back the linker 
region to where the AOS domain begins. As the AOS domain is predicted to begin at residue 
131 according to BLAST analysis, four constructs were made of increasing length: AOSΔ131, 
AOSΔ128, AOSΔ125 and AOSΔ122 (sequences in Appendix 17). 




Figure 3.35: SDS-PAGE analysis of test expression of TamD AOS constructs: (M) Marker (1) insoluble 
and (2) soluble fractions of expression of empty plasmid, (3) insoluble and (4) soluble fractions of 
expression of TamD AOSΔ122, (5) insoluble and (6) soluble fractions of expression of TamD AOSΔ125, (7) 
insoluble and (8) soluble fractions of expression of TamD AOSΔ128, (9) insoluble and (10) soluble 
fractions of expression of TamD AOSΔ131. 
Figure 3.35 shows that none of the constructs with the truncated linker region are soluble, 
as they all contain large bands in the pellet fraction and none in the supernatant. This gives 
some insight into the protein structure, suggesting that the linker region may have a more 
important function for the AOS domain than previously anticipated. However, due to the 




HBM has been successfully biosynthesized for the first time in an in vitro reaction using 
enzymes from the tam cluster. SNAC molecules were synthesized and used to load substrates 
onto the TamF protein without the need for the preceding enzymes in the pathway, allowing 
a more facile method of studying bipyrrole formation. The TamD protein and its ACP subunit 
were post-translationally modified with their critical 4’-PP arms by the PPTase Sfp, both in 
vitro and by in vivo coexpression. TamD was further loaded with its malonyl substrate using 
E. coli FabD in an innovative approach that resulted in the ability of this system to carry out 
more than one turnover. Finally, all the components of the HBM forming reaction were 
combined and an HPLC method was developed to monitor formation of the bipyrrole. This 
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has not only proven that HBM is formed in the tambjamine YP1 pathway but is also an 
important step in elucidation of the biosynthetic pathway of other natural products, such as 
the prodiginine family (Figure 1.2).  
Both the amino acid and heterocyclic substrate specificity of the HBM forming reaction have 
also been explored. Though the TamD protein can accept L-alanine to form a novel bipyrrole, 
this protein appears to have very little promiscuity and would require engineering to accept 
other amino acids. Though no alternative heterocycles were accepted in the reaction system, 
utilizing these substrates has shed light on the constraints of the TamF catalyzed Claisen-like 
condensation. Indole and 4-bromopyrrole substrates appear to be too bulky to be turned 
over in the decarboxylative condensation. Whereas, the other alternative heterocycles 
(furan and pyridine) are too reactive in SNAC form so may inactivate the enzymes. 
Though crystal structures of TamF and TamD were not obtained, some insight into the TamD 
fold has been gained through the cloning of various truncations. The expressed protein 
solubility indicates that the domain boundary for the ACP is around residue 98 of the TamD 
sequence and that the AOS domain requires its disordered linker region for stability. Further 
efforts to obtain a 3D structure of these enzymes will not only reveal the details of these 
interesting fusions but will also allow mutagenesis of these enzymes to accept a broader 
substrate range. This structure could be achieved by homology modelling or by 
crystallography, utilizing a homologous enzyme from an alternative organism. 
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4 Amine Biosynthesis 
4.1 Introduction 
The P. tunicata tambjamine YP1 biosynthetic pathway is predicted to be convergent, 
containing two fragments that are synthesized independently, then combined. The first is 
the bipyrrole moiety with an aldehyde (HBM, discussed in Chapter 3) which is ready to be 
condensed with a long chain amine. The biosynthetic route to the alkyl amine fragment was 
postulated by Burke et al.50 to be initiated by the adenylation of a C12 fatty acid and its 
attachment to coenzyme A (CoA) as a thioester (Figure 4.1). The CoA thioester would be 
subjected to dehydrogenation by the flavin adenine dinucleotide (FAD)-dependent TamT 
enzyme installing the 3,4-alkene. Finally, the bifunctional TamH would reduce the CoA 
thioester and transaminate the product aldehyde to generate the final alkyl amine. 
 
Figure 4.1: Predicted biosynthetic pathway to the alkyl amine of tambjamine YP1 adapted from Burke 
et al.50 This pathway begins with the adenylation of C12 fatty acid by the ANL AfaA, followed by 
attachment of the fatty acid to CoA. The acyl thioester is likely to be dehydrogenated by TamT to give 
the 3,4-alkene and then reduced and transaminated by TamH to give the alkyl amine, though the order 
of the TamT and TamH reactions are unknown. 
Burke et al. hypothesized that the activation reaction would be carried out by AfaA, an 
adenylation enzyme (ANL) that is a member of the fatty acid CoA ligase (FACL) family and is 
encoded outside the tam operon. FACL enzymes adenylate fatty acids using ATP to activate 
the carboxylic acid for nucleophilic attack by the terminal thiol of CoA.189 Deletion of the afaA 
gene aborted biosynthesis of Tambjamine YP1. However, FACLs have many and varied roles 
in the cell, affecting fatty acid catabolism, protein acylation and even transcriptional 
regulation,189 any of which could influence the biosynthesis of secondary metabolites.  
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The aim of this study is to elucidate the biosynthetic route to the tambjamine YP1 tail. Though 
AfaA could play a role in the biosynthesis, several open reading frames (ORFs) within the tam 
operon have not been designated functions within the biosynthetic pathway, so one of these 
could fulfill the role of activating C12 fatty acid for tambjamine YP1 biosynthesis. One in 
particular (tamA) is designated as an adenosine monophosphate (AMP)-ligating enzyme, so 
the enzyme encoded by this gene will be studied in more detail along with the other 
predicted enzymes that are involved in this pathway. 
 
4.2 The TamA Protein 
4.2.1 Bioinformatic Analysis 
The gene encoding the predicted AMP-ligating enzyme TamA, was accessed from NCBI (2 kb, 
Appendix 18). BLAST analysis of the TamA protein sequence suggested that like several 
others in the operon, this 75 kDa enzyme contains two domains. The N-terminal domain 
showed highest similarity to FACL enzymes and the C-terminal domain to an acyl carrier 
protein (ACP, Figure 4.2, shown on the sequence in blue and green respectively).  
 MQCEASSLID LLAFDARNKP SQEVFRFVSD NGESEASYDY QTLSQEISRI AIGLQALIKT 60 
 SHNQDQALIV LPQGVQFVTA FYGCMAANVI AVPSFPPKSQ LQIERLQFAI TDLGNPIVIT 120 
 NRDILPKLQE HIALDSVRWL LIEDLASVIA QPLSDFRTHE HSIALLQYSS GTTGKPKGVI 180 
 ITNQNIMENS ELIRQSFGHK EDHTRMMLWL PPHHDMGLVG GVMQGVYTGY PTLLMPTDLF 240 
 LRSQYRWLKA VSDYRATTTG APNFAYELAV KNIRESRLAE LDLSSLENLF CGAEPINSHS 300 
 INQFLDKFAP CGLKPEAFLP CYGMAEATLM VSGKPHGQQY KQLCIDEPLL KHGMVKPLNT 360 
 PNAHSLWLVS SGVVHSSLQA RIVNPETGTE VAQGQVGEIW LQGSSISPGY WQDAERTAIN 420 
 FGLPLAGYEE TFHRTGDLGF YHQDELFITG RLKEVVIIRG ANFYPQDLEY ETTLAFPELN 480 
 NCRSAAFSVP KEGKEQLIMA IEVPRNVTEF NQYAKILNGR LVERFGIRAD IILFLPRKTI 540 
 KITSSGKLQR VAIKKAYEEQ QLPVYFQYQL QGEQIAPREV SLDISNQDSV AKWLVARVSE 600 
 LTGVAIAQIS EHEPLTNVGL DSVLAMEILF RLEQQTGVYL APDVLYSCNT PSLLAEQIIK 660 
 VAGNVAEKEL NLSC             674 
Figure 4.2: The TamA amino acid sequence (UniProtKB: A4C5W5) encoding a 75 kDa protein with the 
predicted adenylation domain (ANL, blue, 64 kDa) and the acyl carrier protein (ACP, green, 10 kDa) 
with the conserved DSX motif in bold. 
As ACP is the protein analogue of CoA (detailed in Section 1.4.2), it is possible the TamA ANL 
domain could adenylate fatty acids for transfer to its attached ACP instead. Fatty acid AMP 
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ligases (FAALs) are a class of enzymes that transfer their fatty acids to ACP substrates rather 
than CoA.190–193 They differ only slightly in structure to FACLs by the addition of an insertion 
loop that blocks CoA from the active site but is released upon ACP binding. In order to 
determine if the TamA adenylation domain falls into this category, it was aligned with known 
FAAL enzymes from the PDB (Mycobacterium smegmatis FadD32, 5D6J;191 Mycobacterium 
tuberculosis FadD32, 5HM3;192 Mycobacterium marinum FadD32, 5EY9;193 Legionella 
pneumophila FAAL, 3KXW,190 alignment in Appendix 19). It shares around 30% identity with 
these enzymes as well as containing the FAAL insertion loop. Therefore, TamA could be a 
FAAL which transfers C12 fatty acids to its fused C-terminal ACP domain (Figure 4.3), priming 
them for the downstream production of the amine tail. Alignment of the ACP with its closest 
homologues in the PDB (Actinoplanes friulienses LipD, 2N98;194 Burkholderia ambifaria 
Bamb_5917, 5MTI and the Aspergillus parasiticus norsolorinic acid synthase (NSAS), 2KR5195) 
identified the conserved DSX motif where 4’-phosphopantetheine (4’-PP) modification 
occurs but showed little other similarity. 
 
Figure 4.3: Predicted pathway of C12 fatty acid activation by TamA, beginning with adenylation of the 
fatty acid using ATP by the ANL domain, then post-translational modification of the TamA ACP and 
transfer of the fatty acid to the phosphopantetheine (4’-PP) thiol. 
This enzyme appears to be a better candidate than AfaA for activating C12 fatty acids for 
integration into Tambjamine YP1 as it is contained within the tam operon. It would also retain 
the activated fatty acid covalently bound to the enzyme instead of releasing it as a small 
molecule. This would siphon C12 fatty acids out of the primary fatty acid pool, directly into 
the Tam pathway instead of allowing C12-CoA to be metabolized by other enzymes. 
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4.2.2 Cloning, Purification and Characterization 
The tamA gene was cloned from P. tunicata D2 genomic DNA into the pEHISTEV vector to 
express the protein with a TEV-cleavable N-terminal 6xHis tag (sequence in Appendix 21). 
This gene was expressed in 2 L of BL21 (DE3) E. coli cells at 16 °C for ~18 h with 0.1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG). TamA was purified from the cell lysate (Figure 
4.4) by nickel immobilized metal affinity chromatography (IMAC). The 6xHis tag was 
subsequently cleaved by tobacco etch virus (TEV) protease, then purified by a further nickel 
IMAC and gel filtration chromatography (GFC). The GFC was performed on a HiLoad 16/60 
Superdex S200 column, resulting in a peak at 76.4 mL, the expected size of a protein 
monomer (calibration curve in Appendix 5). This is consistent with other FAAL proteins which 
are members of the type I adenylation domain superfamily and are generally 
monomers.109,110 The final yield of the purified TamA protein was 8 mg/L culture.  
 
Figure 4.4: TamA purification (a) SDS-PAGE analysis: (M) marker, (1) protein after nickel IMAC 
purification, (2) wash of TEV-cleaved TamA, (3) elution of uncleaved TamA and TEV protease (4-9) 3 
mL fractions from the Superdex S200 GFC, (b) chromatogram of Superdex S200 GFC monitored at 280 
nm, showing peak elution of the protein at 76.4 mL, indicating that the protein is monomeric. 
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LC ESI-MS analysis (Figure 4.5) showed that TamA, like TamD, was also expressed in its apo-
form without 4’-PP attached to its ACP. The deconvoluted mass was 75271 ± 2 Da consistent 
with the calculated mass of 75270 Da.  
 
Figure 4.5: Denaturing ESI-MS spectrum of recombinant TamA with a deconvoluted mass of 75271 ± 
2 Da consistent with the predicted mass of 75270 Da. 
 
4.2.3 Fatty Acid Selectivity 
The promiscuous PPTase Sfp182 from B. subtilis which is commonly employed to install 4’-PP 
on various ACPs (described in Section 1.4.3) was also used to post-translationally modify 
TamA. The TamA protein was incubated with Sfp, Mg2+ and CoA for ~18 h at 4 °C to attempt 
the phosphopantetheinylation reaction. Figure 4.6 shows the complete shift of TamA from 
one mass to another after the 18 h reaction. The mass of 4’-PP is 340 Da but the observed 
shift was much larger at 513 Da, which was very surprising. The extra 173 Da suggested that 
the TamA ACP domain was acylated in addition to the 4’-PP modification but it was not clear 
how this modification occurred.  




Figure 4.6: Denaturing ESI-MS spectrum of recombinant TamA showing the 60 - 58+ charge states (a) 
as purified, (b) after incubation with Sfp, CoA and Mg2+ at 4 °C for ~18 h. The mass change is presented 
as the deconvoluted mass difference after 4’-PP modification of the protein. 
For TamA to become acylated in the absence of fatty acid and ATP in the reaction, it was 
hypothesized that the recombinant TamA could be isolated from the E. coli expression host 
with bound acyl-adenylate. This adenylate would have to be stably bound in the TamA active 
site throughout the protein purification process and be poised to react with the ACP once it 
has been 4’-PP modified. The adenylate intermediate would not be visible in the denaturing 
MS analysis of apo-TamA if it was non-covalently bound in the active site. 
 
4.2.4 Non-Covalent Intermediate Binding 
Using non-denaturing native mass spectrometry, the as purified TamA was analyzed for 
binding of an acyl-adenylate, utilizing a method previously employed to identify a BioW-
adenylate complex.111 In this method, the enzyme is infused into the MS intact, so that any 
non-covalently bound species will remain attached during the analysis. The enzyme was 
desalted into 100 mM ammonium acetate, pH 8 for direct infusion onto a Waters Synapt 
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instrument (carried out with the assistance of Dr. Van Kelly). Interestingly, the native MS 
(Figure 4.7) shows that the as purified protein exists in two forms. 
 
Figure 4.7: Native ESI-MS of recombinant TamA showing three charge states (18+ to 16+) and two 
species with deconvoluted masses of 75280 Da and 75800 Da respectively, corresponding to apo-
TamA and acyl-adenylate bound TamA. 
The lower abundance species has a deconvoluted mass of around 75280 Da which is 
consistent with the calculated mass of 75270 Da. There is a larger mass error associated with 
native mass spectrometry due to peak broadening caused by sodium ions bound to the 
protein surface.196 However, the second species (of much higher abundance), has a 
deconvoluted mass of 75800 Da which is an increase of ~520 Da. C12 fatty acid adenylate has 
a mass of 529 Da which is within the error of the calculated mass difference. Though this data 
shows that there is a high likelihood that the protein has an acyl-adenylate non-covalently 
bound, it is not accurate enough to determine the nature of the acyl chain. The denaturing 
MS suggested that it is an acyl chain which has a mass of 173 Da however, this mass does not 
correspond to any unsaturated fatty acid. One explanation for this mass difference is that it 
corresponds to a mixture of fatty acids which are not resolved due to the large size and high 
charge state of the protein.  
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4.2.5 ACP Cloning, Purification and Characterization 
To reduce the size of the protein and allow resolution of smaller mass differences, the C-
terminal ACP domain was cloned without its ANL partner, so it could be used in trans to the 
full-length protein. The ACP domain is predicted to span residues 582-675 of TamA while the 
FAAL domain consists of residues 1-572. Therefore, to ensure the full ACP domain was 
encompassed, residues 578-675 were cloned to be used as a stand-alone ACP (Appendix 22). 
This protein was also expressed in the pEHISTEV vector for ~18 h at 16 °C with 0.1 mM IPTG 
in 2L of BL21 (DE3) cells.  
 
Figure 4.8: TamA ACP purification (a) SDS-PAGE analysis: (M) marker, (1) insoluble and (2) soluble 
fractions of the cell pellet, (3-6) 3 mL fractions from Nickel IMAC purification, (7) protein after TEV 
cleavage, (8) wash of TEV-cleaved TamA ACP, (9) elution of uncleaved TamA ACP and TEV protease 
(10-14) 3 mL fractions from the Superdex S75 GFC, (b) chromatogram of Superdex S75 GFC monitored 
at 280 nm showing peak elution at 70.8 mL, consistent with a protein monomer. 
The protein was purified by the same method as full-length TamA (Figure 4.8). The TamA ACP 
GFC produced a symmetrical peak on a HiLoad 16/60 Superdex S75 gel filtration column at 
the expected elution volume (70.8 mL) for the monomer with a yield of 4 mg/L culture. LC 
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ESI-MS analysis of purified TamA ACP, like TamA, showed the protein to be in its apo-form 
without 4’-PP (predicted mass: 10967.5 Da, observed mass: 10967.1 ± 0.2 Da, Figure 4.9). 
 
Figure 4.9: Denaturing ESI-MS spectrum of recombinant TamA ACP with a deconvoluted mass of 
10967.1 ± 0.2 Da consistent with the calculated mass of 10967.5 Da. 
 
Figure 4.10: Denaturing ESI-MS spectrum of recombinant TamA ACP showing the 7+ charge state (a) 
as purified and (b) after coexpression with Sfp. The mass difference presented is the deconvoluted 
mass change after 4’-PP modification. 
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To avoid performing the 4’-PP modification reaction using Sfp in vitro, the two proteins were 
coexpressed in BL21 (DE3). An untagged construct of Sfp was utilized to allow separation of 
the two proteins at the first purification step. After coexpression, full conversion of TamA 
ACP to the holo-form was observed at a mass of 11307.6 ± 0.2 Da (predicted mass: 11307.8 
Da, Figure 4.10). Unlike the full-length TamA enzyme, the ACP mass change was correct for 
the 4’-PP modification on its own (observed: Δ 340.5 Da, predicted Δ 340.1 Da). 
 
4.2.6 Fatty Acid Specificity 
The holo-TamA ACP was incubated 1:1 with as purified apo-TamA to attempt transfer of the 
fatty acid adenylate from apo-TamA to the holo-TamA ACP domain (reaction scheme in 
Figure 4.11a). If the reaction is successful then the acyl chains attached to the stand-alone 
ACP domain will be detected with a greater accuracy.  
When the LC ESI-MS was repeated after incubation, gratifyingly, two new species were 
observed in the TamA ACP spectrum (Figure 4.11c). The new peaks are 168.1 Da and 182.1 Da 
larger than holo-ACP. These masses are within the error for saturated C11 (168.3 Da) and C12 
(182.3 Da) acyl chains. As the two acyl chains are very similar in size, they can account for the 
single unresolved peak observed in the full-length TamA spectrum suggesting a mass 
increase of 173 Da. 
This suggests that TamA is highly selective as it only adenylates two fatty acid chain lengths 
from the large fatty acid pool in E. coli.63,170 Though we would expect only C12 to be selected 
because this is the reported tail length of tambjamine YP1, tambjamines with varying tail 
lengths have been observed in the same organisms.28,197 
 




Figure 4.11: (a) Reaction scheme showing the TamA ACP domain reacting with as purified TamA (R = 
unknown hydrocarbon). Denaturing ESI-MS spectrum of holo-TamA ACP showing the 7+ charge state 
(b) as purified and (c) after incubation with as purified TamA. The mass differences are presented as 
deconvoluted mass changes. 
This new in trans assay was further exploited to explore the specificity of TamA for fatty acid 
chain length. However, instead of using the apo-TamA as purified, the full-length protein was 
modified using the previously described Sfp reaction. This causes any fatty acids bound in the 
TamA active site after purification to be transferred onto the attached ACP. Therefore, the 
active site is now likely to be empty and able to adenylate other fatty acids in the reaction 
(scheme in Figure 4.12). Therefore, 10 µM acyl-TamA, along with 10 µM stand-alone holo-
TamA ACP were incubated with 1 mM fatty acid of different chain lengths (C2-C16, from a 10 
mM stock in dimethyl sulfoxide, DMSO), 5 mM ATP and 10 mM MgCl2. The reaction was then 
subjected to LC ESI-MS to detect transfer of the fatty acids onto the stand-alone ACP 
catalyzed by the full-length protein (Figure 4.12). 




Figure 4.12: Denaturing ESI-MS of TamA ACP after incubation with acyl-TamA, Mg2+, ATP and fatty 
acids of chain lengths varying from C2 to C16. Holo-TamA ACP peaks are highlighted in pink with the 
expected acyl-TamA ACP peaks highlighted in purple. The data show that TamA can accept fatty acid 
chain lengths from C6-C13. 
The LC ESI-MS data highlights TamA’s substrate promiscuity and shows that it can accept 
fatty acids between C6 and C13 in length. The C14-ACP is barely detectable in contrast to the 
abundance of C12 and C13 suggesting the protein has a defined hydrophobic cavity for the 
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fatty acid. The cavity may act as a molecular ruler so extension of the chain length beyond 
C13 causes efficiency to drop off. The fatty acid producing the largest product peak is C12, 
further supporting the hypothesis that this enzyme activates C12 fatty acid for the 
biosynthesis of the tambjamine YP1 alkyl amine tail. 
 
4.2.7 Structural Studies 
In order to get a better understanding of the mechanism and selectivity of TamA, the enzyme 
was subjected to structural studies. The crystallography was carried out in collaboration with 
Dr. Stephen McMahon in Prof. Jim Naismith’s group in the University of St. Andrews. TamA 
was concentrated to 12 mg/mL after purification and kept at 4 °C or on ice. Sitting drop 
crystal trials were prepared by Gryphon robot with four bespoke 96-well screens: SA1-4. Two 
hits for TamA crystals were identified from these screens, wells C1 and F9 in SA3. The best 
condition was C1 (16% (w/v) PEG3350, 100 mM bicine pH 8.5, 0.12 M CaCl2, 2% hexane diol) 
which produced crystals that diffracted to 7.5 Å.  
However, since there were few hits and many of the conditions screened did not produce 
crystals or precipitate, this suggested the protein concentration was too low, so the screening 
was repeated. This time TamA was concentrated to 21 mg/mL. More sitting drop crystal trials 
were set up with six different 96-well screens: JCSG+, WIZARD and PEGS1-4. The best 
conditions whose crystals were shot on the St. Andrews X-ray source are summarized in Table 
4.1. The crystals from JCSG+, well G11 were the only crystals that diffracted to 6 Å. Though 
this was better diffraction than the previous screen, this is still low resolution and crystals 
diffracting to ~2.7 Å are necessary for molecular understanding of the structure.198 These 
crystallization conditions were optimized by varying the BIS-Tris pH from 5.5 to 6.5 and 
ammonium sulphate concentration from 1.75 to 2.25 M. The optimisation was set up by hand 
in a large 6x4 plate with hanging drops. The same concentration of protein as the screening 
(21 mg/mL) was used with three drops containing different ratios of protein: precipitant 
which were 1:1, 2:1 and 1:2. Though crystals grew in several of these wells, the diffraction of 
the crystals did not improve with the best diffraction only 8 Å resolution. 
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Screen Well Conditions 
WIZARD C9 100 mM CAPS pH 10.5 2 M ammonium sulfate, 200 mM lithium sulfate 
WIZARD H1 
100 mM Tris base pH 7.0, 1 M potassium sodium tartrate, 200 mM 
lithium sulfate 
JCSG+ D11 
70 mM sodium acetate pH 4.6, 0.14 M calcium chloride dehydrate, 14% 
(v/v) 2-propanol, 30 % (v/v) glycerol 
JCSG+ E2 
100 mM sodium cacodylate pH 6.5, 2 M ammonium sulfate, 200 mM 
sodium chloride 
JCSG+ G11 100 mM BIS-Tris pH 5.5, 2 M ammonium sulfate  
Table 4.1: Conditions of TamA crystals that were shot on the University of St. Andrews X-ray source. 
Since crystals of TamA were not suitable for X-ray analysis, to get an insight into the enzyme’s 
structural elements, a model of the protein was created based on its sequence and homology 
to proteins of known 3D structure. Though the adenylation domain of TamA is very similar 
to FAALs, no structures of FAALs fused to ACPs exist as these enzymes usually act in trans to 
their ACP partners. The structures in the PDB with highest similarity to TamA are the 
adenylation domains and peptidyl carrier proteins (PCPs) from NRPSs. Six structures of four 
proteins were used to create a model of the TamA protein structure (E. coli EntF: 5T3D, 
5JA2;199,200 Acinetobacter baumannii AB3403, 4ZXI;200 Brevibacillus parabrevis LgrA, 5ES8;200 
Geobacillus sp. strain Y4.1MC1 SrfA-C, 5U89, 2VSQ,201,202 alignment in Appendix 23). The 
model was created with the Phyre2 software in intensive mode (Figure 4.13).203  
The model highlights the ANL domain in blue and the ACP in green. The first view (Figure 
4.13a) clearly depicts the ANL domain with the expected type I adenylation fold (described 
in Section 1.4.5). This fold contains a large N-terminal and smaller C-terminal domain 
separated by a hinge region (pink). The hinge allows rotation of the two domains with respect 
to one another to allow for the conformational change required to carry out adenylation and 
thiolation respectively. The P-loop (yellow) is conserved in all ATP binding proteins and 
anchors ATP in the active site, establishing the active site location. A second loop of ~30 
amino acids, is the FAAL insertion loop (orange) modelled with very little confidence as it is 
not present in the structures used to build the model. However, it is predicted to be a flexible 
loop which in other FAALs interacts with the ANL domain, stabilizing the adenylation 
conformation.190 Binding of the cognate ACP domain results in release of this loop and allows 
the conformational change required for thiolation. Figure 4.13b better illustrates the ACP 
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showing it has the characteristic four helical bundle with Ser622, the predicted 4’-PP site, 
(red spheres) sitting at the top of helix 2. This is where the 4’-PP modification is observed in 
other ACP structures.63,69 The model also shows the two domains interacting with one 
another. With this interaction conformation, modification at Ser622 would allow the 4’-PP 
arm to stretch into the ANL active site cavity, positioning it adjacent to the adenylate ready 
for thiolation. 
 
Figure 4.13: Homology model of the TamA structure constructed with Phyre2 from two angles (a) and 
(b) showing the ACP domain in green with the 4’-PP modified serine residue Ser622 shown as red 
spheres, the ANL domain in blue with the hinge region (pink), the ATP-binding P-loop (yellow) and the 
FAAL insertion loop (orange).  
 
4.2.8 4’-PP Location 
According to the bioinformatic analysis and modelling of TamA, the 4’-PP modification is 
predicted to occur on Ser622. Experimental verification of the position of modification would 
help to validate the structural model. This is especially important as TamA unusually contains 
two DSV sequences in the ACP domain, which is the conserved motif for a 4’-PP binding site.69 
To ensure that the second motif, containing Ser622, is the one post-translationally modified, 
holo-TamA was subjected to digestion by trypsin. Digested TamA was infused onto the FT-
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ICR MS with the help of Dr. Joanna Simpson (Figure 4.14a). The spectrum shows several 
peptides with excellent coverage over the protein sequence (98%).  
 
Figure 4.14: FT-ICR mass spectrum of trypsin digested TamA (a) full spectrum, (b) zoomed in over the 
4’-PP modified peptide, (c) MS/MS analysis of this peptide, (d) structure of the phosphopantetheine 
ejection ion and (e) y- and b-ions of the 4’-PP modified peptide identified in the MS/MS spectrum. 
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The peptide of interest containing the second DSV sequence with the 4’-PP modification is 
illustrated in Figure 4.14b. The predicted m/z distribution for this peptide is also displayed 
on the spectrum as dots which fit the experimental data well. The peptide molecular ion was 
also isolated and subjected to MS/MS analysis to further confirm its identity (Figure 4.14c). 
The largest peak in the spectrum is the m/z consistent with 4’-PP ejection. When 4’-PP 
modified peptides or proteins are subjected to MS/MS, the 4’-PP is ejected as the molecule 
shown in Figure 4.14d204 (predicted [M+H]+: 318.14820 Da, observed: 318.14858 Da). The 
m/z values for the MS/MS were also entered into ProSight Lite software205 and these 
attributed to the possible y- and b- fragment ions of the peptide containing 4’-PP (Figure 
4.14e). No peptide containing the first DSV motif with 4’-PP was observed which confirms 
that Ser622 is the position of the 4’-PP post-translational modification. 
 
4.3 TamT Bioinformatic Analysis and Expression 
After activation and attachment of the C12 fatty acid to the TamA ACP, three additional steps 
are required to reach the final amine tail: the introduction of a 3,4-alkene, thioester 
reduction and transamination (Figure 4.1). Though reduction must occur before 
transamination, installation of the double bond could occur at any stage. However, it seems 
likely that the alkene is installed while the fatty acid is ACP bound. Therefore, P. tunicata 
TamT, a predicted FAD dependent dehydrogenase (DH) is expected to be the subsequent 
enzyme in the pathway (gene and protein sequences in Appendix 24). TamT was cloned into 
pET28a and pET22b to yield recombinant proteins with N- and C-terminal 6xHis tags 
respectively. However, upon test expression of these proteins, both constructs appeared 
completely insoluble with no protein band observed in the soluble fraction (Figure 4.15).  
The predicted tambjamine YP1 pathway to the amine tail (Figure 4.1) suggests that this 
protein installs the double bond prior to reductive amination by TamH. Though this is likely, 
so that the reaction is carried out while the substrate is ACP bound, it is also possible that 
this transformation occurs after release of the amine by TamH. As it is not clear at what stage 
the alkene is installed or whether it is necessary for the activity of the subsequent enzyme, 
coupling of TamA and TamH activity without TamT was attempted. 




Figure 4.15: SDS-PAGE analysis of test expression of TamT constructs in BL21 (DE3) at 16 °C: (M) 
Marker (1) insoluble and (2) soluble fractions of expression of TamT pET28a with 0.1 mM IPTG for 3 h, 
(3) insoluble and (4) soluble fractions of expression of TamT pET28a with 0.5 mM IPTG for 3 h, (5) 
insoluble and (6) soluble fractions of expression of TamT pET28a with 0.1 mM IPTG for 16 h, (7) 
insoluble, (8) soluble fractions of expression of TamT pET28a with 0.5 mM IPTG for 16 h, (9) insoluble 
and (10) soluble fractions of expression of TamT pET22b with 0.1 mM IPTG for 16 h and (11) insoluble 
and (12) soluble fractions of expression of TamT pET22b with 0.5 mM IPTG for 16 h. 
 
4.4 The TamH Protein 
4.4.1 Bioinformatic Analysis 
BLAST analysis of the tamH gene (sequence in Appendix 25) suggests that the encoded 
protein is another didomain enzyme whose N-terminal domain is a class III transaminase (TA) 
and C-terminal domain is a thioester reductase (TR, protein sequence in Figure 4.16). This 
protein has similarity to PigE from Serratia sp. which is involved in the biosynthesis of 
prodigiosin.206 PigE is also predicted to contain the same domains as TamH in the opposite 
orientation with the TR at the N-terminus and the TA at the C-terminus. However, no function 
for the PigE TR domain has been assigned in the prodigiosin pathway, in fact it appears that 
only the TA domain is necessary for the biosynthesis. The PigE crystal structure was also 
solved, to find that the protein had been proteolysed and only the TA domain remained in 
the crystal.207 Therefore, no complete characterization of didomain proteins like TamH have 
been carried out.  
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The TamH N-terminal class III TA domain (discussed in Section 1.5.3) was aligned with four of 
its closest homologues in the PDB (Actinoalloteichus sp. WH1-2216-6 CrmG, 5DDS;166 E. coli 
YgjG, 4UOY;167 Thermus thermophilus acetylornithine aminotransferase (AOAT), 1VEF and 
Serratia sp. strain FS14 PigE, 4PPM,207 Appendix 26) which confirmed the position of the 
conserved catalytic lysine residue Lys340 and identified other conserved residues involved in 
PLP stabilization in the active site. These predicted residues include Asp311 which hydrogen 
bonds with the pyridine nitrogen, Phe206 which engages in a C-H-π interaction with the PLP-
ring, Gly114 and Thr370 which stabilize the phosphate group and Gln314 which forms a 
hydrogen bond with the PLP hydroxyl. 
 MQIRVGQEVL SRESLLESAG LLAQYIRAQG DMLTWQKEDE RIEVLDMVGG FGSTLLGHNH 60 
 PELLATMQQS LSSLRPMWVQ GAERPVAKQL RNALAQKLLR ETGKKYSIVL LNTGTEAVEA 120  
 GLKHAQYEFF QRLQHIQQHC DTNWREFKLR LARNEIQLTS EFYLECERLL QQEPIESLEE 180  
 LQRAVQMRNQ AVFNSSGKIA AFKGDFHGKT RGSLATTYNR DARLPFIANN PDAIFIDDEA 240  
 QFKATLASWQ KAYFTIEFAP LRLQKKPVNL LTALIYEPIQ GEGGVRPLNA RYCALLNELK 300  
 LSHPDVAIIA DEIQCGLGRT GQFLESQAIN TPNDYITLAK SLGGGLCKIS ALAVEQTRYH 360  
 EEFSMLHSTT FADDDLSSAV ALKTLAILER DELTLKAAHL GEQFTTALNA LALEYPDMIA 420  
 DIRGKGCMLG IELAAQENHP SATIAGLDEQ NMLAMAIAGH LLHRHHIRVL PSLGKRRVLR 480  
 LQPSAYLDAA NIALVVDALK ETFELIRHHH VATLLAHLIH TDKPHSAFAT AYQHPIREEA 540  
 IPAGVEKVGF ISHLIDEESL NEIDPSWRLF EGYEQEELNQ HILPITVPGV LARRLVTSAT 600  
 GRKIELVLYG IQMDAESIEA DRRFNQAKIV RAQVNEAYRL AREEGCRLVG FGGYTSIVTN 660  
 NCCDYYYNEP ATTSGNALTV AASINTILNS AQDHGINLAK ATVAICGAAG NIGQVHSAIL 720  
 AKHCHKLLLI TRNVSANNMA MTLNMICEQL YQAVSQDQQG GILVSICRDM LASRIGHEAP 780  
 KVLIDELKEA LLARQLVRIS EHFNDCQQAD IIVSNTSSPT TVIDAQHVNA HKPVLISDVA 840  
 VPRDVPVDIV NARPNIKLIR GGVVNLPINP SFTLPGMLLP TGQVYACCGE TMLLGLAGAF 900  
 SHFSMGALTC EQVEQVQALA AIHGFELNQE KPQYDALQAA S        941 
Figure 4.16: The TamH amino acid sequence (UniProtKB: A4C5V8) encoding a 104 kDa protein with a 
predicted transaminase domain (TA, pink, 56 kDa) and its conserved PLP binding lysine residue (bold) 
and a thioester reductase (TR, red, 43 kDa) with the conserved GXXGXXG nucleotide binding motif 
(bold). 
The C-terminal domain of TamH is predicted to be a reductase containing a nicotinamide 
adenine dinucleotide (phosphate) NAD(P)H binding site. These reductases break the 
thioester bond between an ACP and its acyl chain by attacking the carbonyl with a hydride 
from NAD(P)H (described in Section 1.4.6). Alignment with TRs of known structure 
(Stigmatella aurantiaca MyxA NRPS, 4U7W;124 Mycobacterium tuberculosis NRPS, 4DQV122 
and Mycobacterium marinum carboxylic acid reductase (CAR), 5MSO125) identified the 
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GXXGXXG nucleotide binding motif for NAD(P)H. However, the catalytic triad of threonine, 
lysine and tyrosine could not be aligned with the TamH TR sequence and there are several 
gaps in the alignment due to a lack of homology. Therefore, this predicted TR domain is an 
interesting target for crystallography as very few similar protein structures have been solved. 
Based on the TamH bioinformatic analysis and the role determined for TamA in this 
biosynthetic pathway, TamH is likely to carry out thioester reduction and transamination of 
a TamA ACP-bound fatty acid (Figure 4.17). A growing number of natural products containing 
terminal amines have identified the same mechanism of TR and TA cascade to produce this 
moiety.121,124 However, none of these exhibit the TamH fused domain structure. 
 
Figure 4.17: Predicted activity of TamH including reduction of acyl-TamA to produce a C12 aldehyde, 
then transamination of the aldehyde to produce a C12 alkyl amine. 
 
4.4.2 Cloning, Purification and Characterization 
In order to study these interesting reactions, TamH was cloned from P. tunicata genomic DNA 
and expressed in pET28a with an N-terminal 6xHis tag. Though expression of this construct 
produced a large soluble band, the protein appeared to degrade throughout the purification 
process with two peaks observed in the GFC chromatogram along with other contaminating 
bands in the SDS-PAGE analysis. Recloning the gene into pEHISTEV, facilitated the 
introduction of a further purification step by cleavage of the 6xHis tag. However, upon 
expression of the new construct, a large insoluble band was observed with very little soluble 
protein. One method of improving protein solubility is to grow the expressing cells in the 
presence of high concentrations of sorbitol. This places the E. coli cells under osmotic stress, 
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leading to the production of osmotic regulator proteins which promote proper protein 
folding.208 Utilizing this expression medium resulted in a much larger soluble protein fraction 
(Figure 4.18a, lane 2). Therefore, the protein was expressed in BL21 (DE3) in 3 L of this 
medium and purified from the cell lysate by nickel IMAC. TamH was subsequently cleaved by 
TEV protease to remove the 6xHis tag, subjected to a second nickel IMAC and finally GFC. 
The Superdex S200 GFC shows a symmetrical peak with a slight shoulder eluting at 54.6 mL 
(Figure 4.18). This is consistent with the protein dimer (calibration curve in Appendix 5) which 
is expected of a PLP protein.135 The final yield of the protein is quite low at only 2 mg/L 
culture, however, the protein no longer degrades.  
 
Figure 4.18: TamH purification (a) SDS-PAGE analysis: (M) marker, (1) insoluble and (2) soluble 
fractions of the cell pellet (3-8) 3mL fractions from nickel IMAC purification, (9-14) 3 mL fractions from 
the Superdex S200 GFC, (b) chromatogram of Superdex S200 GFC monitored at 280 nm showing peak 
elution at 54.6 mL consistent with a protein dimer. 
The protein was also subjected to LC ESI-MS however, an accurate mass could not be 
obtained. This is due in part to the large size of the protein (104 kDa) which is at the limit of 
detection of the instrument.  
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4.5 Biosynthesis of C12 Alkyl Amine 
Based on the bioinformatic analysis of the TamH sequence and the role that TamA has been 
shown to undertake, coupling of the two enzymes should result in biosynthesis of C12 alkyl 
amine from C12 fatty acid (Figure 4.19). This begins with adenylation of the fatty acid and its 
attachment to the TamA ACP (A), followed by TamH reduction to the aldehyde (B) and 
transamination to the amine product (C). 
 
Figure 4.19: Reaction scheme for the biosynthesis of C12 amine from C12 fatty acid (lauric acid) using 
TamA and TamH. The transformations are (A) adenylation of C12 fatty acid and attachment to TamA 
ACP, (B) reduction of C12-TamA ACP to C12 aldehyde with NAD(P)H and (C) transamination of the 
aldehyde with an amino acid to produce C12 amine. 
As there are several steps in the pathway to reach the amine product, each transformation 
was monitored in isolation prior to combination of all the enzymes and substrates. Section 
4.2.6 showed that the holo-TamA enzyme is able to produce C12-TamA ACP from C12 fatty 
acid and ATP (A), so the TamH reduction of C12-TamA ACP was tested first (B). This reaction 
could be NADH or NADPH dependent, a distinction that cannot be determined from enzyme 
sequence alone.121,124 Therefore, separate reactions were set up containing 10 µM TamH, 
10 µM TamA, 10 mM MgCl2, 1.25 mM ATP, 1.25 mM C12 fatty acid (from a 25 mM stock in 
DMSO), 250 µM PLP  and 160 µM of either NADH or NADPH. The reaction was monitored for 
10 min, taking advantage of the absorbance of NAD(P)H at 340 nm (data not shown). 
Depletion of the cofactor should result in a decrease in the absorbance at 340 nm as NAD+ 
and NADP+ do not absorb at this wavelength. Unfortunately, there was no downward trend 
in the absorbance, only some fluctuation above and below the baseline suggesting that 
neither cofactor was depleted. However, since pyridoxal 5’-phosphate (PLP), the TamH TA 
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cofactor, absorbs in the same range as these molecules (330-420 nm), it could be interfering 
with the assay, so direct detection of the product was necessary. Aldehydes are difficult to 
detect by MS because the aldehyde group does not protonate easily. However, the product 
of the transamination is an amine which ionizes more readily and can be easily detected by 
LC ESI-MS. 
The closest homologue of the TamH TA in the PDB is Actinoalloteichus sp. WH1-2216-6 CrmG, 
a TA involved in caerulomycin biosynthesis.166 This protein prefers L-glutamic acid as its 
amino donor and class III transaminases tend to prefer either L-glutamic acid or L-alanine.133 
Therefore, L-glutamic acid was used to test the transamination activity of TamH (C) in 
isolation. TamH was incubated with 5 mM L-glutamic acid and 1 mM C12 aldehyde (from a 
10 mM stock in DMSO), at 37°C for ~18 h. Positive and negative controls were also 
undertaken with the transamination product standard (1 mM C12 amine) and without 
enzyme respectively.  
The extracted ion chromatograms (EICs) of the [M+H]+ m/z for C12 amine (186.2222 Da, 
C12H28N) for each of these reactions are presented in Figure 4.20. The EIC for the negative 
control is flat whereas peaks are displayed in the standard and reaction at the same retention 
times (12.6 min). These peaks have the same m/z of 186.2226 Da which is within 2 ppm error 
of the calculated mass (186.2222 Da). Though MS usually requires an internal standard to be 
quantitative,209 as both the standard and reaction were prepared in the same buffer 
conditions and run at the same time, the ionization can be assumed to be consistent. 
Therefore, since the peaks are very close in intensity, this suggests a similar concentration of 
C12 amine, indicating that the reaction occurred with almost complete conversion. This 
activity is excellent for an equilibrium TA reaction which often require very high 
concentrations of amino donors to reach significant conversions. 




Figure 4.20: Extracted ion chromatograms (EICs) for the C12 amine m/z of 186.2222 ± 50 ppm for 
transamination reactions of TamH (10 µM), L-glutamic acid (5 mM) and C12 aldehyde (1 mM) (a) 
without TamH (b) without C12 aldehyde but with C12 amine standard (1 mM) and (c) the full reaction. 
The data show that the reaction produces a peak with the same retention time and intensity as the 
standard. 
Coupling the activities of the two TamH domains with TamA to produce C12 amine 
(transformations A-C) from C12 fatty acid was attempted using 10 µM holo-TamA, 1 mM C12 
fatty acid (from a 10 mM stock in DMSO), 10 mM MgCl2, 5 mM ATP, 10 µM TamH, 2 mM 
NAD(P)H and 5 mM L-glutamic acid. Reactions were set up with both NADH and NADPH 
independently. Initially, no product was observed, however a new peak in the chromatogram 
with an m/z of 330.2256 Da appeared. Recent work in the Flitsch group has illustrated that 
adenylation domains can be used to form amides.210 This occurs when the ANL domain 
produces an adenylate intermediate which is intercepted by nucleophilic attack of an amine 
to form an amide. In the cited work, this occurred because the ACP domain of the CAR 
enzyme was not 4’-PP modified. However, in the TamA/TamH system the reduction of the 
ACP thioester may be slow and thus the adenylate is intercepted by the amine of L-glutamic 
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acid before the 4’-PP thiol can attack. This would result in the production of an L-glutamic 
acid acyl amide (Figure 4.21, calculated mass: 330.2280 Da for C17H32NO5), explaining the 
observed m/z of 330.2256 Da.  
 
Figure 4.21: Predicted side product for the TamA/H reaction due to reaction of the fatty acid adenylate 
with L-glutamic acid (L-Glu). Predicted and observed m/z for the side product are 330.2280 and 
330.2256 Da respectively. 
To prevent this side reaction from occurring, the reactants were initially incubated without 
L-glutamic acid for ~18 h at 37 °C. L-glutamic acid was added the following day, and the 
reaction incubated for an additional 3 h (scheme in Figure 4.22). EICs show that the control 
contains no C12 amine and the standard C12 amine peak elutes at 13 min. Excitingly, the 
same peak is also produced in the full reaction containing the NADH cofactor. This definitively 
shows that the TamA/TamH reaction system can produce C12 amine from C12 fatty acid 
using NADH. In contrast, no amine is produced in the NADPH reaction illustrating that TamH 
is specific for NADH. The reaction was also carried out with 1 mM C12-CoA in place of holo-
TamA with ATP and fatty acid. Again, no C12 amine was produced (Figure 4.22e), further 
confirming that this pathway requires the TamA ACP-bound substrate for activity and cannot 
utilize the free C12-CoA substrate as previously suggested. 
Though the MS analysis is not quantitative, the amine reaction product is produced with a 
lower intensity than the standard, suggesting that the reaction does not go to completion. 
However, some protein precipitation was observed which may affect the conversion rate. 
Perhaps this occurred due to the addition of DMSO to solubilize the fatty acid, therefore, 
decreasing DMSO content or lowering the reaction temperature may improve the 
conversion. Additionally, some reductases have shown around 10 fold increase in activity 
with the addition of 200 mM KCl to the reaction.126,127 It appears the potassium ions may play 
a structural role in the enzyme. Though there is room for improvement of the reaction 
system, this preliminary data has provided evidence for the novel role of TamA and TamH in 
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the biosynthesis of tambjamine YP1 and has exposed an interesting biosynthetic route from 
fatty acid to alkyl amine. 
 
Figure 4.22: Extracted ion chromatograms for the m/z of C12 amine (186.222 +/- 20ppm) for the 
reaction detailed in the scheme containing TamA, C12 fatty acid, ATP, Mg2+, TamH, NAD(P)H incubated 
at 37 °C for ~18 h before the addition of L-glutamic acid and further incubation for 3 h. EIC for (a) the 
reaction mixture without TamH enzyme, (b) the reaction without C12 fatty acid but with C12 amine 
standard, (c) the reaction with NADH, (d) the reaction with NADPH and (e) the reaction with C12-CoA 
instead of TamA, ATP and fatty acid. 




The tam biosynthetic pathway to the amine tail of Tambjamine YP1 has been successfully 
probed in vitro. The ANL protein encoded by the tamA gene which had no previously 
hypothesized function has been shown to select and activate C11 and C12 fatty acids from 
the endogenous E. coli fatty acid pool during expression. These AMP-activated nucleophiles 
are ready for transfer onto the TamA ACP domain once it becomes 4’-PP modified. This 
reaction can also be carried out in trans between the full-length TamA and the stand-alone 
TamA ACP domain. This novel transthioesterification reaction was utilized to screen a panel 
of fatty acid substrates which showed that TamA accepts fatty acids with chain lengths 
between C6-C13. It also indicated that C12 fatty acid is the best accepted substrate for TamA, 
providing evidence for the hypothesized fatty acid activation role of this enzyme in the 
biosynthetic pathway.  
The downstream didomain enzyme TamH, is able to reduce the C12-TamA thioester to 
produce C12 aldehyde using NADH. It subsequently transaminates the aldehyde using 
L-glutamic acid to yield C12 amine. The fact that these enzymes work together and that TamH 
is unable to produce C12 amine from C12-CoA is strong evidence that TamA is indeed the 
fatty acid activating enzyme in this branch of the tambjamine YP1 biosynthetic pathway, 
contrary to the previously proposed biosynthetic route.  
Full reconstitution of the pathway requires the soluble expression of TamT to confirm its role 
in installing the 3,4 alkene in the fatty acid and to determine at which stage this modification 
occurs. Further work on the TamA/TamH system is necessary to improve the turnover of the 
enzymes as well as determine kinetic parameters and percentage conversion. This would also 
allow probing of the substrate scope of the system, potentially leading to the production of 
useful alkyl amines.  
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5 Amide Biocatalysis 
5.1 Introduction 
Biocatalysis employs enzymatic catalysts to produce high value chemical compounds.211 
Enzymes are increasingly being used over traditional chemical catalysis because they 
synthesize products with high stereo- and enantioselectivity in an ecofriendly manner. 
Natural product enzymes are often chosen as biocatalysts because these proteins carry out 
interesting and very specific chemistry. Recently, the adenylation (ANL) domain of a 
carboxylic acid reductase (CAR) was used to produce valuable amides by Flitsch and 
coworkers.210 This was achieved by mutating the ACP domain, so it could not be post-
translationally modified, leaving the adenylate bound in the ANL active site. Therefore, this 
adenylate could be intercepted by the addition of an amine, synthesizing an amide, a process 
eventually used to produce the anticonvulsant drug ilepcimide.  
In the previous chapter (Section 4.5) TamA was also shown to produce the amide product 
dodecyl-L-glutamic acid (Figure 4.21) as a side reaction during the attempt to produce C12 
amine. As the ANL domain can accept L-glutamic acid, a fairly bulky substrate, in the amide 
forming reaction, it may be able to form other interesting and relevant amides according to 
the reaction scheme in Figure 5.1.  
 
Figure 5.1: Reaction scheme of the TamA ANL domain producing C12 amides by attack of a free amine 
on its C12-adenylate to generate the amide. 
The amide synthesizing reaction does not require the ACP domain but only requires the 
adenylation activity of the protein. In order to study the action of this enzyme domain on its 
own, the ANL domain was cloned without the TamA ACP. The substrate specificity of the 
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amide synthase reaction was probed for both the fatty acid substrate and the amine 
substrate in order to produce interesting amide products. 
 
5.2 TamA ANL Cloning, Purification and Characterization 
Rather than mutating Ser622 in TamA to remove the ACP 4’-PP binding site (as previously 
reported),210 the ACP domain was deleted from the adenylation domain completely. Several 
constructs of differing lengths in pEHISTEV were produced (576, 581, 586 and 591 residues) 
as the FAAL domain is predicted to span residues 1-571. The constructs were test expressed 
in BL21 (DE3) (Figure 5.2), all of them showing protein of the expected size (65 kDa). Protein 
length did not have an effect on the solubility of this protein so the shortest construct (TamA 
ANL576, sequence in Appendix 28) was used for subsequent experiments.  
 
Figure 5.2: SDS-PAGE analysis of test expression of TamA ANL domain constructs (M) Marker (1) 
insoluble and (2) soluble fractions of expression of TamA ANL576, (3) insoluble and (4) soluble fractions 
of expression of TamA ANL581, (5) insoluble and (6) soluble fractions of expression of TamA ANL586, (7) 
insoluble and (8) soluble fractions of expression of TamA ANL591. 
Since the ANL domain was expressed in pEHISTEV in the same way as TamA, the same 
purification method was used, consisting of: immobilized metal affinity chromatography 
(IMAC), tobacco etch virus (TEV) cleavage, a second IMAC and gel filtration chromatography 
(GFC, Figure 5.3). The Superdex S200 gel filtration showed a symmetrical monomeric peak at 
76.3 mL and produced protein with no visible contaminating bands on the SDS-PAGE analysis. 
LC ESI-MS analysis of the protein confirmed the deconvoluted mass as 64653 Da ± 1 Da 
consistent with the prediction of 64651 Da. 




Figure 5.3: TamA ANL576 purification (a) SDS-PAGE gel showing (M) marker, (1) insoluble and (2) 
soluble fractions of the cell pellet (3-6) 3 mL fractions from nickel IMAC purification, (7) wash of TEV-
cleaved TamA ANL, (8) elution of uncleaved TamA ANL and TEV protease (9-13) 3 mL fractions from 
the Superdex S200 GFC, (b) chromatogram of Superdex S200 GFC monitored at 280 nm showing peak 
elution at 76.3 mL consistent with the protein monomer (c) denaturing ESI-MS spectrum with a 
deconvoluted mass of 64653 ± 1 Da consistent with the predicted mass of 64651 Da. 
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5.3 Scope of Amide Synthesis 
The fatty acid substrate scope for the ANL amide reaction was tested with addition of 
ammonia to produce simple amides. Reaction conditions for amide synthesis established by 
Flitsch and co-workers were employed:210 10 μg TamA ANL, 100 mM ammonia (pH 9), 5 mM 
ATP, 10 mM MgCl2 and 1 mM fatty acid in DMSO (final concentration 4% DMSO). The reaction 
was carried out with a range of fatty acids varying from C2-C16 in length which were analyzed 
by LC ESI-MS and the ion chromatograms extracted for the predicted mass of each product 
(Figure 5.4). The amide products for C9-C14 are clearly visible and increase in retention time 
with increasing chain length. Below C9 no peaks are observed even though production of C6 
and C8 amides would be expected, as these were utilized in the TamA substrate specificity 
assay (Section 4.2.6). However, it may be that these products do not bind to the C18 column 
used in this LC ESI-MS method and thus are not observed. The rest of the data displays a 
similar pattern to the TamA fatty acid specificity assay with the C12 amide showing the best 
conversion and a drop off in intensity after C13. This suggests that the limiting factor is the 
production of the adenylate as ammonia can trap any chain length. 
 
Figure 5.4: Reaction scheme and LC ESI-MS extracted ion chromatograms (EICs) for each of the amide 
products from the ANL catalyzed reactions of (C2-C16) fatty acids with ATP and ammonia. 
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Though the TamA ANL is unlikely to catalyze the amine attack on its bound adenylate, the 
enzyme active site must be large enough to accommodate the entering amine. Therefore, 
the reaction was attempted with different amine substrates and C12 fatty acid to see if it has 
any specificity for the amine. L- and D-glutamic acid were used to determine if the enzyme 
has enantioselectivity since L-glutamic acid was previously accepted (Figure 5.5a,b).  
 
Figure 5.5: LC ESI-MS EICs for the amide products of the TamA ANL catalyzed reactions of C12 fatty 
acid, ATP, Mg2+ with (a) L-glutamic acid, (b) D-glutamic acid, (c) L-aspartic acid, (d) L-histidine, (e) 
ethanolamine and (f) benzylamine. The data show that all of these substrates are turned over by the 
TamA ANL. 
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The enzyme does not appear to have a preference between the two enantiomers as both 
could be observed with similar intensity in the LC ESI-MS along with the very similar L-aspartic 
acid which has a side chain one carbon shorter.   
Since TamA ANL could be useful biocatalytically, other interesting commercially important 
targets were identified. N-acyl histidines have recently been discovered in Legionella 
pneumophila, a human pathogen.212 These metabolites are upregulated during the L. 
pneumophila infection cycle and could regulate human signaling pathways, analogously to 
other identified acyl amides. Since these molecules are important for studying human-
pathogen interactions and they are not commercially available, L-histidine was also tested as 
a substrate for the TamA ANL amide synthesis activity (Figure 5.5d). The LC ESI-MS data 
clearly shows TamA production of this important molecule. 
Palmitoylethanolamide (PEA), the amide produced by the coupling of C16 fatty acid and 
ethanolamine is a drug which has been widely used to treat chronic pain.213 This molecule is 
commercially available from Sigma Aldrich for £72 for 10 mg at the time of writing. However, 
this simple molecule could be biosynthesized from two cheap starting materials (namely, 
palmitic acid and ethanolamine). Though the TamA ANL domain does not currently accept 
palmitic acid, C12 fatty acid could be utilized to produce a similar molecule. Therefore, 
ethanolamine and C12 fatty acid were combined with TamA ANL to produce C12 
ethanolamine (Figure 5.5e). In the future, with the help of a TamA ANL structure, the enzyme 
could be evolved to accept longer fatty acids and produce PEA.  
Finally, a benzylamine acyl amide was also biosynthesized (Figure 5.5f), showing that larger 
aromatic molecules can also be accepted by the TamA ANL active site. This molecule would 
be useful for determining the kinetics of this reaction due to its aromatic ring which allows 
detection of the product by HPLC instead of requiring LC ESI-MS analysis. 
 
5.4 Conclusions 
With the growing call for green industrial processes, biocatalysis remains one of the most 
promising methods of achieving ecofriendly and sustainable reactions. The TamA ANL 
domain from tambjamine YP1 biosynthesis has proved to be a useful biocatalyst for the 
production of a variety of interesting fatty acyl amides, with a wide range of applications. 
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Initial reaction conditions for this transformation have been explored and the substrate 
specificity probed. Though the full potential of this tool has not yet been determined, this 
preliminary data illustrates that it can be used to produce exciting N-acyl histidines, 
important molecules in the L. pneumophila human-pathogen interaction. Future work will 
involve determining rates of reaction and conversion to allow scale up of this process to 
industrial standards. TamA ANL also has the potential to be used to biosynthesize the high 
value compound PEA and other N-acyl amide signaling molecules, if the protein can be 
engineered to accept longer fatty acids. TamA is an exciting, new biocatalytic tool and further 
research into the amine substrates that can be employed in this reaction could also open 
new doors to other useful compounds. 
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6 Materials and Methods 
6.1 Materials and Reagents 
Reagents, chemicals and media were purchased from Sigma-Aldrich, Thermo Fisher Scientific 
or Bio-Rad and used without further purification. Competent cells, pET plasmids and 
restriction enzymes were purchased from New England Biolabs (NEB) and Life Technologies. 
Primers were obtained from Sigma-Aldrich and chromatography columns were purchased 
from GE Healthcare. The Pseudoalteromonas tunicata D2 strain was acquired from DSMZ.  
 
6.1.1 Competent E. coli Cell Lines 
Various E. coli cell lines were used to store and amplify plasmids during cloning and for 
producing recombinant proteins. These are summarized in Table 6.1. 
Cell Line Supplier Application 
C2987 New England Biolabs 
High transformation efficiency, plasmid storage and 
amplification during cloning 
DH5α Life Technologies Plasmid storage and amplification 
BL21 (DE3) New England Biolabs Protein expression host  
Table 6.1: E. coli strains utilized in this work, the supplier and the applications of their use. 
 
6.1.2 Plasmids 
Target genes were cloned into various plasmids (Table 6.2) to yield recombinant proteins 
with specific purification tags. The pEHISTEV plasmid was a gift from Prof. Jim Naismith, 
University of St. Andrews.181 
Plasmid Resistance Application 
pET22b Ampicillin 
Expression of protein with a C-terminal 6xHis tag or no 
affinity tag 
pET28a Kanamycin Expression of protein with an N-terminal 6xHis tag 




Expression of protein with an N-terminal Tobacco Etch 
Virus (TEV) protease-cleavable 6xHis tag 
pACYC Chloramphenicol Expression of protein with no affinity tag 
Table 6.2: Expression plasmids utilized in this work, the antibiotic resistance conferred to the host and 
their applications. 
 
6.1.3 Growth Media 
Growth media were prepared by dissolving the components listed in Table 6.3 in distilled 




10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl 
LB Agar 10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl, 15 g/L agar 
Super Optimal 
Broth (SOC) 
10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 2% w/v glucose 
LB + Sorbitol 
LB components were dissolved in 100 mM Na phosphate pH 7.5 along 
with 0.5 M sorbitol 
VNSS Agar46 
1 g/L peptone, 0.5 g/L yeast extract, 0.5 g/L glucose, 0.01 g/L FeSO₄·7H₂O, 
0.01 g/L Na2HPO4, 17.6 g/L NaCl, 1.47 g/L Na2SO4, 0.08 g/L NaHCO₃, 0.25 
g/L KCl, 0.04 g/L KBr, 1.87 g/L MgCl2.6H2O, 0.41 g/L CaCl2, 0.008 g/L SrCl2, 
0.008 g/L H3BO3 and 15 g/L agar 
Table 6.3: Components of the growth media utilized in this work. 
Appropriate antibiotic was added to cool growth media after sterilisation when growing cell 
lines transformed with plasmid. Kanamycin, ampicillin and chloramphenicol stocks were 
made with concentrations of 30 mg/mL, 100 mg/mL and 35 mg/mL respectively. The 
kanamycin and ampicillin stocks were dissolved in water and the chloramphenicol stock in 
ethanol. The stocks were added to media in a ratio of 1:1000 for final concentrations of 
30 µg/mL, 100 µg/mL or 35 µg/mL. 
 




Buffers (Table 6.4) were prepared by dissolving components in distilled water and adjusting 
to the correct pH using concentrated hydrochloric acid or sodium hydroxide. Buffers were 
filtered through 0.22 µm filters and degassed by sonication prior to chromatography. When 
pyridoxal 5’-phosphate (PLP) dependent enzymes were purified (TamD, TamD AOSΔ96, 
TamH), PLP was added to buffers A-D in a 1:1000 dilution from a stock of 25 mM PLP for a 
final concentration of 25 μM PLP. 
Medium Components 
A 50 mM Tris pH 8, 250 mM NaCl, 10 mM imidazole, 10% glycerol 
B 50 mM Tris pH 8, 250 mM NaCl, 500 mM imidazole, 10% glycerol 
C 50 mM Tris pH 8, 250 mM NaCl, 1 mM DTT, 10% glycerol 
D 50 mM Tris pH 8, 250 mM NaCl, 10% glycerol 
E 25 mM Potassium phosphate pH 8, 250 mM NaCl, 1 mM DTT 




Genes were cloned from P. tunicata genomic DNA using sequence specific primers containing 
restriction sites matching the host vector. The primers were used to amplify the gene by 
polymerase chain reaction (PCR). PCR products and host vectors were digested using two 
restriction enzymes, then purified by agarose gel electrophoresis. The digested PCR product 
and vector backbone were ligated to form a new plasmid and transformed into high 
efficiency competent E. coli cells. Single colonies were grown up and the plasmid extracted. 
To ensure the plasmid harbored the new cloned gene, the plasmid was subjected to 
analytical digest, which if positive was followed by gene sequencing. Protein subunits were 
cloned directly from plasmids containing the full gene.  
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6.2.2 P. tunicata genomic DNA 
P. tunicata was streaked onto VNSS agar plates and grown at room temperature for 5 days. 
The cells were scraped into PBS and resuspended. They were subsequently spun down at 
17000 xg in a VWR MicroStar 17 centrifuge for microfuge tubes. The genomic DNA was 
extracted using Qiagen DNeasy Blood and Tissue kit according to the manufacturer’s 
instructions. 
 
6.2.3 Polymerase Chain Reaction (PCR) 
Primers were used to amplify specific fragments of P. tunicata genomic DNA in a PCR. Primer 
oligonucleotides were stored as 100 µM stocks at -20 °C after resuspension. These were 
diluted to 10 µM stocks for use. Primer sequences with restriction sites in bold are presented 
in Table 6.5. 
Primer Sequence 
TamF For GCCGCATATGAGCAAGCAGAAGTATGTGATATCGCTG 
TamF Rev GCGCCTCGAGGACTTGTGATCCGCAATAGTCAC 
TamD For CCATGGCAGACAATAAAAACACCGCTA 
TamD Rev CTCGAGTCATGCCACAAAACCGGGTAATTT 
TamD ACP For CTCTCCATGGGAATGACAGACAATAAAAACACCGCTA 
TamD ACP95 Rev TTTCCTCGAGTCATTGTGCCAGTTTTTGCACTC 
TamD ACP98 Rev TTTCCTCGAGTCAAAGTCCTAATTGTGCCAGTTTTTG 
TamD ACP101 Rev TTTCCTCGAGTCATGCTGCTGCAAGTCCTAATTG 
TamD ACP104 Rev TTAACTCGAGTCAAGCTTGTGGTGCTGCTGCAA 
TamD AOSΔ96 For CATATGTTAGGACTTGCAGCAGCACCACAAGC 
TamD AOSΔ96 Rev CTCGAGTGCCACAAAACCGGGTAATTTCAC 
TamD AOSΔ131 For CCGGCATATGCCTGACTTATTTAGTAAAGTGCGTAAG 
TamD AOSΔ128 For CCGGCATATGGATGGTAGCCCTGACTTATTTAGTAAAG 
TamD AOSΔ125 For TTGTCATATGTTTGTCGCAGATGGTAGCCCTGACTTAT 
TamD AOSΔ122 For ATTACATATGCGAGATTTTGTCGCAGATGGTAGCCCT 
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TamD AOS Rev CTGTCTCGAGTGCCACAAAACCGGGTAATTTCA 
TamS For GGCCCATGGTAAGCGAGAATTTGTTAACGC 
TamS Rev GCGGCCGCTCATGCATAATTAGGTTCTACATA 
TamA For TCGCCCATGGAATGTGAAGCAAGTAGTTTGATT 
TamA Rev GGCCCTCGAGCTAACATGATAAATTCAGCTCCT 
TamA ACP For GAGCCCATGGCGCCACGTGAAGTGTC 
TamA ACP Rev GGCCCTCGAGCTAACATGATAAATTCAGCTCCT 
TamA ANL For TCGCCCATGGAATGTGAAGCAAGTAGTTTGATT 
TamA ANL576 Rev CGTACTCGAGTCACGCAATTTGCTCGCCTTG 
TamA ANL581 Rev GCTACTCGAGTCACGACACTTCACGTGGC 
TamA ANL586 Rev CGTACTCGAGTCAATTGCTGATATCAAGCGACAC 
TamA ANL591 Rev GATCCTCGAGACTAGCAACACTGTCTTGATTGCTGA 
TamT For GCCGCATATGCATGACGATAATACTTTTTATGCTG 
TamT Rev Stop ATATGCGGCCGCTTATATTGGCAAAAGTGAAAACCATTTT 
TamT Rev No Stop ATTAGCGGCCGCTATTGGCAAAAGTGAAAACCATTTT 
TamH For ATTACCATGGAAATTCGTGTTGGACAAGAAGTTTTAAGCCGAG 
TamH Rev ATATCTCGAGTCAGCTAGCGGCTTGCAAGGCGTCATATT 
Table 6.5: Primer sequences for cloning of target P. tunicata genes. 
All PCR reactions were prepared on ice with 5x Phusion HF Buffer (10 μL), 10 µM forward 
primer (1.5 µL), 10 µM reverse primer (1.5 µL), 10 mM dNTPs (1 µL), genomic DNA (~100 ng), 
Phusion (1 µL), and distilled water to a final volume of 50 µL. Thermal cycling was carried out 
according to Table 6.6 with annealing temperatures dependent on the melting temperature 
of the primers used in the reaction. Denaturing and annealing times were dropped to 30 secs 
for amplification of protein subunits from a plasmid instead of genomic DNA. 
Initial Denaturing 98 °C 3 min 
Cycle x30 
Denaturing 98 °C 1 min 
Annealing 52-58 °C 1 min 
Extension 72 °C 1.5-3 min 
Final Extension 72 °C 10 min 
Table 6.6: PCR cycling conditions used for amplification of P. tunicata genes from genomic DNA. 
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6.2.4 Gel Electrophoresis and Extraction 
DNA gels were prepared with agarose (1 g) in TAE buffer containing 40 mM Tris, 20 mM acetic 
acid and 1 mM EDTA (100 mL). The mixture was heated until the agarose was dissolved and 
further cooled to ~50 °C before addition of GelRed (10 µL). The solution was stirred, poured 
into a casting mold and allowed to set. PCR products and other DNA samples were mixed 
with 6x Purple DNA loading dye (NEB) and loaded onto the gel next to a marker (Hyperladder 
I, Bioline). Gels were run at a constant voltage of 100 V for around 50 min. DNA bands were 
visualized using UV light and DNA bands of interest were excised from the gel using a scalpel. 
The gel band was weighed and DNA extracted using Qiagen QIAquick gel extraction kit 
according to the manufacturer’s instructions. 
 
6.2.5 Restriction Digest 
PCR product or plasmid to be digested (50 µL) was mixed with CutSmart buffer (6 µL), two 
appropriate restriction enzymes (2x 1 µL) and water (2 µL). The reaction was incubated at 
37 °C for 3 h. PCR products were purified using Qiagen QIAquick PCR purification kit and the 
plasmid backbone was purified by gel electrophoresis and extraction with Qiagen QIAquick 
gel extraction kit. 
 
6.2.6 Ligation 
Plasmid backbone (50 ng) and insert containing the gene of interest (~75 ng, 1:3 molar ratio 
of backbone to insert) was mixed with T4 DNA ligase (1 µL) and 10x ligation buffer (1 µL) and 
made up to 10 µL with water. The reaction was incubated at room temperature for 15 min. 
3 µL of the reaction was used to transform C2987 cells which were grown on LB agar + 
appropriate antibiotic.  
 




Single colonies were picked from agar plates and inoculated in 10 mL LB + appropriate 
antibiotic. These cultures were shaken at 37 °C for ~18 h. In the morning, the cultures were 
harvested at 3500 xg in a Heraeus Function Line centrifuge for 10 min and the supernatant 
discarded. The plasmid DNA was extracted from the pellet using Qiagen QIAprep Miniprep 
kit according to the manufacturer’s instructions. 
 
6.2.8 Analytical Digest and Sequencing 
Plasmid DNA from clones were checked for incorporation of the gene of interest by analytical 
digest. Plasmid DNA (7 µL) was mixed with CutSmart buffer (1 µL), 2x appropriate restriction 
enzyme (2x 1 µL) and incubated at 37 °C for 2 h. These digests were mixed with 6x purple 
DNA loading dye (NEB) and were analyzed by agarose gel electrophoresis. Positive clones 
have two bands, one with correct size for backbone and the other with correct size for gene 
of interest. Positive clones were sequenced by GATC using their T7 and pET-RP primers to 
determine if the gene of interest was correctly incorporated.  
 
6.3 Protein Production 
6.3.1 Transformation 
Plasmid DNA (1 µL) was added to competent E. coli cells (25 µL) and incubated on ice for 20-
30 min. The cells were subsequently heat shocked at 42 °C for 30 sec and replaced on ice for 
2 min. SOC (100 µL) was added to the cells and these were recovered with shaking at 37 °C 
for 1 h. 40 µL of the recovered cells were grown on LB agar with appropriate antibiotic at 
37 °C for ~18 h. 
 
6.3.2 Gene Expression 
Test expressions were carried out on a small scale to determine optimal conditions of 
expression prior to large scale expression. A single colony of E. coli cells containing an 
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expression plasmid was inoculated in 10 mL LB medium with appropriate antibiotic and 
grown for ~18 h at 37 °C with orbital shaking. The optical density of the cells at 600 nm (OD600) 
was measured and this culture added to 250 mL LB with appropriate antibiotic for a final 
OD600 of 0.1. The new culture was grown to an OD600 between 0.6-0.8 at 37 °C with shaking. 
Sterile filtered stock solution of IPTG (0.5 M) was added to 18x 5 mL aliquots of the culture 
for a final concentration of 0.1 mM, 0.5 mM and 1 mM IPTG for six cultures each. Half of each 
of the cultures were further shaken at 16 and 30 °C respectively for 3 h, 5 h and ~18 h time 
points before harvesting by centrifugation at 3500 xg for 10 min. The cell pellet was 
resuspended in 1 mL of phosphate buffered saline (PBS) and lysed by sonication for 1.5 min 
(10 sec on and 10 sec off). The pellet and supernatant were separated by centrifugation at 
24000 xg with a Heraeus Multifuge X3R equipped with an F15-8x50 rotor. Each fraction was 
tested by denaturing 12% or 15% SDS-PAGE gels run at 200 V. Optimal conditions for 
expression were determined and applied to large scale expression. The TamH protein was 
expressed in alternative LB media containing sorbitol to improve solubility of the protein 
(described in Section 6.1.3). Cells were harvested on a large scale at 4000 xg with a Heraeus 
Multifuge X3R equipped with a TX-1000 rotor for 30 min and cell pellets were stored at -20 °C 
prior to use.  
 
6.4 Protein Purification 
6.4.1 Cell Lysis 
Cells were defrosted on ice, then resuspended in 30 mL Buffer A. The resulting solution was 
sonicated on ice for 15 min in 30 sec intervals in order to lyse the cells. The cell free extract 
was centrifuged at 24000 xg for 30 min and the supernatant filtered with a 0.45 µm filter. 
Protein was purified from the filtered supernatant. 
 
6.4.2 Nickel NTA Purification 
All purification steps were carried out at 4 °C or on ice. Proteins were purified by nickel 
immobilized metal affinity chromatography (IMAC) using a 1 mL HisTrap HP column attached 
to an ÄKTA Explorer which monitored the eluent at 280 nm. The supernatant from the cell 
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free extract was loaded onto the column at 1 mL/min, followed by washing of the column 
with Buffer A for 10 column volumes (CVs) to remove unbound protein. The protein of 
interest was eluted from the column with a gradient between Buffers A and B over 30 CVs. 
Eluted protein was concentrated to 5 mL and subjected to gel filtration chromatography 
(GFC) with the attached 6xHis tag in the case of proteins expressed in pET28a or pET22b. In 
the case of proteins expressed in pEHISTEV, the tag was removed by mixing the eluted 
protein with 1 mg of TEV protease and dialyzing this against Buffer D for 1 h. The resulting 
protein was purified by a second nickel IMAC step with the flow-through and wash fractions 
containing the cleaved protein. This protein was concentrated to 5 mL and subjected to GFC. 
 
6.4.3 Gel Filtration Chromatography 
HiLoad 16/60 Superdex S200 or Superdex S75 (for TamD ACP98 and TamA ACP) from GE 
healthcare were equilibrated with 1 CV of Buffer C on an ÄKTA Explorer. Proteins were eluted 
using 1 CV of Buffer C at 1 mL/min with 3 mL fractions collected and the eluent monitored at 
280 nm. The fractions were analyzed by 12% or 15% denaturing SDS-PAGE gel. Those 
containing clean protein of interest were combined and concentrated for use or flash frozen 
at -80 °C. 
 
6.4.4 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
A typical SDS-PAGE consisted of a 15% running gel: water (5.7 mL), 40% acrylamide (6 mL), 
1.5 M Tris pH 8.8 (4 mL), 10 % (w/v) SDS (150 μL), 50 mg/mL ammonium persulfate (APS, 350 
μL) and N,N,N’,N’-tetramethylethylenediamine (TEMED, 20 μL) and a 4% stacking gel: water 
(2.9 mL), 40% acrylamide (0.75 mL), 0.5 M Tris pH 6.8 (1.25 mL), 10 % (w/v) SDS (50 μL), 50 
mg/mL APS (100 μL) and TEMED (5 μL). Protein samples were denatured by the addition of 
2x SDS loading buffer containing: 0.5 M Tris pH 6.8 (2.5 mL), glycerol (2 mL), 10% (w/v) SDS 
(4 mL), β-mercaptoethanol (1 mL) and 0.1 % (w/v) bromophenol blue (0.5 mL) and boiling for 
10 min. Samples were loaded onto gels alongside protein molecular weight markers 
(PageRuler Unstained Protein Ladder, Thermo Fisher Scientific or Low Molecular Weight 
Marker, GE Healthcare)  and were run for approximately 50 min at a constant voltage of 200 
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V. Subsequently gels were immersed in Expedeon Instant Blue Coomassie stain and 
incubated for 30 min at room temperature with gentle shaking.  
 
6.5 Mass Spectrometry (MS) 
6.5.1 Intact Protein LC ESI-MS 
Bradford assay was used to determine protein concentration for liquid chromatography 
electrospray-MS (LC ESI-MS). Protein was diluted to a concentration of 10 µM and 
centrifuged for 10 min at 17000 xg. 5 µL of the supernatant was subjected to LC ESI-MS on a 
Synapt G2-Si Q-TOF (Waters) instrument with Phenomenex C4 3.6 µm LC column coupled to 
an ESI source. The LC gradient ran from 5% acetonitrile and water with 0.1% formic acid to 
95% acetonitrile over 15 min. The MS source was set at 120 °C, backing pressure 2 mbar and 
sampling cone voltage of 54 V. Protein spectra are presented after subtraction using 
MassLynx V4.1 software. Peak m/z annotations were extracted from smoothed and 
centroided data which was also used in the component algorithm to extract the protein 
average masses. 
 
6.5.2 4-Hydroxy-2,2’-Bipyrrole 5-Methanol (HBM) LC ESI-MS 
Reactions producing HBM and its analogues were quenched with a 1:1 volume of acetonitrile 
with 0.01% trifluoroacetic acid (TFA) and centrifuged at 17000 xg. 5 μL of the supernatant 
was injected into a Phenomenex Kinetex 5 µm C18 100 Å column coupled to a micrOTOF II 
(Bruker). The LC gradient ran from 5% acetonitrile and 95% water with 0.1% formic acid to 
95% acetonitrile over 10 min. Extracted ion chromatograms (EICs) and masses were 
determined on DataAnalysis V4.3 software. 
 
6.5.3 Amines and Amides LC ESI-MS 
Amine or amide producing reactions were quenched with a 1:1 volume of acetonitrile with 
0.01% TFA and centrifuged at 17000 xg. 5 µL of supernatant was subjected to LC ESI-MS on a 
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Synapt G2-Si Q-TOF (Waters) instrument with Phenomenex Jupiter C18 5 µm 300 Å LC 
column coupled to an ESI source. The LC gradient ran from 5% acetonitrile and 95% water 
with 0.1% formic acid to 95% acetonitrile over 30 min. The MS source was set at 120 °C, 
backing pressure 2 mbar and sampling cone voltage of 54 V. Extracted ion chromatograms 
(EICs) and masses were determined on MassLynx V4.1 software. 
 
6.5.4 Native MS 
Protein was desalted into 300 mM ammonium bicarbonate using a P6 Micro BioSpin column 
to remove excess salt. Protein concentration was determined by Bradford assay and diluted 
to 10 µM. Protein was infused onto a Synapt G2-Si Q-TOF (Waters) instrument by nano-ESI 
using a TriVersa NanoMate (Advion) set at 1.7 kV and 0.8 psi. The MS source was set at 80 °C, 
backing pressure 5 mbar and sampling cone voltage of 200 V. The spectra were averaged 
over 4 min of acquisition and are presented without further data processing. Peak m/z 
annotations were extracted from smoothed and centroided data which was also used in the 
component algorithm to extract the protein average masses. 
 
6.5.5 Peptide Digest and MS 
50 µg of holo-TamA was denatured by addition of 8 M urea to a concentration of 6 M before 
incubation at room temperature for 2 h. Reduction of the protein was achieved with DTT 
added to a final concentration of 5 mM and further incubated at room temperature for 
30 min. Iodoacetamide was added to a final concentration of 10 mM at room temperature 
in the dark for 30 min in order to acylate the protein. This reaction was quenched by adding 
additional DTT to a concentration of 10 mM with incubation at room temperature for 30 min. 
The sample was subsequently diluted to a urea concentration of less than 1 M with 50 mM 
ammonium bicarbonate. Finally, 1 µg of trypsin was added to the sample and the reaction 
was incubated at 37 °C for ~18 h. The samples were cleaned and concentrated using 100 µL 
C18 ziptips and washed in 0.2% formic acid. The peptides were eluted in 60% acetonitrile 
with 0.2% formic acid. The resulting peptide mixture was analyzed using a Bruker solariX X 
12T in positive ion mode. The protein was infused using nano-ESI on a TriVersa NanoMate 
(Advion). Data were acquired over an m/z range of 200 – 5000 with an average of 30-50 scans 
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and an accumulation time of 0.2 sec. Resulting spectra were processed and calibrated with 
DataAnalysis V4.3. The [M+3H]3+ ion containing the 4’-PP modification was isolated for 
further MS/MS analysis by increasing the accumulation time to 2 sec and averaging over 50 
spectra which were acquired with a 2 Da window. The resulting product ion spectrum of 
[M+3H]3+ was analyzed using ProsightLite205 for y- and b- ions corresponding to a 4’-PP 
modification.  
 
6.6 SNAC Synthesis 
 
S-(2-Acetamidoethyl) 1H-pyrrole-2-carbothioate: 2-Pyrrole carboxylic acid (500 mg, 4.5 
mmol) and DMAP (137 mg, 1.1 mmol) were dissolved in dichloromethane (DCM, 50 mL). The 
mixture was stirred at 0 °C with the sequential addition of N-acetylcysteamine (0.44 mL, 4.5 
mmol) and NEt3 (0.69 mL, 5.0 mmol). EDC.HCl (1294 mg, 6.75 mmol) also dissolved in DCM 
was added dropwise. The mixture was stirred for ~18 h at room temperature under an Ar 
atmosphere. The reaction was quenched with saturated ammonium chloride and extracted 
with DCM. The organic phase was extracted, dried over MgSO4, filtered and concentrated 
under reduced pressure. The crude product was purified by flash column chromatography 
with 95:5 DCM:MeOH. The colourless solid was obtained in 71% yield (674 mg). Rf 
(DCM:MeOH, 95:5) = 0.59; δH (500 MHz, CDCl3), 1.97 (3H, s, CH3), 3.19 (2H, m, CH2), 3.51 (2H, 
m,  CH2), 5.96 (1H, br s, NH), 6.29 (1H, m, CH), 7.03 (2H, m, CH), 9.19 (1H, s, NH), δC (126 MHz, 
CDCl3), 23.4 (CH3), 27.8 (CH2), 40.2 (CH2), 111.2 (CH), 115.8 (CH), 124.1 (CH), 130.0 (C), 170.4 
(CO), 181.8 (CO). mlz (ESI) for [C9H12N2O2SNa]+ predicted: 235.0517, observed: 235.0540. 
Spectroscopic data is consistent with literature values.178  
 
 




S-(2-Acetamidoethyl) furan-2-carbothioate: 2-Furoic acid (500 mg, 4.5 mmol) and DMAP 
(137 mg, 1.1 mmol) were dissolved in DCM (50 mL). The mixture was stirred at 0 °C with the 
sequential addition of N-acetylcysteamine (0.44 mL, 4.5 mmol) and NEt3 (0.69 mL, 5.0 mmol). 
EDC.HCl (1294 mg, 6.75 mmol) also dissolved in DCM was added dropwise. The mixture was 
stirred for ~18 h at room temperature under an Ar atmosphere. The reaction was quenched 
with saturated ammonium chloride and extracted with DCM. The organic phase was 
extracted, dried over MgSO4, filtered and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography with 95:5 DCM:MeOH. The colourless 
solid was obtained in 80% yield (762 mg). Rf (DCM:MeOH, 95:5) = 0.52; δH (500 MHz, CDCl3), 
1.97 (3H, s, CH3), 3.21 (2H, t, J = 6.4 Hz, CH2), 3.52 (2H, q, J = 6.0 Hz,  CH2), 5.96 (1H, br s, NH), 
6.55 (1H, dd, J = 3.6, 1.7 Hz, CH), 7.21 (1H, dd, J = 3.6, 0.8 Hz, CH), 7.60 (1H, dd, J = 1.7, 0.8 
Hz, CH), δC (126 MHz, CDCl3), 23.4 (CH3), 28.0 (CH2), 39.9 (CH2), 112.5 (CH), 116.3 (CH), 146.7 
(CH), 150.7 (C), 170.5 (CO), 180.8 (CO). mlz (ESI) for [C9H11NO3SNa]+ predicted: 236.0357, 
observed: 236.0358. Spectroscopic data is consistent with literature values.178 
 
 
S-(2-Acetamidoethyl) pyridine-2-carbothioate: 2-Picolinic acid (554 mg, 4.5 mmol) and 
DMAP (137 mg, 1.1 mmol) were dissolved in DCM (50 mL). The mixture was stirred at room 
temperature with the sequential addition of N-acetylcysteamine (0.44 mL, 4.5 mmol) and 
NEt3 (0.69 mL, 5.0 mmol). EDC.HCl (1294 mg, 6.75 mmol) also dissolved in DCM was added 
dropwise. The mixture was stirred for ~18 h at room temperature under an Ar atmosphere. 
The reaction was quenched with saturated ammonium chloride and extracted with DCM. The 
organic phase was extracted, dried over MgSO4, filtered and concentrated under reduced 
pressure. The crude product was purified by flash column chromatography with 95:5 
DCM:MeOH. The colourless solid was obtained in 74% yield (749 mg). Rf (DCM:MeOH, 95:5) 
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= 0.51;  δH (500 MHz, CDCl3), 1.97 (3H, s, CH3), 3.21 (2H, t, J = 6.3 Hz, CH2), 3.55 (2H, q, J = 6.3 
Hz,  CH2), 5.88 (1H, br s, NH), 7.54 (1H, m, CH), 7.87 (1H, m, CH), 7.96 (1H, m, CH) 8.71 (1H, 
m, CH), δC (126 MHz, CDCl3), 23.4 (CH3), 28.7 (CH2), 39.6 (CH2), 120.7 (CH), 128.2 (CH), 137.5 
(CH), 149.4 (CH), 151.8 (C), 170.3 (CO), 193.7 (CO). mlz (ESI) for [C10H12N2O2SNa]+ predicted: 
247.0517, observed: 247.0503. Spectroscopic data is consistent with literature values.178 
 
 
S-(2-Acetamidoethyl) 4-bromo-1H-pyrrole-2-carbothioate: Ethyl 4-bromopyrrole 
2-carboxylate (300 mg, 1.38 mmol) was dissolved in methanol (10 mL) and KOH (20 M, 2 mL) 
and stirred at 50 °C for ~18 h. The solvent was removed under reduced pressure and HCl (0.5 
M, 40 mL) was added to the residue. This solution was partitioned in diethyl ether and the 
organic fraction dried over MgSO4. The solvent was again removed under reduced pressure 
to yield 4-bromopyrrole 2-carboxylic acid (244.5 mg, 94% yield) which was used in the 
subsequent step without further purification. 4-Bromo 2-pyrrole carboxylic acid (239 mg, 
1.25 mmol) and DMAP (38 mg, 0.3 mmol) were dissolved in DCM (30 mL). The mixture was 
stirred at room temperature with the sequential addition of N-acetylcysteamine (0.12 mL, 
1.25 mmol) and NEt3 (0.19 mL, 1.4 mmol). EDC.HCl (360 mg, 1.88 mmol) also dissolved in 
DCM was added dropwise. The mixture was stirred for ~18 h at room temperature under an 
Ar atmosphere. The reaction was quenched with saturated ammonium chloride and 
extracted with DCM. The organic phase was extracted, dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash column 
chromatography with 95:5 DCM:MeOH. The cream coloured solid was obtained in 47% yield 
(173 mg). Rf (DCM:MeOH, 95:5) = 0.30; δH (500 MHz, CDCl3), 1.97 (3H, s, CH3), 3.20 (2H, t, J = 
6.3 Hz, CH2), 3.51 (2H, q, J = 5.9 Hz,  CH2), 5.89 (1H, s, NH), 7.01 (2H, m, CH), 9.23 (1H, s, NH), 
δC (126 MHz, CDCl3), 23.3 (CH3), 28.0 (CH2), 39.8 (CH2), 98.5 (CBr), 116.9 (CH), 123.6 (CH), 
130.0 (C), 170.3 (CO), 181.2 (CO). mlz (ESI) for [C9H12BrN2O2S]+ predicted: 290.9803 (97%), 
292.9702 (100%), observed: 290.9772 (91%), 292.9759 (100%). 
 




S-(2-Acetamidoethyl) 1H-indole-2-carbothioate: 2-Indole carboxylic acid (725 mg, 4.5 
mmol) and DMAP (137 mg, 1.1 mmol) were dissolved in DCM (50 mL). The mixture was 
stirred at room temperature with the sequential addition of N-acetylcysteamine (0.44 mL, 
4.5 mmol) and NEt3 (0.69 mL, 5.0 mmol). EDC.HCl (1294 mg, 6.75 mmol) also dissolved in 
DCM was added dropwise. The mixture was stirred for ~18 h at room temperature under an 
Ar atmosphere. The reaction was quenched with saturated ammonium chloride and 
extracted with DCM. The organic phase was extracted, dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash column 
chromatography with 95:5 DCM:MeOH. The colourless crystalline solid was obtained in 19% 
yield (230 mg). Rf (DCM:MeOH, 95:5) = 0.35; δH (500 MHz, CDCl3), 1.99 (3H, s, CH3), 3.27 (2H, 
m, CH2), 3.55 (2H, m, CH2), 5.91 (1H, s, NH), 7.18 (1H, m, CH), 7.36 (2H, m, CH), 7.42 (1H, m, 
CH), 7.71 (1H, m, CH), 8.90 (1H, s, CH), δC (126 MHz, CDCl3), 23.3 (CH3), 28.2 (CH2), 39.9 (CH2), 
108.9 (CH), 112.0 (CH), 121.3 (CH), 123.0 (CH), 126.5 (CH), 127.3 (C), 133.6 (C), 136.8 (C), 
170.3 (CO), 184.0 (CO). mlz (ESI) for [C13H14N2O2SNa]+ predicted: 285.0674, observed: 
285.0633. 
 
6.7 Enzymatic Reactions 
6.7.1 ACP Post-Translational Modification 
Where indicated TamD, TamD ACP, TamA and TamA ACP were 4’-phosphopantetheine (4’-
PP) modified during the purification process. After the TEV protease cleavage and dialysis, 
the protein was concentrated and added to a 10 mL reaction containing 10 µM Sfp, 10 mM 
MgCl2 and 500 µM CoA in Buffer D. This reaction was left shaking for ~18 h at 4 °C. The 
protein purification was subsequently continued in the same way with the second nickel 
affinity chromatography step removing the 6xHis tagged Sfp along with the TEV protease. 
Alternatively, the proteins were 4’-PP modified in vivo by coexpression with untagged Sfp in 
pACYC.  
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6.7.2 HBM Reactions 
Reactions producing HBM or any of its intermediates and analogues were carried out in 
Buffer C with 50 µM PLP and reactants in the following concentrations: 10 µM TamF, 2 mM 
SNAC, 500 µM malonyl-CoA, 5 µM E. coli FabD and 50 mM amino acid. Reaction time for 
generation of intermediates was 15 min at room temperature. Detection of the 
intermediates was carried out by intact protein MS as they are covalently protein bound. 
HBM and its analogues were produced in reactions incubated at room temperature that were 
quenched with a 1:1 volume of 0.01% TFA in acetonitrile at various time points (0 min, 2 min, 
5 min, 10 min, 15 min, 30 min, 1 h, 2 h, 3 h and 5 h). These samples were analyzed by LC ESI-
MS and high performance liquid chromatography (HPLC).  
 
6.7.3 TamA and TamA ACP Transthioesterification 
Holo-TamA ACP was mixed 1:1 with as purified apo-TamA at a final concentration of 10 µM 
of each protein in Buffer C. The mixture was incubated for ~18 h at room temperature before 
being subjected to LC ESI-MS to determine the fatty acids bound in the TamA active site after 
purification. To test the transfer of alternative fatty acids, 10 µM holo-TamA and 10 µM holo-
TamA ACP were incubated with 1 mM fatty acid (from a 10 mM stock in DMSO), 5 mM ATP 
and 10 mM MgCl2 in buffer C for 20 h at room temperature. The reactions were subsequently 
subjected to LC ESI-MS. 
 
6.7.4 TamH Reduction 
In order to determine whether the thioester reductase (TR) domain of TamH utilizes NADH 
or NADPH as its cofactor, reactions with each substrate were monitored at 340 nm. The 
reactions were carried out in Buffer C and contained 10 µM holo-TamA, 1.25 mM  C12 lauric 
acid (from a 25 mM stock in DMSO), 1.25 mM ATP, 10 mM MgCl2, 10 µM TamH, 250 µM PLP 
and 160 µM NAD(P)H. Control reactions were carried out without enzyme. These were 
monitored continuously on a Varian Cary® UV/Vis spectrophotometer at 340nm for 10 min. 
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6.7.5 TamH Transamination 
The TamH transamination reaction contained 10 µM TamH, 250 µM PLP, 5 mM L-glutamic 
acid and 1 mM C12 aldehyde (from a 10 mM stock in DMSO) in Buffer C. The reactions were 
incubated at 37 °C for 24 h before being analyzed by LC ESI-MS.  
 
6.7.6 Amine Reactions 
The reactions producing dodecamine from C12 lauric acid by TamA and TamH were carried 
out in Buffer C and contained 10 µM holo-TamA, 1 mM C12 lauric acid (from a 25 mM stock 
in DMSO), 5 mM ATP, 10 mM MgCl2, 10 µM TamH, 250 µM PLP and 2 mM NAD(P)H. Reactions 
substituting the TamA protein with C12-CoA contained 1 mM C12-CoA, 10 µM TamH, 250 
µM PLP and 2 mM NAD(P)H. Reactions were carried out with both NADH and NADPH 
separately along with a negative control without the TamH enzyme. The reactions were 
incubated at 37 °C for ~18 h before the addition of 5 mM L-glutamic acid to allow 
transamination. The reactions were then further incubated for 3 h at 37 °C. 
 
6.7.7 ANL Reactions 
Reactions were carried out according to the methodology of the Flitsch group.210 They 
contained 10 µg ANL, 1 mM fatty acid (from a 25 mM stock in DMSO), 5 mM ATP, 10 mM 
MgCl2 and 100 mM amine (pH 9) in 100 mM sodium carbonate-sodium bicarbonate buffer 
(pH 9). 
 
6.8 UV/Visible Spectroscopy  
6.8.1 PLP Enzyme-Amino Acid Dissociation Constants (Kd) 
UV/visible spectroscopy was carried out on a Varian Cary® UV/Vis spectrophotometer. Excess 
PLP and Tris base was removed by PD10 column (GE healthcare) and the enzyme exchanged 
into Buffer E. Assays were carried out in 1 cm pathlength cuvettes and baseline correction 
was carried out before acquiring spectra. Protein was diluted to a concentration ~40 µM and 
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amino acid substrates were added from a 1 M stock solution to various final concentrations 
(0-100 mM). Enzyme and substrate mixtures were allowed to equilibrate at room 
temperature for 5 min before spectra were acquired. The spectra were normalized against 
the 280 nm peak to account for dilution of the sample with addition of substrate solution. 
Changes in the absorbance maximum of the ketoenamine peak (~420 nm) were plotted and 
fitted with a hyperbolic saturation curve using Origin software. The dissociation constant (Kd) 
was calculated according to the following equation: 
∆Aobs =
∆Amax [amino acid]
Kd + [amino acid]
 
Where ΔAobs is the observed change in absorbance at ~420 nm, ΔAmax is the maximal 
absorbance change and [amino acid] is the concentration of the added amino acid substrate. 
 
6.8.2 High Performance Liquid Chromatography (HPLC) 
HBM producing reactions were quenched by addition of a 1:1 volume of acetonitrile with 
0.01% TFA. The samples were centrifuged at 17000 xg for 10 min before injection of 10 μL of 
the supernatant onto a Phenomenex Luna 5 μm C18 100 Å HPLC column. Samples were 
eluted with water and 0.1% TFA for 5 min followed by a 15 min gradient to 55% acetonitrile 
and 0.1% TFA. This concentration was maintained for 5 min and then returned to 100% water 
and 0.1% TFA for an additional 5 min. The eluent was monitored at 345 nm. 
 
6.9 X-ray Crystallography 
Structural studies were carried out in the Scottish Structural Proteomics Facility (SSPF) in 
collaboration with Dr. Stephen McMahon in the Naismith group at the University of St. 
Andrews. Proteins were concentrated by Vivaspin column to (10-21 mg/mL) and centrifuged 
at 17000 xg for 10 min to remove particulate. Crystallization conditions were screened by a 
nano-drop crystallization robot (Gryphon). This robot sets up sitting drop 96-well plate crystal 
trials with three different ratios of protein: precipitant 1:1, 2:1 and 1:2 for drop sizes of 0.2 
or 0.3 µL. The plates were left at 20 °C for several weeks before checking for the formation 
of crystals.  
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7 Conclusions and Future Work 
Tambjamine YP1 is an important bipyrrole natural product with an attached fatty amine tail 
that has antibacterial and cytotoxic activity. Understanding of the biosynthetic pathway to 
this molecule is important not only for the production of improved tambjamines but also for 
the continued exploration of natural product biosynthetic enzymes. This work encompasses 
the first detailed research into the activity and mechanism of the enzymes involved in 
tambjamine YP1 biosynthesis in P. tunicata. A summary of the enzymes studied and their 
roles in the biosynthetic pathway are shown in Figure 7.1. 
Recombinant forms of TamF and TamD have been cloned, expressed, purified and their roles 
in the biosynthesis of the bipyrrole moiety of tambjamine YP1 have been determined. MS 
analysis of the interesting CLF-KS didomain protein TamF illustrated that covalent 
attachment of a pyrrole substrate occurs as the first step of the catalyzed reaction. The native 
PCP-pyrrole substrate can be substituted with a pyrrole SNAC mimic for simple loading of this 
protein. TamD, the ACP-AOS didomain enzyme must be loaded with its 4’-PP arm for activity, 
which can be achieved in vitro or in vivo with B. subtilis Sfp. Further loading of the protein 
with a malonyl group was carried out in a novel manner with E. coli FabD to allow for multiple 
turnovers of this enzyme. MS analysis of the stand-alone TamD ACP98 domain has shown that 
the TamF KS can subsequently catalyze the decarboxylation of malonyl-TamD ACP and attack 
of its thioester bound substrate to produce the diketopyrrole-ACP thioester. This thioester is 
turned over in the presence of L-serine by the catalytic TamD AOS domain to produce a linear 
α-oxoamine product. Spontaneous cyclisation then occurs to form the first bipyrrole 
intermediate, HBM, which has been detected for the first time in vitro using a combination 
of UV/visible spectroscopy, HPLC and MS analysis.  
This work represents an advance in the understanding of bipyrrole biosynthesis not just for 
the tambjamine family but also for the prodigiosins and other polyketides. In previous work 
on the MBC based natural products HBM had never been identified as a product of the MBC 
biosynthetic enzymes. This was likely due to the limitation in the previously discussed assay 
method which only allowed one turnover of the reaction system. Therefore, this is the first 
observation of HBM as an intermediate in the production of this family of natural products. 
It has also been the first exploration of the substrate scope of the bipyrrole forming enzymes.  




Figure 7.1: Updated biosynthetic pathway to tambjamine YP1 from L-proline, malonyl-CoA, L-serine 
and lauric acid in P. tunicata, with the enzymes and transformations studied in this work indicated by 
the coloured domains, corrected from Burke et al.50 
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The potential for these proteins to accept a range of substrates may be low; of the few amino 
acids tested L-alanine was the only other amino acid accepted in the reaction and none of 
the alternative heterocycles could be utilized. However, only a limited number of substrates 
were employed in the system and a more comprehensive review of potential substrates is 
needed. Determination of 3D structures of these enzymes could also lead to engineering of 
the system to accept novel substrates. Therefore, this elucidated pathway opens the door to 
the production of novel tambjamines as well as other unusual bipyrrole or bicyclic systems.  
The previously unexplored pathway to the tambjamine YP1 amine tail has also been 
elucidated for the first time and the predicted biosynthetic route has been revised. A gene in 
the tambjamine YP1 cluster without a previously hypothesized function (tamA) has proved 
to be the protein necessary for activation of C12 fatty acid. This protein is an ANL-ACP fusion 
which creates a fatty acid adenylate using ATP, activating the carboxylic acid for attack by the 
4’-PP modification of its C-terminal ACP. Transthioesterification reactions between the full-
length TamA and a truncated TamA ACP domain have shown the substrate specificity of the 
protein for saturated fatty acids to range from C6-C13 in chain length. TamA was also coupled 
with the activity of the downstream TA-TR didomain enzyme TamH to show that together 
these two proteins can convert a fatty acid to the corresponding alkyl amine. The TamA ACP-
bound fatty acid thioester is reduced by TamH using NADH to produce an aldehyde 
intermediate. The aldehyde is subsequently transaminated using L-glutamic acid to yield the 
final amine product. In contrast to the previous hypothesis, this work has proven that TamA 
is the activating enzyme required for the biosynthesis of the tambjamine YP1 amine tail. 
TamH, a unique enzyme fusion has also been explored for the first time. However, full 
characterization of this pathway will also require the soluble expression and purification of 
TamT, the DH domain that generates the 3,4 alkene moiety. Future work will require 
optimization of this reaction system as well as determination of the kinetic parameters. This 
will allow its exploration as a potential biocatalytic cascade for alkyl amine production as well 
as the production of novel tambjamine derivatives with alternative hydrophobic tails.  
Finally, the TamA ANL domain was truncated from its ACP partner in an attempt to use this 
protein for a biocatalytic application. The adenylation domain is able to create fatty acid 
adenylate intermediates which can be attacked by an amine molecule to yield an amide. 
Simple amides were produced from C9-C13 fatty acids with ammonia. As the C12 fatty acid 
was the best fatty acid substrate for this reaction, it was used to test the amine specificity of 
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the reaction. The TamA ANL domain could accept all the amines tested including L-glutamic 
acid, D-glutamic acid, L-aspartic acid, L-histidine, ethanolamine and benzylamine. Therefore, 
this reaction does not have enantioselectivity, suggesting that the ANL domain is not 
catalyzing the amide bonding forming reaction. Instead, the amine enters the active site 
without binding and traps the already activated intermediate.  However, this data shows that 
this enzyme has broad substrate scope and is an excellent addition to the biocatalytic tool 
box. Future work on this enzyme should include scale up and determination of kinetic 
parameters for the production of the interesting N-acylhistidine molecules produced by the 
human pathogen L. pneumophila. Determination of the TamA ANL structure would also allow 
the engineering of this enzyme to accept longer chains for the synthesis of other high value 
products such as PEA or fluorescent fatty acids. 
This thesis has explored the convergent biosynthesis of the two building blocks of the 
important, biologically active tambjamine YP1 molecule. The pathway to each fragment has 
been elucidated and has shed light on the methods of bipyrrole and alkyl amine biosynthesis. 
Natural product enzymes have often been used for biocatalytic application due to their 
remarkable and specific chemistry. One of the Tam enzymes has already been exploited for 
this purpose and the characterization of these proteins has opened the door to further 
development of this pathway.  
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Appendix 2: Alignment of the TamF protein sequence with RedX (UniProtKB: O54142) and PigJ 
(UniProtKB: Q5W262), homologues from prodiginine biosynthesis showing that that the majority of 
the homology is in the C-terminal ketosynthase domain.  
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Appendix 3: Alignment of the TamF protein sequence with RedX (UniProtKB: O54142), PigJ 
(UniProtKB: Q5W262), Mycobacterium smegmatis mycocerosic acid synthase (MAS), 5BP1; Moorea 
producens CurL, 4MZ0 and Bacillus subtilis BacS, 5ENY. Conserved KS catalytic residues (Cys507, His637 
and His675 in TamF) are highlighted in green. 
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Appendix 4: TamF recombinant protein sequence from pET22b expression construct including C-
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Appendix 5: Calibration curve of the Superdex HiLoad 16/60 S200 gel filtration column and resulting 
equation for calculating approximate molecular weight (MW) of a protein. 
 









MW is measured in Da 
Ve = Elution volume 
Vo = Void volume (41.9 mL) 
Vt = Total bed volume (120 mL) 
 
  
Page | 158 
 
 






























Page | 159 
 
 
Appendix 7: Alignment of TamD protein sequence with homologues from prodiginine biosynthesis, 
RedN (UniProtKB: O54153) and PigH (UniProtKB: Q5W264). Alignment shows that the TamD ACP is 
homologous to the second RedN/PigH ACP domains. The conserved DSX motif for 
4’-phosphopantetheine (4’-PP) binding is shown in purple. 
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Appendix 8: Alignment of TamD protein sequence with RedN (UniProtKB: O54153), PigH (UniProtKB: 
Q5W264), Sphingomonas paucimobilis SPT, 2JG2 and Escherichia coli AONS, 1DJE (UniProtKB: 
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Appendix 9: TamD recombinant protein sequence from pEHISTEV expression construct. Tobacco Etch 
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Appendix 10: TamD ACP recombinant protein sequences from pEHISTEV expression constructs. 
Tobacco Etch Virus (TEV) protease cleavage removes the residues shown in bold including the 6xHis 
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Appendix 11: Calibration curve of the Superdex HiLoad 16/60 S75 gel filtration column and resulting 
equation for calculating approximate molecular weight (MW) of a protein. 
 









MW is measured in Da 
Ve = Elution volume 
Vo = Void volume (41.9 mL) 
Vt = Total bed volume (120 mL) 
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Appendix 13: Characterization of pyridine SNAC (a) high resolution MS, (b) 1H NMR and (c) 13C NMR 
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Appendix 14: Characterization of 4-bromopyrrole SNAC (a) HRMS, (b) 1H NMR and (c) 13C NMR 
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Appendix 15: Characterization of indole SNAC (a) HRMS, (b) 1H NMR and (c) 13C NMR. 
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Appendix 16: TamD AOSΔ95 recombinant protein sequence from expression in pET22b including a 
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Appendix 17: TamD AOS recombinant protein sequences from expression in pET22b including a 
C-terminal 6xHis tag (bold) with different linker region truncations. None of these constructs without 
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Appendix 19: Alignment of TamA protein sequence with Mycobacterium smegmatis FadD32, 5D6J; 
Mycobacterium tuberculosis FadD32, 5HM3; Mycobacterium marinum FadD32, 5EY9 and Legionella 
pneumophila FAAL, 3KXW). The conserved ATP binding P-loop is highlighted in yellow, the FAAL 
insertion loop in orange and the hinge region in pink. 
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Appendix 20: Alignment of the predicted TamA ACP protein sequence with Actinoplanes friulienses 
LipD, 2N98; Burkholderia ambifaria Bamb_5917, 5MTI and the Aspergillus parasiticus norsolorinic acid 
synthase (NSAS), 2KR5. The conserved DSX motif is highlighted in green. 
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Appendix 21: TamA recombinant protein sequence from pEHISTEV expression construct. Tobacco Etch 
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Appendix 22: TamA ACP recombinant protein sequence from pEHISTEV expression construct. Tobacco 
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Appendix 23: Alignment of TamA protein sequence with E. coli EntF: 5T3D, 5JA2; Acinetobacter 
baumannii AB3403, 4ZXI; Brevibacillus parabrevis LgrA, 5ES8 and Geobacillus sp. strain Y4.1MC1 SrfA-
C, 5U89, 2VSQ. The conserved ATP binding P-loop is highlighted in yellow, the FAAL insertion loop in 
orange, the hinge region in pink and the carrier proteins in green. 
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Appendix 24: The tamT gene sequence (GenBank: EAR29351) and the resulting TamT protein 
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Appendix 26: Alignment of TamH transaminase (TA) protein sequence with Actinoalloteichus sp. WH1-
2216-6 CrmG, 5DDS; E. coli YgjG, 4UOY; Thermus thermophilus acetylornithine aminotransferase 
(AOAT), 1VEF and Serratia sp. strain FS14 PigE, 4PPM. The conserved amino acids involved in PLP 
binding are highlighted in pink. 
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Appendix 27: Alignment of the TamH thioester reductase (TR) protein sequence with Stigmatella 
aurantiaca MyxA NRPS, 4U7W; Mycobacterium tuberculosis NRPS, 4DQV and Mycobacterium 
marinum carboxylic acid reductase (CAR), 5MSO. The conserved GXXGXXG motif for nucleotide 
binding is highlighted in yellow. The catalytic triad (threonine, tyrosine and lysine) are highlighted in 
orange but these cannot be identified in the TamH TR sequence probably due to a lack of homology. 
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Appendix 28: TamA ANL recombinant protein sequence from pEHISTEV expression construct. Tobacco 
Etch Virus (TEV) protease cleavage removes the residues shown in bold including the 6xHis tag. 
MSYYHHHHHHDYDIPTTENLYFQGAMECEASSLIDLLAFDARNKPSQEVFRFVSDNGESEAS
YDYQTLSQEISRIAIGLQALIKTSHNQDQALIVLPQGVQFVTAFYGCMAANVIAVPSFPPKS
QLQIERLQFAITDLGNPIVITNRDILPKLQEHIALDSVRWLLIEDLASVIAQPLSDFRTHEH
SIALLQYSSGTTGKPKGVIITNQNIMENSELIRQSFGHKEDHTRMMLWLPPHHDMGLVGGVM
QGVYTGYPTLLMPTDLFLRSQYRWLKAVSDYRATTTGAPNFAYELAVKNIRESRLAELDLSS
LENLFCGAEPINSHSINQFLDKFAPCGLKPEAFLPCYGMAEATLMVSGKPHGQQYKQLCIDE
PLLKHGMVKPLNTPNAHSLWLVSSGVVHSSLQARIVNPETGTEVAQGQVGEIWLQGSSISPG
YWQDAERTAINFGLPLAGYEETFHRTGDLGFYHQDELFITGRLKEVVIIRGANFYPQDLEYE
TTLAFPELNNCRSAAFSVPKEGKEQLIMAIEVPRNVTEFNQYAKILNGRLVERFGIRADIIL
FLPRKTIKITSSGKLQRVAIKKAYEEQQLPVYFQYQLQGEQIA 
 
